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Abstract 
Platelets are an essential factor in wound repair and blood clotting, where exposed sub-
endothelial extracellular matrix (ECM) proteins induce activation during vascular 
injury. However, platelets can also be activated by a diverse range of stimuli that share 
little-to-no resemblance in structure to each other, or to recognized ligands of platelet 
receptors. These stimuli include diesel exhaust particles (DEP), various peptides 
including 4N1-1 and Champs, lipoproteins such as PAM3-CSK4, and large 
polysaccharides for example, fucoidan, and dextran.  
In this thesis, I demonstrate that this seemingly miscellaneous group of stimuli cause 
aggregation of human and mouse platelets through Src and Syk tyrosine kinases in 
association with stimulus-specific tyrosine phosphorylation of the GPVI/FcRγ-chain 
complex and/or CLEC-2. A critical role for GPVI and/or CLEC-2 in mediating 
aggregation is shown using platelets from receptor-deficient mouse platelets. 
Additionally, in double deficient mouse platelets these stimuli activate Src tyrosine 
kinases independent of GPVI and CLEC-2. DEP, fucoidan and dextran were shown to 
activate transfected GPVI or CLEC-2 in a cell line model. However, 4N1-1, Champs 
and PAM3-CSK4 did not activate transfected GPVI or CLEC-2 in a cell line model, nor 
could they bind to recombinant forms of either receptor. In addition, I demonstrate the 
unexpected observation that fibrin also activates GPVI revealing a new stage of 
haemostasis in which the generation of fibrin from fibrinogen reinforces platelet 
activation. 
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Chapter 1 GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2  
1.1 Platelet Overview and Formation 
 
Platelets are an essential factor in wound repair and blood clotting. When the 
sub-endothelial extracellular matrix (ECM) is exposed during vascular injury, 
activation of platelets leads to the formation of a haemostatic plug which serves to 
prevent excessive blood loss. Platelets are essential for haemostasis most notably in the 
high shear environment found in arteries and arterioles. Excessive and uncontrolled 
platelet activation is however detrimental to human health. One classic example is at 
sites of rupture of atherosclerotic plaques where uncontrolled thrombosis may lead to 
obstruction of blood vessels and myocardial infraction or stroke. Therefore careful 
regulation of platelet function is required. 
The origin of all blood cells is the common haematopoetic stem cell (HSC). 
Blood cells are classified into two major classes that are known as myeloid 
(macrophages, neutrophils, basophils, eosinophils, erythrocytes, platelets) and 
lymphoid (T and B cells) lineages (Figure 1-1). A mutual progenitor exists for the 
anuclear cells platelets and erythrocytes. This progenitor produces a colony of cells 
from which the megakaryocyte/erythroid lineages are formed. These divide into 
megakaryocyte and erythroid lineages by binary fission. Platelets are produced by 
megakaryocytes, which are very large polyploid cells present in bone marrow. As these 
progenitors grow into giant cells platelets are released into the peripheral circulation by 
a processes called fragmentation. The hormone thrombopoietin (TPO), synthesized 
mainly by the liver and to a lesser extent by the kidneys, regulates platelet formation, 
which signals through the c-Mp1 receptor on megakaryocytes (Murone et al., 1998). 
Platelets survive for 7-10 days in the human circulation. In a healthy human adult, the 
platelet count ranges from 150–400 x 109 per liter.  
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Figure 1-1 Haematopoietic stem cell (HSC). Development of white blood cells (basophils, 
eosinophils, monocytes, neutrophils), lymphocytes cells (T and B cells), red blood cells and 
platelets from a common stem cell through common myeloid and lymphoid precursors – 
reproduced from (Cabrita et al., 2003). 
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1.2 Platelet Structure 
 
Platelets are the smallest of the blood cells, with a diameter of 2-3 μm, and a 
discoid shape in their inactive state. It is proposed that their small size and discoid shape 
helps to position platelets close to the endothelium (Ruggeri, 2009). To facilitate their 
function in the repair of vascular damage, red blood cells marginate platelets to the edge 
of blood vessels. This allows for platelets to be maintained in a position near to the 
endothelium, where they can respond quickly if vascular damage is detected.  
 When scanned under high resolution electron microscope the plasma 
membrane can be seen to invaginate into the cell to form a structure known as the open 
canicular system (OCS) (Hartwig, 2006). The function of these membrane folds is to 
provide additional membrane when platelets spread on a surface increasing the ratio of 
surface area. The OCS contains channels that facilitate the exchange of small molecules 
and prevents entry of larger proteins such as antibodies between the blood and the 
interior of the cell (Hartwig, 2006, Jin et al., 1998). 
The cytoskeleton of a platelet is necessary for maintaining its discoid shape. 
When a platelet becomes activated, it goes through extensive structural changes which 
are mediated by the regulation of actin polymerisation. The platelet cytoskeleton 
consists of three layers:  
(1) A spectrin-based skeleton that is required for attachment of the cytoplasmic 
surface to the plasma membrane;  
(2) A microtubule network consisting of the β1 isoform of tubulin rolled into a 
coil and located under the cell membrane which runs along the whole circumference of 
platelet (Hartwig, 2006, Italiano and Shivdasani, 2003, Jin et al., 1998, Savi et al., 
1998); 
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(3) A rigid actin filament-based network that fills the cytoplasmic space of the 
cell.  
Actin is the most highly expressed platelet protein (Bearer et al., 2002). The 
filaments of actin are joined to the spectrin-based skeleton and are interlinked by two 
other proteins; filamin and actinin. Filamin interacts with one of the other most 
abundantly expressed platelet surface glycoprotein, GPIb-IX-V, which mediates 
tethering to sites of vessel injury through binding to von Willebrand factor (VWF) 
(Italiano and Shivdasani, 2003, Hartwig, 2006). Remodelling of the platelet 
cytoskeleton, which involves the formation of filopodia and lamellipodia, is initiated 
by platelet activation. In addition, platelets produce a contractile force through 
formation of actin stress fibres that stabilize the aggregate. Non-muscle myosin IIA and 
B expressed by platelets are vital for producing this contractile force (Hartwig, 2006).  
As described above, platelets are formed from megakaryocytes which provide 
a broad range of pre-synthesized molecules required for their physiological responses. 
Platelets lack a nucleus and so their capability to express new proteins is much reduced 
(and indeed controversial). Typical cellular organelles such as mitochondria, lysosomes 
and endoplasmic reticulum are present in the cytoplasm of platelets. Besides these, they 
also contain major two types of platelet specific granules: (1) α-granules and (2) dense 
granules, as well as lysosomes which are of uncertain physiological significance. 
About 80 α-granules are present in each human platelet having an approximate 
size of 0.2 - 0.4 μm in diameter (Italiano and Battinelli, 2009, Hartwig, 2006, Woulfe, 
2005, Wei et al., 2009). Matrix adhesive proteins such as fibrinogen, fibronectin and 
VWF are stored in these granules. In addition, glycoprotein receptors are embedded in 
their membranes, which play a role in regulating attachment of platelets to the ECM. 
These include P-selectin and the major platelet integrin αIIbβ3. Coagulation factors, 
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including prothrombin, factors V and XIII are also present in α-granules (Harrison and 
Cramer, 1993).  
Platelet dense granules are about 10 times less in number than α-granules and 
are smaller, with an approximate size of 0.15 m in diameter (Blair and Flaumenhaft, 
2009). Dense granules contain a number of small molecules that are important for cell 
activation including ADP, ATP, Ca2+ and the vasoconstrictor, serotonin (Harrison and 
Cramer, 1993, Kahn et al., 1999). ADP plays an essential role in ‘secondary’ platelet 
activation and platelet recruitment to the forming thrombi. Glycoproteins are also 
embedded in the membranes of dense and lysosomal granules that are assimilated into 
the plasma membrane following granule fusion, including CD63, LAMP1, LAMP2 and 
CD68 (Nofer et al., 2004, Kahn et al., 1998).  
There are a number of other structural features which help platelets to perform 
their physiological functions. These include the high expression of glycoprotein 
receptors and signalling proteins that permit a quick response to vascular damage. In 
addition, expression of the negatively charged phosphatidylserine (PS) is increased in 
the outer lipid bilayer in activated platelets and provides a platform for the gathering of 
clotting factors. This helps to concentrate factors such as thrombin at the site of injury 
reinforcing platelet activation (Zwaal et al., 2004). 
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1.3 Platelet Function  
 
Prevention of excessive blood loss by plugging the holes in damaged vessels is 
the fundamental physiological role of the platelets. In more recent studies, the 
involvement of platelets in additional processes including angiogenesis, inflammation 
and immunity has been reported. However, for this thesis I will concentrate on the 
traditional platelet actions, namely haemostasis and thrombosis. 
Upon detection of exposed ECM during vascular injury, circulating platelets 
attach, become activated and attract other platelets from the circulation to form a 
haemostatic plug. At the site of injury, thrombus formation is further accelerated by 
thrombin generation from the coagulation cascade which also cleaves fibrinogen to 
fibrin. Platelet activation in haemostasis is summarised in Figure 1-2 and has been 
extensively reviewed (Woulfe, 2005, Wei et al., 2009, Stegner and Nieswandt, 2011, 
Jackson, 2011a).  
 
1) Tethering, rolling and adhesion.  
At shear conditions >500/s, as found in the small arteries, arterioles and stenotic 
diseased arteries, platelets accumulate by tethering and activation. The high molecular 
weight plasma glycoprotein VWF bridges exposed collagen and the platelet surface 
receptor GPIb-IX-V mediating platelet capture. The rapid ‘on/off’ rates of association 
and dissociation between GPIb-IX-V and immobilized VWF underlie the ability of the 
platelet to tether and roll on the VWF. A weak activation signal within the platelets is 
generated by this interaction and it is proposed that this helps to initiate further 
activation. At low shear (<500/s), conditions common in large arteries and veins, the 
VWF/GPIb-IX-V axis is not required. Rather, the integrins α2β1 (specific for 
interaction with collagen), α5β1 (specific for interaction with fibronectin), α6β1 
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(specific for interaction with laminin) and αIIbβ3 (which binds fibrinogen, fibronectin, 
VWF) are used for direct binding of the platelets to the ECM proteins indicated 
(Ruggeri and Mendolicchio, 2007).  
2) Integrin activation and stable adhesion.  
Following tethering, rolling and non-firm adhesion of platelets with the ECM, 
rapid, sustained activation is initiated. The low affinity collagen receptor GPVI binds 
to collagen, clusters, and initiates a strong and sustained activation signal. This triggers 
integrins αIIbβ3 and α2β1 to undergo a conformational change from a low affinity to a 
high affinity state and thereby bind to their immobilised ligands, namely VWF and 
collagen, respectively. The platelets are then strongly attached to the exposed ECM and 
VWF bound to collagen.  
3) Spreading.  
Cytoskeletal remodelling mediates the major morphological changes in the 
platelets induced by platelet activation. Long finger-like projections termed 
filopodia are extended by the now strongly attached and activated platelets. These 
filopodia ensure an even stronger adherence to the damaged vessel by the platelets. 
These projections are filled with lamellipodia, which help to increase the surface 
area and strengthen adhesion to the exposed subendothelial matrix and to each 
other. A large vascular lesion can therefore be quickly and efficiently covered by 
platelet spreading.  
4) Secretion.  
The potent platelet agonist thromboxane A2 (TxA2) along with the contents of 
α- and dense granules are rapidly released by the activated and spread platelets. A 
synergistic effect is produced by the combination of ADP and TxA2 which induces 
maximal platelet activation. At this time the platelet plug grows with further recruitment 
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of new platelets. The localized generation of thrombin is accelerated by released 
components including Factors V, XIII and prothrombin (Wei et al., 2009). 
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Figure1-2 Platelets tethering, adhesion, aggregation and thrombus formation. 
Platelet interaction with VWF leads to initiation of platelet tethering. GPVI interaction with 
collagen enables integrin conformational changes from low affinity to high affinity. These 
interactions lead to strong platelet binding to the exposed ECM and VWF. Platelets then spread 
and release ADP and TxA2 leading to platelets aggregation and clot formation (Jackson, 2011a, 
Wei et al., 2009). 
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5) Aggregation.  
Fibrinogen derived from plasma and platelets, along with VWF, act as the 
facilitators of platelet aggregation. The interaction between αIIbβ3 and fibrinogen, and 
αIIbβ3 and VWF develop strong affinity interactions which further accelerates the 
growth of the thrombus (Jackson, 2007).  
6) Thrombus stabilisation.  
The PS exposed on the activated platelet surface, and also on the surface of 
activated endothelial cells, supports the activation of the coagulation cascade 
components (Factors V, VIII, IX and X) leading to thrombin generation (Heemskerk et 
al., 2002). In addition, the extrinsic coagulation pathway is initiated by the tissue factor 
exposed on damaged endothelial cells and smooth muscle cells in the vessel wall 
Figure. This pathway concludes at thrombin generation (figure 1-3). Platelet activation 
is increased by a high localized concentration of thrombin along with conversion of 
fibrinogen to fibrin and stabilisation of thrombus against embolization (Gibbins, 2004). 
7) Clot retraction.  
The platelet-fibrinogen/fibrin aggregate stabilises the thrombus through clot 
retraction via αIIbβ3. Non-muscle myosin II generates contractile forces required to 
pull together the interlocking cytoskeletons of platelets (Shattil and Newman, 2004). 
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Figure 1-3 Extrinsic coagulation pathways. Tissue factor pathway includes Factors V, VIII, 
IX and X lead to thrombin formation and fibrinogen conversion to fibrin by the action of 
thrombin- reproduced from (Davie et al., 1991) .  
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1.4 Platelet Receptors 
 
Receptors that control the platelet-dependent phases of haemostasis and 
thrombosis are expressed on the surface of platelets. They are divided into two distinct 
groups: tyrosine kinase-linked receptors (section 1.4.1) and G protein-coupled receptors 
(GPCRs) (Section 1.4.2).  
1.4.1 Tyrosine Kinase-Linked Receptors 
 
The major tyrosine kinase-linked receptors are the collagen activation receptor 
GPVI/FcR γ-chain complex; the collagen adhesion integrin α2β1; C-type lectin-like 
receptor 2 (CLEC-2); the fibrinogen/VWF integrin receptor αIIbβ3 and the VWF 
receptor GPIb-IX-V. The following sections describe the distinctive features of these 
receptors and their signalling pathways. 
1.4.1.1 Collagen Receptors – GPVI and α2β1 
 
The most abundant protein present in animals is collagen (Shoulders and 
Raines, 2009, Rivera et al., 2009). Vessel injury exposes blood to collagen since this 
fibrous structural protein is the foremost component of the ECM that lines all walls of 
the vessels. The most thrombogenic forms of collagen types are type I and type III 
present in the most luminal areas of the sub-endothelial matrix (Shoulders and Raines, 
2009, Yang et al., 2000). The immunoreceptor GPVI and the integrin α2β1 are the 
major two collagen receptors expressed by platelets (Nieswandt and Watson, 2003, 
Pozgajová et al., 2006). GPVI and α2β1 bind to unrelated areas of collagen fibrils; 
GPVI to GPO repeat sequences, and α2β1 to GFOGER and related sequences. Affinity 
for their cognate motifs also differ, with GPVI binding with low affinity and activated 
α2β1 with high affinity. A rapid initiating signal is principally performed by GPVI 
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while firm adhesion is mediated by activated α2β1 (Nieswandt and Watson, 2003, 
Lanza et al., 1986). The two receptors work together but also have their own separate 
tasks in the regulation of platelet adhesion and the formation of thrombus on collagen 
(Sarratt et al., 2005, Massberg et al., 2003, Holtkotter et al., 2002). 
1.4.1.2 GPVI/FcR γ-Chain Complex 
 
Found in the ECM upon endothelial cell disruption, collagen and laminin are 
the physiological ligands of GPVI (Inoue et al. 2006). synthetic ligands include 
collagen-related-peptide (CRP) which is GPVI-specific (Asselin et al., 1997); and the 
snake toxin convulxin that bind to GPVI and GPIb-IX-V (Kanaji et al., 2003, Jandrot-
Perrus et al., 1997, Canobbio et al., 2004, Wei et al., 2009) are used in in vitro studies 
to investigate downstream signalling events that are independent of integrin 21. 
GPVI is a 62 kDa type I transmembrane receptor (Clemetson et al., 1999, Wei 
et al., 2009), located on chromosome 19 the human genome. Expressed solely in 
megakaryocytes and platelets, GPVI consists of two IgG–like domains and a stalk that 
is mucin-like in its extracellular region. There follows a trans-membrane region, and a 
small cytoplasmic tail that in humans contains 51 amino acids. This domain contains 
only 27 residues in the murine GPVI, suggesting that the absent amino acids may not 
play a critical role in GPVI function (Moroi and Jung, 2004, Jackson, 2011b).  
GPVI occurs partially as a dimer on the platelets surface. Ligand-mediated 
clustering triggers signalling via Src family tyrosine kinases (SFKs) (Horii et al., 2009). 
GPVI forms a constitutive non-covalent contact with the FcR γ-chain via a positively 
charged arginine in its trans-membrane region (Watson et al., 2005a, Nieswandt and 
Watson, 2003). The interaction of GPVI with the γ-chain is essential for both expression 
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of GPVI on the platelet surface and for signalling, (Gibbins et al., 1996, Poole et al., 
1997, Quek et al., 2000, Severin et al., 2012). 
GPVI induces sequential activation of SFKs, predominantly via Lyn and Fyn, 
with Src also playing a minor role (Severin et al., 2012). The SFK Lyn is constitutively 
associated with a proline-rich area in the cytoplasmic tail of GPVI through its SH3 
domains (Suzuki-Inoue et al., 2002) where it phosphorylates the conserved 
immunoreceptor tyrosine-based activation motif (ITAM) (YXX [L/I] X6-12YXX [L/I]) 
in the FcR γ-chain (Gibbins et al., 1996, Poole et al., 1997). By means of its tandem 
SH2 domains, the tyrosine kinase Syk binds to the phosphorylated FcR γ-chain ITAM 
leading to auto-phosphorylation and additional phosphorylation by SFKs (Watson et 
al., 2005b). This highly activated protein mediates further downstream signalling events 
in lipid rafts, which includes formation of the ‘LAT signalosome’ containing the 
adaptors LAT, SLP-76, Gads/Grb2, Tec family kinases, The Vav family of guanine 
nucleotide exchange factors (GEF) and effector proteins, including PI 3-kinase and 
PLCγ2 (Watson et al., 2005b). Formation of the second messengers by 1 2-
diacylglycerol (DAG) and inositol 1, 4, 5- trisphosphate (IP3) is induced by PLCγ2. The 
two second messenger stimulate PKC and release of Ca2+ from intracellular stores, 
respectively (Figure 1-4). Integrin activation, release of α- and dense-granules, and the 
discharge of the secondary mediators ADP and TxA2, which prime stimulatory signals 
and thrombus growth, reinforce GPVI signalling (Offermanns, 2006, Nieswandt and 
Watson, 2003). 
Clinical cases of bleeding diathesis in patients harbouring quantitative or 
qualitative defects in GPVI are rare due to compensatory mechanisms of platelet 
activation by multiple platelet receptors. However, there has been a report of idiopathic 
thrombocytopenic purpura (ITP) due to reduced levels of GPVI surface expression, 
 
 
16  
where auto-antibodies directed towards GPVI were observed in the patient leading to 
GPVI shedding and clearance of the GPVI/FcRγ -chain complex from the platelet 
surface (Boylan et al., 2004). In addition, patients with genetic defects in GPVI that 
present with a bleeding diathesis have been reported in recent studies (Matus et al., 
2013, Hermans et al., 2009). The use of GPVI-deficient mice have provided further 
supporting evidence for the vital role of this receptor in collagen-induced platelet 
activation, thrombosis and haemostasis by phenocopying GPVI deficiency in humans 
(Matsumoto et al., 2007, Lockyer et al., 2006, Konishi et al., 2002). 
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Figure 1-4 Collagen binding to GPVI leads to activation of phosphorylation of Src kinases, 
Syk and PLCγ2 
.  
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1.4.1.3 Integrin α2β1 
 
The first collagen receptor identified on platelets, which functions almost 
predominantly as an adhesion receptor, is the integrin α2β1 (also known as GPIa/IIa) 
(He et al., 2003, Nieswandt and Watson, 2003). Expression levels fluctuate between 
individuals with approximately 2,000 – 4,000 copies per resting human platelet (Best 
et al. 2003; Samaha et al. 2004). It engages with high affinity to collagen types I – V 
(Holtkotter et al., 2002, Leitinger and Hogg, 2002). Its level of expression is unaltered 
upon platelet activation. The integrin is usually in a ‘low-affinity’ state on the surface 
of resting platelets. Upon interaction with collagen, ‘inside-out’ signalling induces a 
conformational change to a ‘high-affinity’ state (Jung and Moroi, 2000a, Jung and 
Moroi, 2000b). In addition to supporting platelet adhesion, binding to integrin α2β1 
also increases the net binding of collagen to GPVI and therefore potentiation of 
signalling by the immunoglobulin receptor (Nieswandt and Watson, 2003, Jung and 
Moroi, 2000b). On the other hand, α2β1 signalling is much weaker than that of GPVI 
and possibly plays little role in thrombus formation despite the fact that the α2β1 
signalling pathway utilises many of the same signalling molecules as the GPVI 
signalling pathway, including Src, Syk, SLP-76, and PLCγ2 (Inoue et al., 2003). It is 
established in genetic and pharmacological studies that α2β1 has almost no protective 
influence in arterial thrombosis and plays only a small part in platelet aggregate 
formation on collagen under flow (Holtkotter et al., 2002, Farndale et al., 2004, He et 
al., 2003). 
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1.4.1.4 CLEC-2 receptor 
 
The C-type lectin-like (CLEC)-2 receptor is expressed on human and mouse 
platelets (Suzuki-Inoue et al., 2006, Severin et al., 2012). It is located on chromosome 
12 in the human genome, is a type II membrane protein, and has a single trans-
membrane region, an N-terminal cytoplasmic domain, and a C-terminal extracellular 
domain (Figure 1- 5). CLEC-2 has also been identified in inflammatory dendritic cells. 
The endogenous ligand for CLEC-2 is the type I trans-membrane glycoprotein, 
podoplanin (Suzuki-Inoue et al., 2007a, Chaipan et al., 2006a). The expression of 
podoplanin on cancer cells has been shown to induce powerful platelet aggregation (Tsuruo 
and Fujita, 2008). In addition, CLEC-2 and podoplanin are required for lymphatic 
development, as mice deficient in either gene have blood-lymphatic mixing (Uhrin et al., 
2010, Herzog et al., 2013).  
Rhodocytin is a snake venom toxin derived from Calloselasma rhodostoma venom 
that was used in the original affinity purification of CLEC-2 receptor. It is used in vitro to 
activate CLEC-2 and induces platelet activation via Syk and Src family kinases (Suzuki-
Inoue et al., 2011, Severin et al., 2011a) which subsequently leads to activation of PLCγ2 
(Suzuki-Inoue et al., 2006). Platelet activation and protein tyrosine phosphorylation are 
blocked by SFK inhibitors such as PP2 (Severin et al., 2011a) and by the Syk inhibitors 
R406 or PRT-060318 (Spalton et al., 2009a, Hughes et al., 2013). 
In contrast to GPVI receptors, CLEC-2 signals through a hemITAM sequence in its 
cytoplasmic tail, which is a single YxxL. Syk mediates phosphorylation of hemITAM with 
the SFKs regulating Syk (Hughes et al., 2013, Severin et al., 2011a) (Figure 1-5). Both SH2 
domains of Syk are required for CLEC-2 signalling, with point mutations in either SH2 
domain abolishing signalling (Fuller et al., 2007). As is the case for GPVI-FcR γ-chain, 
activation of Syk leads to formation of a LAT signalosome that includes the adapter SLP-
76, Tec family tyrosine kinases, Vav GTP exchange factors and PLCγ2 (Fuller et al., 2007, 
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Suzuki-Inoue et al., 2006). In CLEC-2-deficient murine platelets, high concentrations of 
rhodocytin induce weak platelet aggregation in the absence of SLP-76 or combined Vav1 
and Vav3, in contrast to the abolition of aggregation to CRP or convulxin (Suzuki-Inoue et 
al., 2006). 
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Figure 1-5 CLEC-2 by binding of Rhodocytin or podoplanin leads to activation of platelets 
through Src and Syk kinase. 
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1.4.1.5 Integrin αIIbβ3 
 
The most abundant glycoprotein expressed on the platelet surface with 
approximately 60,000 – 80,000 copies per resting human platelet is the integrin αIIbβ3 
(also known as GPIIb/IIIa). The GPIIb gene and the GPIIIa gene are located on 
chromosome 17 in the human genome (Shattil et al., 1998). αIIbβ3 is also stored in 
platelet α-granules, therefore upon platelet activation it translocates to the platelet 
surface, increasing expression by 30 – 50% (Shattil et al., 1998, Shattil and Newman, 
2004). The β3 subunit is expressed in numerous cell types where it co-operates with 
other α subunits whereas the αIIb subunit is restricted to the megakaryocyte/platelet 
lineage (Shattil and Newman, 2004). Fibrinogen, fibronectin and VWF all bind to 
platelets via αIIbβ3. 
The integrin αIIbβ3 is usually in a ‘low-affinity’ state on the surface of resting 
platelets and experiences a conformation alteration to a ‘high-affinity’ state when 
induced by ‘inside-out’ signalling (Shattil and Newman, 2004). Outside-in signalling, 
filopodia and lamellipodia formation, secretion and clot retraction are all activated by 
ligand mediated clustering of αIIbβ3 (Shattil et al., 1998). Adhesion and aggregate 
formation at sites of vascular injury require αIIbβ3 (Shattil and Newman, 2004). 
Outside-in signalling events of αIIbβ3 and GPVI signalling share a number of 
similarities (Watson et al., 2005a, Kasirer-Friede et al., 2007). The consecutive 
activation of SFKs, Syk, employment of adapter proteins including SLP-76 and 
activation of downstream effector enzymes, including PLCγ2, PI 3-kinase and Vav are 
all caused as a result of fibrinogen-mediated clustering of αIIbβ3 (Kasirer-Friede et al., 
2007, Watson et al., 2005a). 
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SFKs (Src and Fyn) are successively linked with the β3 subunit and Syk 
becomes engaged to the integrin as a result of clustering analogous to events 
downstream of GPVI receptor activation. However, there are a number of key 
differences; firstly it remains controversial as to whether an whether an ITAM-
containing protein facilitates this interaction or Syk solely interacts with the β3 subunit 
tail (Woodside et al., 2001b, Mocsai et al., 2006, Hughes et al., 2015); secondly, αIIbβ3 
is excluded from lipid rafts: and thirdly the transmembrane adapter protein LAT, which 
is necessary for GPVI signalling, is not required for αIIbβ3 signalling (Wonerow et al., 
2002). There is also evidence for differences between mouse and human platelets, with 
FcRIIa, which is absent in the mouse genome, playing a role in human αIIbβ3 
signalling (Boylan et al., 2008). 
In recent years, the molecular processes that underlie outside-in integrin αIIbβ3 
signalling have been studied in detail. The C-terminal Src kinase (Csk) which, as the 
name suggests, phosphorylates an inhibitory tyrosine in the C-terminal tail of Src, holds 
integrin αIIbβ3-associated Src in an inactive conformation in resting platelets (Tyr-529) 
(Obergfell et al., 2002, Arias-Salgado et al., 2005) Csk detaches from the αIIbβ3-Src 
complex and is substituted by the non-transmembrane protein tyrosine phosphatase, 
PTP-1B, which dephosphorylates the inhibitory tyrosine of Src and initiates the 
signalling pathway as integrin clustering occurs (Arias-Salgado et al., 2005). Syk is 
then recruited to the complex and activated via phosphorylation by Src and by 
autophosphorylation (Woodside et al., 2001b, Mocsai et al., 2006). Other SFKs also 
play a role in the initiation of outside-in integrin αIIbβ3 signalling including Fyn, Lyn 
and Yes (Obergfell et al., 2002, Arias-Salgado et al., 2003, Senis et al., 2009). The 
interaction between Syk and tyrosine phosphorylation at these sites is terminated by 
phosphorylation of the two conserved tyrosines in the β3-tail (Woodside et al., 2001a). 
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It is functionally important that phosphorylation of the two conserved tyrosine residues 
in the β3 subunit occurs (Law et al., 1999). A conserved NPXY motif that facilitates 
binding to proteins with phosphotyrosine binding (PTB) domains including the Dok 
family of adapter proteins is mediated by phosphorylation (Law et al., 1999, Garcia et 
al., 2004, Gibbins et al., 1996). A NXXY motif contains a second tyrosine and binds a 
separate group of PTB domain containing proteins, including Shc (Phillips et al., 2001). 
In a diYF knock-in mutant mouse model, increased bleeding and impairment in clot 
retraction is observed (Law et al., 1999). It has been proposed that this is because of 
loss of binding of myosin to the phosphorylated β3 tail (Phillips et al., 2001).  
Glanzmann thrombasthenia, a severe bleeding disorder associated with 
impaired adhesion and abolished aggregation of platelets, is a result of the absence of, 
or reduced function of αIIbβ3 (Nurden, 2006). Mice lacking the IIb- or β3-integrin 
subunits phenocopy Glanzmann thrombasthenia (Hodivala-Dilke et al., 1999). 
Haematopoiesis as well as platelet function have been studied in both αIIb-deficient 
and β3-deficient mice models (Tropel et al., 1997, Emambokus and Frampton, 2003). 
Extended tail bleeding times and spontaneous haemorrhage are displayed by mice that 
are β3-deficient. In addition, they do not form thrombi at sites of vascular damage as 
shown by intravital microscopy (Ni et al., 2000).  
The clear involvement of αIIbβ3 in platelet adhesion and accumulation has 
made it a popular pharmacological target for the prevention of ischemic cardiovascular 
events. Antibodies including abciximab, peptides based on those isolated from venom 
of snakes such as eptifibitide, and analogues of an RGD-containing peptide (for 
example lamifiban and tirofiban) that constrain ligand binding are just some of the 
strategies that can be used to inhibit its function (Coller and Shattil, 2008). However, 
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due to excessive bleeding, these inhibitors are not used widely outside of the hospital 
(Quinn et al., 2003). 
1.4.1.6 VWF Receptor – GPIb-IX-V Complex 
 
Restricted to platelets and megakaryocytes, the structurally distinctive receptor 
complex GPIb-IX-V is expressed at a high level of 25,000 copies per platelet (Berndt 
et al., 2001). The genes that encode the receptor complex, GPIb α- and β-subunits, 
GPIX, and GPV, are all members of the leucine-rich repeat protein superfamily (Berndt 
et al., 2001). When first described, the complex was suggested to be made up of two 
GPIbα subunits, two GPIbβ subunits, two GPIX subunits and a single GPV subunit 
(Berndt et al., 2001). More recently, it was proposed that it exists as a molar ratio of 
2:4:2:1 of GPIbα, GPIbβ, GPIX, and GPV, respectively (Luo et al., 2007). 
Platelets are captured at the site of injury by reducing their velocity to allow the 
interaction of other receptors with the injured surface. This capturing function is carried 
out by GPIb-IX-V. The high shear rates observed in small arteries, arterioles, and 
stenosed arteries, coupled with the interaction of GPIbα and VWF restrained on 
collagen or on the surface of activated platelets is critical for the early tethering of 
platelets under flow (Savage et al., 1998). To facilitate stable adhesion, the activation 
of integrins is essential. Original reports suggested that the rapid on/off rate between 
GPIb-IX-V and VWF was not long enough to initiate signalling (Savage et al., 1996). 
However, more recent data reveal that weak intracellular signalling through Src family 
kinase and PLCγ2-related pathways is mediated by GPIb-IX-V and results in the 
activation of platelets and the development of αIIbβ3-mediated aggregates (Yap et al., 
2002, Mangin et al., 2003). First proposed by Ozaki et al, a theoretical GPIb-IX-V 
signal transduction pathway was anticipated to take place, principally in lipid rafts 
(Ozaki et al., 2005). In agreement with this model, GPIb-IX-V is constitutively linking 
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with the p85 subunit of PI 3-kinase via 14-3-3ζ, (Mangin et al., 2004, Mu et al., 2008). 
The interaction between PI 3-kinase and Src, which produces downstream signals, 
including activation of PLCγ2, is induced by the interaction between GPIb-IX-V and 
VWF. 
A condition known as Bernard-Soulier syndrome which is a congenital bleeding 
disorder described by mild thrombocytopenia, giant platelets and the incapability of 
platelets to form aggregates in response to the antibiotic ristocetin is suffered by humans 
missing or expressing dysfunctional GPIb, GPIb or GPIX subunits (Lopez et al., 
1998).  
A number of coagulation factors like thrombin and Factors XI, XII and VII, 
which may add to the severe bleeding defect shown by Bernard-Soulier syndrome 
patients, also bind to GPIb-IX-V (Dumas et al., 2003, Vanhoorelbeke et al., 2007). 
1.4.2 G Protein–Coupled Receptors 
 
Various GPCRs expressed by platelets play a vital role in controlling platelet 
activation (Woulfe, 2005, Offermanns, 2006). The platelet activation receptors which 
are the most significant are: (1) the thrombin protease-activated receptors (PAR)-1 and 
PAR-4; (2) the ADP receptors P2Y1 and P2Y12; and (3) the TxA2 receptor (TP) (Figure 
1-6).  
1.4.2.1 Thrombin receptors - Protease Activated Receptors (PARs) 
 
Thrombin (also called Factor IIa) is a soluble plasma serine protease produced 
as a result of a series of enzymatic reactions, usually called the ‘coagulation cascade’ 
that occurs on the surface of activated platelets (Hoffman and Monroe, 2001). Active 
thrombin is formed by the conversion of the inactive zymogen prothrombin; this active 
thrombin converts the soluble fibrinogen into insoluble fibrin polymers via its serine 
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protease activity. Thrombin is also classified as a dominant platelet agonist (Coughlin, 
2000). It activates platelets by cleaving PARs on platelet surfaces to expose peptide 
ligand that mediate platelet activation (Coughlin, 2005). Human platelets have two PAR 
receptors, PAR-1 and PAR-4 (Kahn et al., 1999). PAR-1 is the main thrombin receptor in 
humans but is not expressed in mice platelets, whereas PAR-4 is expressed in platelets of 
both humans and mice (Kahn et al., 1998). Almost 1,000 – 2,000 copies of PAR-1 are 
expressed by human platelets (Brass et al., 1992, Ramstrom et al., 2008). PAR-1 and 
PAR-4 can couple to the heterotrimeric G proteins Gq and G12/13 (Coughlin, 2000). PAR-
1 and PAR-4 activate PLCβ to produce IP3 and DAG, which subsequently release Ca2+ 
and activate PKC as described above. Both receptors are coupled to the Gq α-subunit. 
In addition, they activate the G12/13 pathway resulting in activation of Rho kinase which 
leads to cytoskeletal rearrangements (Coughlin, 2000). Downstream of the thrombin 
receptors, there is a minor Src kinase-dependent component to the signalling pathway 
which is G protein-coupled (Coughlin, 2000, Murugappan et al., 2005). Along with 
PAR-4, mouse platelets also express PAR-3, however this receptor does not mediate 
transmembrane signalling unlike its other family members. Instead, it acts as a cofactor 
that binds and localizes thrombin in close vicinity of PAR-4 in mouse platelets 
(Coughlin, 2000). 
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Figure 1-6 soluble agonists ADP, thrombin and TxA2 bind to their G protein coupled-
receptors. Gi, Gq, and G12/13: G proteins. DAG: 1,2-diacylglycerol, Rho-GEF: guanine 
nucleotide exchange factor, PLC-β: phospholipase, IP3: inositol 1,4,5-trisphosphate, PI3K: 
phosphatidylinositol 3-kinase, PIP2: phosphatidylinositol 4,5-bisphosphate, PIP3: 
phosphatidylinositol 3,4,5-triphosphate, PKC: protein kinase C. (Nieswandt et al., 2000). 
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1.4.2.2 ADP Receptors - P2Y1 and P2Y12 
 
ADP is released by activated platelets, red blood cells, and damaged endothelial 
cells at the site of vascular injury. ADP functions to improve platelet activation through 
a positive feedback mechanism and is important for the recruitment of platelets to a 
thrombus that is developing (Offermanns, 2006). P2Y1 and P2Y12 are the two ADP 
receptors expressed by platelets (Gachet et al., 2006). Human platelets express a low 
number of copies of P2Y1 (150 copies) and approximately ten-fold more of P2Y12. 
Studies using selective inhibition or deletion of one or the other receptor leads to a 
decrease in platelet aggregation, with co-activation of P2Y1 and P2Y12 essential for 
ADP-induced platelet activation (Gachet et al., 2006). Therefore, by working together, 
activation of these two receptors results in rapid and sustained platelet activation. P2Y12 
couples to the Gi heterotrimeric G protein α-subunits while P2Y1 couples to Gq (Gachet 
et al., 2006). Ca2+ mobilization, platelet shape alteration and weak, temporary 
aggregation in response to ADP are all initiated by the P2Y1 receptor (Gachet et al., 
2006). In contrast, P2Y12 inhibits the adenylyl cyclase-dependent reduction in 
intracellular cAMP levels and independently acivates PI3-kinase and Rap-1B (Gachet 
et al., 2006). Persistent platelet aggregation and intensification of signals mediated by 
other agonists, including collagen, TxA2 and the integrin αIIbβ3, are mediated by P2Y12 
activation (Gachet et al., 2006). It has also been reported that Src kinase are activated 
downstream of both the P2Y1 and P2Y12 receptors (Hardy et al., 2004, Shankar et al., 
2006).  
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1.4.2.3 Thromboxane A2 Receptor – TP 
 
To increase and sustain activation signals and to recruit more platelets to the site 
of thrombus formation, activated platelets release TxA2 which is a short-lived lipid 
mediator (Hamberg et al., 1975). TxA2 also plays a role as a potent vasoconstrictor 
(Francois et al., 2004). This lipid mediator is produced from prostaglandin H2 (PGH22) 
using thromboxane-A synthase in activated platelets (Nakahata, 2008, Huang et al., 
2004). Its lipid soluble nature allows for diffusion across the plasma membrane, thereby 
leaving the platelet and binding to the TxA2 receptor (TP) on the surface of either the 
same or other platelets in the locality, in an auto- and paracrine way, respectively (Davi 
and Patrono, 2007, Suzuki-Inoue et al., 2002, Shen and Tai, 1998). Platelet activation 
and release are brought about by signalling through the TP receptor. Like thrombin 
receptors PAR-1 and PAR-4, and the P2Y1 ADP receptor, the activated TP receptor in 
platelets couples mainly to the Gq and G12/13 α-subunits (Djellas et al., 1999). A minor 
Src signalling component has also been reported (Huang et al., 2004). Patients lacking 
or having low TxA2 production, exhibit a minor bleeding disorder demonstrating the 
significance of TxA2 as a positive feedback agonist (Mumford et al., 2010) (Dawood et 
al., 2012). In addition, the TP knockout mouse model has an extended bleeding time 
supporting these observations (Thomas et al., 1998). 
1.5 Fibrin  
 
Fibrin is formed from soluble fibrinogen through the action of thrombin. As the 
final product of the coagulation cascade, fibrin plays a crucial role in the formation of 
stable thrombi. The interaction between thrombin and fibrinogen occurs at the central 
domain region of fibrinogen. The binding leads to a cleavage in fibrinogen peptides Aα 
and Bβ, and the release of fibrinopeptide A (FpA) and fibrinopeptide B (FpB), 
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respectively, a process that forms fibrin from fibrinogen (Undas and Ariens, 2011, 
Mosesson, 2005). In solution, FpA is released first and more promptly than FpB. 
However, when fibrinogen is attached to a surface, FpA cleaved slower than FpB 
(Weisel and Litvinov, 2013, Undas and Ariens, 2011) .  
Thrombin has been reported to bind to fibrin at non-substrate high- and low-
affinity binding sites. The site of high-affinity binding is at the D domain of the γ’ 
chain, whereas that for low-affinity binding is at the E domain (Meh et al., 1996). 
Furthermore, the molecules released from the amino-terminal β15–42 fibrin sequence 
inhibit low-affinity thrombin binding. Hirudin, a peptide that inhibits thrombin activity, 
inhibits thrombin binding to fibrin at the high and low affinity sites (Meh et al., 1996). 
A low thrombin concentration leads to the formation of a thick fibrin fibre with high 
permeability, whereas a high thrombin concentration generates a thinner and less 
permeable fibrin fibre (Wolberg and Campbell, 2008). In addition, clinical studies have 
shown that an increase in thrombosis risk is linked to an increase in fibrin fibre density 
(Ariens, 2013). Thrombin also activates FXIII, a transglutaminase enzyme, which is 
known as a fibrin-stabilising factor that cross-links fibrin to form blood clots and 
support fibrinolysis resistance (Ariens, 2013, Weisel and Litvinov, 2013). Fibrin clots 
dissolve through the fibrinolytic system.  
The fibrinolytic system is initiated by the activation of plasminogen (PLG). 
Plasminogen is a plasma zymogen that circulates in the inactive form of plasmin. It is 
activated by the tissue PLG activator (tPA), which is released from endothelial cells, 
and the urokinase PLG activator (uPA) produced by the kidney and tumour cells. PLG 
binds to tPA on a fibrin surface to generate plasmin, which then cleaves fibrin at the 
Lys-X and Arg-X bonds to form soluble degradation products, such as D dimer and X, 
Y, D and E fragments. uPA has a lower affinity than tPA for binding to fibrin, and is 
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able to activate PLG in the presence or absence of fibrin. However, its activity is 
increased up to 10-fold in the presence of fibrin (Cesarman-Maus and Hajjar, 2005).  
Many studies have described the importance of fibrin in a variety of 
physiological processes including angiogenesis, inflammation and wound healing (van 
Hinsbergh et al., 2001, Mosesson, 2005, Dempfle and Mosesson, 2003, Jennewein et 
al., 2011). Fibrin has been shown to increase the production of cytokine and 
chemokines, and to regulate macrophage adhesion and leukocyte migration in 
inflammation (Petzelbauer et al., 2005, Szaba and Smiley, 2002).  
Fibrin has been shown to bind to platelets through αIIbβ3 receptors via the 
sequence ATWKTRWYSMKK, which is in the γC-peptide: this region binds to the 
αIIb -propeller domain. (Podolnikova et al., 2014). Polymerised fibrin has been shown 
to mediate adhesion and spreading of platelets (Hamaguchi et al., 1993).  
1.6 Platelet Inhibition 
 
To avoid undesirable thrombus development, platelets must be kept in a 
quiescent or ‘resting’ state in the peripheral circulation. This resting state is maintained 
by two major mechanisms which act via receptors for (1) prostacyclin (PGI2) and (2) 
nitric oxide (NO), both of which are released from endothelial cells. Immunoreceptor 
tyrosine-based inhibition motif (ITIM)-containing receptors (including PECAM-, G6b-
B and CEACAM1) expressed on the cell surface of platelets also inhibit platelet 
activation (Cicmil et al., 2002, Wong et al., 2009, Mori et al., 2008). However, they 
make a relatively small contribution to platelet inhibition in comparison to cAMP and 
cGMP elevation and so are not discussed in further detail. 
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1.6.1 PGI2 Receptor 
 
Prostaglandin I2 (PGI2) is produced by endothelial cells from PGH2 by 
prostacyclin synthase and constitutively released into the circulation of the body, a 
powerful inhibitor of platelet activation, adhesion, aggregation and secretion. It has a 
short half-life, exerts its effects on platelets near the vessel wall and is released in low 
concentrations (Jin et al., 2005). Gs-coupled PGI2 receptor initiates a signal cascade; 
the cAMP-dependent Ser/Thr protein kinase A (PKA) is activated by cAMP which is 
generated as a result of adenylyl cyclase activated by Gs. A number of the substrates 
for PKA which mediate platelet inhibition have been described and include vasodilator-
stimulated phosphoprotein (VASP) which interacts with many cytoskeletal proteins at 
focal adhesions (Niebuhr et al., 1997) and in stress fibres (Sudo et al., 2003, Price and 
Brindle, 2000) . 
1.6.2 Nitric oxide 
 
Constitutively synthesized and release by endothelial cells, and vital in 
maintaing platelets in a resting state, is nitric oxide (NO). This gaseous inhibitor 
diffuses through the platelet plasma membrane into the cytosol where it exhibits 
inhibitory effects via activation of soluble guanylyl cyclase. Subsequent generation of 
cGMP triggers activation of the Ser/Thr protein kinase G (PKG) in concert with 
increasing intracellular levels of cAMP which activate PKA (Walter et al. 2009). 
Platelet activation is repressed when VASP is phosphorylated by both PKG and PKA 
(Butt et al., 1994, Li et al., 2003). Furthermore, NO also inhibits activation of PLC and 
IP3-mediated mobilization of intracellular Ca
2+ (Gambaryan and Tsikas, 2015) . 
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1.7 Platelet Ligands 
 
Platelets can be activated also by a diverse range of stimuli that share little or 
no resemblance in structure to each other or to recognised ligands of platelet receptors, 
including diesel exhaust particles, various peptides (4N1-1 and Champs) and proteins 
(PAM3-CSK4) and large polysaccharides (e.g. fucoidan and dextran) as described 
below. 
1.7.1 Diesel exhaust particles (DEP) 
 
Air pollution has been shown to contribute to cardiovascular morbidity and 
mortality. Combustion of diesel fuel leads to the generation of gases and 
nanoparticulate matter with diameter <2.5 µm (PM2.5) and <100nm (PM0.1) (D'Amato 
et al., 2010). It is one of the major types of nanoparticles in ambient particulate materials 
that cause an impact on human health (Popovicheva, 2014). DEP are made up of 
spherical carbon nanoparticles that contain the organic carbon, organic materials 
sulphated, nitrate and polyaromatic hydrocarbons (PAH) and carry an electrical surface 
charge (Jung and Kittelson, 2005, D'Amato et al., 2010). Visualization of DEP by using 
transmission electron microscope shows that DEP is spherical in appearance and 
present as individual particles, complex agglomerates, chained agglomerates and 
simple agglomerates. DEP diameter range from 40-70nM (Solomon et al., 2013). DEP 
have been shown in different studies to be associated with respiratory disorders and 
cardiovascular disease (Nemmar et al., 2007, Nemmar et al., 2003, Poss et al., 2013). 
DEP have been reported to cross the lung epithelium and enter the blood stream and 
have been proposed to cause inflammation and to be cytotoxic (Boland et al., 1999, 
Suzuki-Inoue et al., 2006). Several studies have shown that DEP induce platelet 
aggregation and activation but the mechanism remains unknown (Nemmar et al., 2003, 
 
 
35  
Forestier et al., 2012, Solomon et al., 2013, Mourao-Sa et al., 2011b, Chaipan et al., 
2006a, Tang et al., 2010). 
1.7.2 Fucoidan 
 
Fucoidan is a sulphated polysaccharide. Fucoidan contains fucose, sulfate, 
uronic acid, galactose, glucose and xylose (Ale et al., 2011). It is composed of sulfate 
groups which bind to the 4-position of fucose residues (Chevolot et al., 1999). The 
relationship between fucoidan structure and platelets activation is not established. It is 
used widely for its anti-coagulant (Liu et al., 2006), anti-thrombotic (Zhu et al., 2010), 
and anti-oxidant effects (Wang et al., 2010). Fucoidan bioactivity, however, varies 
according to the algae used for extraction, due to differences in fucoidan structure and 
charge (Ale et al., 2011). It has been reported that inhibition of tissue factor pathway 
inhibitor (TFPI) by fucoidan lead to increase clotting in hemophilia A and B patients 
(Liu et al., 2006). Recently it is has been shown fucoidan extract from Fucus 
vesiculosus activate platelets (Manne et al., 2013). It is known that fucoidan binds to 
several receptors on macrophage membranes, including the Toll-like receptor-4 (TLR-
4), CD14, CR-3, and scavenging receptor (SR) (Teruya et al., 2009).   
1.7.3 Dextran 
 
Dextran is a bacterial polysaccharide produced primarily by the Leuconostoc 
strains, with L. mesenteroides NRRL B512F the main strain used in industrial preparations. 
It is a member of the glycosaminoglycans (GAGs) family and is used as a blood plasma 
volume expander (Abir et al., 2004) and as an anticoagulant in biological research 
(Zeerleder et al., 2002). The activity of dextran sulphate on platelet function has been 
shown using the PFA-100 closure time (CT) test. Samples that contain dextran cause a 
prolongation in CT with the collagen and ADP cartridge (Zeerleder et al., 2002). Dextran 
sulphate has no effect on platelet aggregation in platelet rich plasma to a variety of agonists 
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such as ADP and collagen, but aggregation is inhibited in response to ristocetin (Zeerleder 
et al., 2002). Furthermore, it has also been reported that dextran sulphate can affect 
secondary haemostasis by prolonging activated partial thromboplastin time (aPTT) and 
slightly increasing prothrombin time (PT) (Zeerleder et al., 2002). Recently dextran 
sulphate has been shown to activate platelets through SFKs (Getz et al., 2013a) .  
1.7.4 Pam3-CSK4 
 
Pam3-Cys-Ser-Lys4 (Pam3-CSK4) is a TLR1/TLR2 complex ligand. It is an 
artificial triacylated lipopeptide (LP), which mimics acylated amino terminus on 
bacterial pathogen LPs. It binds to TLR1/TLR2 leading to stimulation of the pro-
inflammatory transcription nuclear factor NF-(kB). Pam3-CSK4 has been shown to 
stimulate platelet aggregation and activation (Blair et al., 2009, Falker et al., 2014, 
Suzuki-Inoue et al., 2011, Severin et al., 2011a) through TLR2 dependent pathways 
leading to activation of αIIbβ3 and P selectin expression (Blair et al., 2009). Moreover, 
it has been shown that Pam3-CSK4 activates platelets through Src, Syk, LAT and PLCγ2 
(Falker et al., 2014).  
1.7.5 4N1-1 
 
Thrombospodin-1 (TSP1) is a glycoprotein stored in platelet α granules. It is 
released upon platelet activation. A minimal sequence from the C-terminal domain of 
TSP1, known as 4N1-1, promotes strong platelet activation including aggregation 
(Tulasne et al., 2001b). 4N1-1 stimulates a similar pattern of tyrosine phosphorylation 
similar to that used by GPVI including tyrosine phosphorylation of the FcRγ chain, 
Syk, SLP-76, and PLCγ2. Platelet activation by 4N1-1 is partially dependent on the 
FcRγ chain, suggesting that 4N1-1 may bind to GPVI and to a second receptor (Tulasne 
et al., 2001b). 
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1.7.6 Champs peptide 
 
Computed helical anti-membrane protein (Champs) is a method that is used to 
design a peptide that binds with high affinity to the helical trans-membrane of 
endogenous proteins. The αIIbβ3 Champs peptide, also called the integrin-activation 
peptide (IAP), was shown using biophysical fluorescence-based and functional assays, 
to bind specifically to αIIbβ3 and to induce platelet aggregation (Yin et al., 2007) . 
However, in human platelets, IAP has been shown to induce platelet activation through 
integrin αIIbβ3-dependent and independent pathways (Grygielska et al., 2009). In 
addition, and similar to other peptides including 4N1-1 and LSARLAF, IAP has the 
ability to activate platelets through the FcRγ chain, Syk and PLCγ2 (Grygielska et al., 
2009). 
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1.8 Aims of the thesis  
 
In previous publications it has been shown that a large number of structurally 
unrelated ligands have the ability to activate platelets; in most cases, the molecular basis 
of activation is unclear. The aim in this thesis is to investigate the signaling mechanisms 
of structurally diverse agonists, including DEP, fucoidan, dextran, Pam3CSK4, 4N1-1, 
and Champs peptide IAP, and specifically to test the hypothesis that they induce platelet 
activation through the receptors CLEC-2 and GPVI. Unexpectedly, this programme of 
work led to the led discovery that fibrin also activates GPVI and this has been 
characterized.  
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This chapter reports that sulphated polysaccharide, fucoidan is a novel platelet 
agonist that activates CLEC-2. In this paper I have shown that intermediate 
concentrations of fucoidan stimulate aggregation of mouse platelets. Platelets 
aggregation is blocked in mouse platelets deficient in CLEC-2. In addition, fucoidan 
stimulates tyrosine phosphorylation of human CLEC-2 (figure 2-6). I have prepared 
mouse and human platelets as shown in method of chapter 3. I have designed and 
performed experiments, analysed data relating to Figures 2-6. The other 
experiments were performed by one of the other authors in the manuscript. The 
manuscript was written by one of other authors. Fucoidan used in this chapter is 
same as the Fucoidan used in Chapter 3.  
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Abstract 
 
Fucoidan, a sulfated polysaccharide from Fucus vesiculosus, decreases bleeding 
time and clotting time in hemophilia, possibly through inhibition of tissue factor 
pathway inhibitor. However, its effect on platelets and the receptor by which 
fucoidan induces cellular processes has not been elucidated. In this study, we 
demonstrate that fucoidan induces platelet activation in a concentration-dependent 
manner. Fucoidan-induced platelet activation was completely abolished by the pan-
Src family kinase (SFK) inhibitor, PP2, or when Syk is inhibited. PP2 abolished 
phosphorylations of Syk and Phospholipase Cγ2. Fucoidan-induced platelet 
activation had a lag phase, which is reminiscent of platelet activation by collagen 
and CLEC-2 receptor agonists. Platelet activation by fucoidan was only slightly 
inhibited in FcRγ chain null mice, indicating that fucoidan was not acting primarily 
through GPVI receptor. On the other hand, fucoidan-induced platelet activation was 
inhibited in platelet-specific CLEC-2 knock-out murine platelets revealing CLEC-
2 as a physiological target of fucoidan. Thus, our data show fucoidan as a novel 
CLEC-2 receptor agonist that activates platelets through a SFK dependent signaling 
pathway. Furthermore, the efficacy of fucoidan in hemophilia raises the possibility 
that decreased bleeding times could be achieved through activation of platelets.  
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2.1 Introduction  
 
Platelets act as essential mediators in maintaining homeostasis of the circulatory 
system, and their activation is tightly regulated in vivo under normal physiological 
conditions. However, when there is vascular damage, exposure of subendothelial 
collagen facilitates platelet activation, mainly through the glycolprotein VI receptor 
(GPVI), which is essential for hemostasis (Packham, 1994, Broos et al., 2012, 
Clemetson, 2012). Failure of platelet activation leads to excessive bleeding. Subsequent 
to platelet activation, coagulation proteins are activated resulting in thrombin 
generation and fibrin clot formation (Shuman and Levine, 1978). Deficiencies in 
coagulation proteins also lead to bleeding diathesis. For example, hemophilia A is a 
bleeding disorder in which the patient has an increased bleeding tendency due to factor 
VIII absence or dysfunction (Zimmerman and Fulcher, 1985, Zimmerman et al., 1971). 
Sulfated polysaccharides of natural origin, which are characterized by their 
biological activities, have a favorable therapeutic profile in animals and humans 
because most have minimal side effects. These polysaccharides are composed of a 
broad range of subclasses similar to heparins, glycoaminoglycans, fucoidan, dermatan, 
or dextran sulfates (Zimmerman et al., 1971). Notably, compounds of natural origin 
exhibit different biological activities depending on the concentration or dose (Liu et al., 
2006, Prasad et al., 2008). Fucoidan, a non-anticoagulatory sulfated polysaccharide, is 
derived from the brown seaweed Fucus vesiculosus. When compared with other 
sulfated polysaccharides, fucoidan demonstrates superior procoagulant properties 
(Zimmerman et al., 1971, Tsuji et al., 1997, Suzuki-Inoue et al., 2006). Pharmacological 
activity of this compound was tested in several animal models in vitro and in vivo. In 
humans, in vitro experiments with fucoidan demonstrated several beneficial effects on 
ulcers and bleeding disorders (Suzuki-Inoue et al., 2006, Sobanov et al., 2001). Non-
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anticoagulatory sulfated polysaccharides were originally considered as a novel 
approach to improve coagulation because of their inhibitory effect on physiological 
anticoagulation, especially fucoidan, which inhibits tissue factor pathway inhibitor and 
accelerates clotting in hemophilia A and B patients (Liu et al., 2006). Therefore, 
fucoidan is in clinical trials as a new candidate drug for hemophilia patients. In prior 
studies, fucoidan was shown to enhance the survival rate in murine models of 
hemophilia A and B (Liu et al., 2006) and a canine model of hemophilia A (Prasad et 
al., 2008) by decreasing bleeding times. However, the effect of fucoidan on platelet 
aggregation, which regulates bleeding times, has not been studied. 
GPVI signaling in platelets depends on FcR γ-chain activation leading to 
tyrosine kinase pathways resulting in the activation of Syk and PLC γ2(Tsuji et al., 
1997). C-type lectin-like receptor 2 (CLEC-2), also linked to activation of Syk and PLC 
γ2 (Suzuki-Inoue et al., 2006), is highly expressed in platelets and at lower levels in 
neutrophils and dendritic cells (Sobanov et al., 2001, Colonna et al., 2000). CLEC-2 
was identified by using the snake venom protein rhodocytin, purified from 
Calloselasma rhodostoma (Suzuki-Inoue et al., 2006), as a ligand on affinity 
chromatography, and later shown to be an endogenous receptor for podoplanin. The 
crystal structure of rhodocytin shows that CLEC-2 receptors are activated through 
clustering by this tetrameric ligand (Watson et al., 2008, Hooley et al., 2008, Watson et 
al., 2009). CLEC-2 and podoplanin are implicated in tumor metastasis (Christou et al., 
2008, Suzuki-Inoue, 2011) and hemostasis and thrombosis (May et al., 2009). Unlike 
GPVI, CLEC-2 has an immunoreceptor tyrosine-based activation motif (hemITAM) 
sequence that is phosphorylated by Src and Syk tyrosine kinases, whereas 
phosphorylation of the ITAM is mediated solely by Src kinases (Spalton et al., 2009b). 
Rhodocytin and podoplanin are the only two known agonists for the CLEC-2 receptor 
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(Christou et al., 2008, Watson and O'Callaghan, 2011, Suzuki-Inoue et al., 2007b). In 
the present study, we show that fucoidan causes platelet activation, leading to αIIbβ3 
mediated aggregation. We show that fucoidan signals through a tyrosine kinase-
dependent signaling pathway downstream of CLEC-2 receptor and propose that this 
contributes to a decrease in bleeding time in hemophilia animal models. These results 
support the notion that decreased bleeding times can be achieved in hemophilia patients 
through activation of platelets. 
 
2.2 Materials and Methods 
 
All animal experiments were performed in compliance with the Institutional Animal 
Care and Use Committee at Temple University (Philadelphia, PA). 
2.2.1 Mice 
 
Platelet specific CLEC-2 knock-out mice were produced as described previously 
Briefly, the CLEC-2 gene (CLEC1b) was flanked with LoxP sites, and this mouse 
was cross-bred with a PF4-Cre expressing mouse to drive excision of the gene in 
only the megakaryocyte/platelet lineage. 
2.2.2 Materials 
 
Apyrase (type VII), acetylsalicylic acid, fucoidan (80% pure, with the major 
contaminant being fucose), and indomethacin were obtained from Sigma. 
Convulxin was purified as described (Francischetti et al., 1997). YM-254890 was a 
gift from Yamanochi Pharmaceutical Co., Ltd (Ibaraki, Japan). FURA-2 AM was 
from Molecular Probes (Eugene, OR). PP3 and PP2 were purchased from Biomol 
Research Laboratories (Plymouth Meeting, PA). OXSI-2 was from Calbiochem 
(Darmstadt, Germany). Whatman protein nitrocellulose transfer membrane was 
obtained from Fisher Scientific (Pittsburgh, PA), LI-COR Odyssey blocking buffer 
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was purchased from LI-COR Biosciences (Lincoln, NE). Antibodies to Syk 
(Tyr
525/526
), PLC γ2 (Tyr
759
), Lat (Tyr
191
), and f3-actin were bought from Cell Sig- 
naling Technology (Beverly, MA), Total Syk and Lat antibodies were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal mouse anti-CLEC-2 
antibody was obtained from Santa Cruz Biotechnology. FITC-labeled PAC-1and 
mouse IgG isotype control antibodies were obtained from BD Technologies 
(Franklin Lakes, NJ). P-selectin-PE antibodies were purchased from BD 
Biosciences. 
2.2.3 Preparation of Human Platelets 
 
Blood was collected from informed healthy volunteers in to one-sixth volume of 
acid/ citrate/dextrose (2.5 g of sodium citrate, 2 g of glucose, and 1.5 g of citric acid 
in 100 ml deionized water). Platelet-rich plasma was obtained by centrifugation at 
250 X g for 20 min at ambient temperature and incubated with 1 mM aspirin for 30 
min at 37°C. Platelets were isolated from plasma by centrifugation at 980 X g for 
10 min at ambient temperature and resuspended in Tyrode’s buffer, pH 6.5 (138 
mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 0.42 mM NaH2PO4, 5 mM glucose, 10 
mM PIPES (pH 6.5) containing 20 nM PGE1, 10 µM indomethacin, 500 µM 
EGTA, and 0.2 units/ml apyrase,). Platelets were isolated from Tyrode’s buffer, pH 
6.5, by centrifugation at 980 X g for 10 min and resuspended in Tyrode’s buffer, pH 
7.4 (138 mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 0.42 mM NaH2PO4,5 mM glucose, 
10 mM HEPES, and 0.2 units/ml apyrase, pH 7.4). The platelet count was adjusted 
to 2–2.5 X 10
8
/ml. Approval was obtained from the institutional review board of 
Temple University for these studies. Informed consent was provided prior to blood 
donation. 
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2.2.4 Preparation of Murine Platelets 
 
All mice were maintained in a specific pathogen-free facility, and animal procedures 
were carried out in accordance with institutional guidelines after the Temple 
University Animal Care and Use Committee approved the study protocol, or they were 
performed under UK Home Office Project license (PPL 40/2803). Fccer1g (FcRγ 
knock-out) or γ-chain-deficient mice were purchased from Taconic (Germantown, 
NY). Age and gender-matched wild-type mice were used as controls. Blood was 
drawn via cardiac puncture into one-tenth volume of 3.8 % sodium citrate. Blood was 
spun at 100 X g for 10 min, and the platelet rich plasma (PRP) was separated. Red 
blood cells were mixed with 400 µl of 3.8 % sodium citrate and spun for a further 10 
min at 100 X g. Resulting platelet rich plasmas (PRPs) were combined, and 1 µM 
PGE1 added and centrifuged for 10 min at 400 X g. Platelet poor plasma was removed, 
and the platelet pellet was resuspended in Tyrode’s buffer (pH 7.4) containing 0.2 
units/ml apyrase. Platelet counts were determined using a Hemavet 950FS blood cell 
counter (Drew Scientific Inc., Dallas, TX). For aggregation studies, a density of 2 X 
10
8 platelets/ml was used. 
2.2.5 Platelet Aggregation 
 
Platelet aggregation was measured using a lumi-aggregometer (Chrono-Log, 
Havertown, PA) at 37°C under stirring conditions. A 0.5-ml sample of aspirin- 
treated washed platelets was stimulated with different agonists, and change in light 
transmission was measured. Platelets were preincubated with different inhibitors 
where noted before agonist stimulation. The chart recorder was set for 0.2 mm/s. 
2.2.6 Measurement of Intracellular Ca
2+ Mobilization 
 
Platelet- rich plasma was incubated with 5 µM Fura-2/AM and 1 mM aspirin for 45 
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min at 37°C. Platelets were prepared as described above, and fluorescence was 
measured in a Perkin-Elmer apparatus with excitation set at 340 nm and emission set 
at 510 nm. Fluorescence measurements were converted to Ca
2+ concentrations using 
the equation as reported (Grynkiewicz et al., 1985).  
 
2.2.7 Flow Cytometry 
 
Washed and aspirin-treated human platelets were used to measure agonist-dependent 
levels of αIIbβ3 activated receptor by PAC-1-FITC antibody and CD62P-PE 
antibody. Aliquots (0.5 ml) of washed platelet suspension in Tyrode’s buffer (pH 
7.4) containing 1 mM CaCl2 were preincubated with the indicated concentration of 
inhibitors for 5 min at 37°C. Prior to the activation with fucoidan, an aliquot 
containing 10
6 platelets was gently mixed with 40 µl of anti-body mixture and 
incubated for 20 min at 37°C in the dark. Platelets were identified and gated 
according to the forward and side scatter signals. As control for immunolabeling, 
platelets were incubated with non-immuno-IgG isotype control antibody. To fix the 
platelets, 1 % parafarmaldehyde dissolved in phosphate-buffered saline was added. 
A total of 10,000 platelet events were acquired per sample, and the percentage of 
positive gated cells was analyzed. All determinations were performed on a FACS 
Caliber flow cytometer (BD Biosciences). 
2.2.8 Immunoprecipitation 
 
Washed human platelets (1 X 10
9
/ ml) were stimulated with rhodocytin (50 nM) or 
fucoidan (50 µg/ml). Reactions were terminated by adding equal volume of 2X 
Nonidet P-40 lysis buffer (20 mM Tris-HCl, pH 7.6, 300 mM NaCl, 2 mM EGTA, 2 
mM EDTA, 2% Nonidet P-40, 2 mM PMSF, 5 mM Na3VO4, 10 µg/ml leupeptin, 
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10 µg/ml aprotinin, 1µg/ml pepstatin). Cell debris was removed by centrifugation 
at 15,000 X g for 10 min. Antibodies against CLEC-2 (5 µg/ml) or control IgG were 
added to the resultant supernatant and incubated overnight with protein A 
Sepharose. Precipitated proteins were separated by SDS-PAGE and Western blotted 
with the 4G10 antibody. 
2.2.9 Western Blot Analysis 
 
Platelets were stimulated with agonists in the presence of inhibitors or vehicles for the 
appropriate time under stirring conditions at 37°C, and the reaction was stopped by 
the addition of 0.6 N HClO4. The resulting acid precipitate was collected and kept 
on ice. The samples were centrifuged at 13,000 X g for 4 min followed by 
resuspending in 0.5 ml of deionized water. The protein was again pelleted by 
centrifugation at 13,000 X g for 4 min. The protein pellets were solubilized in sample 
buffer containing 0.1 M Tris, 2% SDS, 1% (v/v) glycerol, 0.1% bromphenol blue, 
and 100 mM DTT and then boiled for 10 min. Proteins were resolved by SDS-poly 
acrylamide gels and transferred to nitrocellulose membrane (Whatman Protran). 
Membranes were blocked with Odyssey blocking buffer for1h at ambient 
temperature, incubated overnight at 4°C with the desired primary antibody, and then 
washed four times with TBS-T. Membranes were then incubated with appropriate 
secondary infrared dye-labeled antibody for 60 min at room temperature and 
washed four times with TBS-T. Membranes were examined with a Li-Cor Odyssey 
infrared imaging system. 
2.2.10 Statistical Analysis 
 
Each experiment was repeated at least three times. Results are expressed as means ± 
S.E. with number of observations (n). Data were analyzed using KaleidaGraph 
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software. Significant differences were determined using Student’s t test. Differences 
were considered significant at p < 0.05.
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2.3 Results 
 
2.3.1 Fucoidan Causes Platelet Activation 
 
As fucoidan reduced bleeding times in hemophilia animal models (Liu et al., 2006, 
Prasad et al., 2008), we evaluated whether fucoidan can cause platelet activation. 
Fucoidan caused aggregation of washed human platelets in a concentration-
dependent manner (Fig. 1A). Fucoidan caused only shape change at a concentration 
of 10 µg/ml, whereas maximum aggregation was achieved at 50 µg/ml (Fig. 2-1A). 
We also evaluated the effects of fucoidan on other platelet functional responses, 
including integrin activation (Fig. 2-1B), dense granule secretion (Fig. 2-1C), P-
selectin expression (Fig. 2-1D), and thromboxane generation (Fig. 2-1E) in human 
platelets. These results show that fucoidan causes platelet activation. 
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Figure 2-1 Fucoidan-induced platelet responses. (A) Washed aspirin-treated human platelets 
were stimulated with increasing concentrations of fucoidan at 37°C under stirring conditions. 
Platelet aggregation was measured using a Lumi aggregometer. The traces are representative 
of data from at least three independent experiments. (B) fucoidan-induced αIIbβ3 activation 
was measured by activating washed, aspirin-treated human platelets with fucoidan (50 μg/ml) 
and analyzed with FITC-PAC1 antibody by flow cytometry. (C) Dense granule secretion was 
assessed by measuring fucoidan-induced (50 μg/ml) ATP release from human platelets. (D) α 
granule expression was measured by CD62P (P-selectin) expression in response to fucoidan 
(50 μg/ml) and was analyzed using flow cytometry. Graphs represent mean ± S.E. of % positive 
cells from at least three different experiments (***, p ≤ 0.05). (E) Washed human platelets 
without aspirin treatment were stimulated in a platelet aggregometer, and levels of TXB2 were 
determined according to established protocol (Shankar et al., 2006). 
 
 
61  
2.3.2 Role of Src Family Kinase (SFK) dependent Pathways in Fucoidan-
induced Platelet Activation  
 
Many platelet surface receptors, which mediate positive functional responses, are 
coupled to either Gqdependent or tyrosine kinase-dependent pathways (Brass, 2010) 
. To determine the signaling mechanism involved in fucoidan-induced platelet 
activation, we used the selective Gq inhibitor YM-254890 (Uemura et al., 2006, 
Kawasaki et al., 2006) or the pan SFK inhibitor PP2 (Li et al., 2010). Platelets 
pretreated with YM-254890 had only a minimum reduction in aggregation in 
comparison with the full inhibition of aggregation to AYPGKF (Fig. 2-2A), 
suggesting that the Gq pathway plays a minimal role in the activation of platelets 
by fucoidan, presumably through the feedback action of TxA2. As shown in Fig. 2-
2B, fucoidan induced platelet activation was completely abolished by PP2 but not 
by its inactive analog, PP3. These data demonstrate that SFK-dependent pathways 
are required for fucoidan-induced platelet activation. It is known that SFK-mediated 
signaling pathways involve activation and phosphorylation of Syk and Lat in 
platelets (Speich et al., 2008, Pasquet et al., 1999). Therefore, we evaluated the 
phosphorylation status of Syk and Lat following stimulation of platelets with 
fucoidan. As shown in Fig. 2-3A, Syk and Lat phosphorylations occurred as early 
as 15 s and dephosphorylated in a time-dependent manner. Fucoidan-induced Syk 
and Lat phosphorylations were abolished by pretreatment of platelets with PP2 (Fig. 
2-3B). These data support our observation that fucoidan-mediated signaling 
pathways involve Syk and Lat activation downstream of SFKs. Intracellular Ca
2+ 
mobilization was also measured in response to fucoidan in the presence of the pan 
SFK inhibitor PP2. PP2 completely blocked calcium mobilization compared with 
control (PP3) platelets (Fig. 2-3C). These data suggest that fucoidan activates a 
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SFK-dependent pathway leading to intracellular Ca
2+ mobilization.  
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Figure 2-2 Role of Src family tyrosine kinase (SFK)-dependent pathways in fucoidan-
induced platelet activation. (A) Washed, aspirin-treated human platelets were incubated 
with YM-254890 (50 nm), a selective Gq inhibitor, for 5 min and stimulated with fucoidan 
(50 μg/ml) for 3 min at 37°C under stirred conditions. Platelet aggregation was measured 
using lumi-aggregometer. The traces are representative of data from at least three 
independent experiments.( B) washed, aspirin-treated human platelets were pretreated with 
SFK inhibitor PP2 (10 μm) or PP3 (control) at 37 °C for 5 min followed by stimulation 
with fucoidan (50 μg/ml) for 3 min under stirred conditions. Platelet aggregation was 
measured by aggregometry. The tracings are representative of data from at least three 
independent experiments. DMSO, dimethyl sulfoxide.  
 
 
64  
 
 
 
Figure 2-3 Effect of SFK inhibition on fucoidan-induced platelet activation.  
(A) fucoidan-induced phosphorylation of Syk and Lat. Washed, aspirin-treated human 
platelets were stimulated with fucoidan (50 μg/ml) for different time periods. Samples 
were subjected to SDS-PAGE and analyzed for phosphorylation of Syk and Lat. The results 
are representative of data from platelets at least three independent experiments. (B) 
Washed, aspirin-treated human platelets were stimulated with fucoidan (50 mg/ml) in the 
presence of the SFK inhibitor PP2 for 30 s, and the effect on Syk (Y525/26) and LAT 
(Y191) phosphorylation were analyzed. C, washed, aspirin-treated human platelets 
loaded with 5 μm FURA-2 AM were pretreated with PP3 or PP2 (10 μm) and 
activated with fucoidan (50 μg/ml) to measure intracellular Ca2+ mobilization.  
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2.3.3  Syk Mediates Platelet Activation by Fucoidan 
 
The functional role of Syk in signaling by fucoidan was investigated by pretreating 
platelets with the Syk inhibitors OXSI-2 or Go6976 (Getz et al., 2011, Bhavaraju et 
al., 2008). Fucoidan-induced platelet activation was completely inhibited when 
treated with the Syk inhibitors, which was measured by percentage PAC1 binding 
using flow cytometry (Fig. 2-4A). To determine whether or not OXSI-2 was 
affecting the activity of SFKs, phosphorylation of Tyr
416 (marker of SFK 
activation) was examined under similar experimental conditions. As demonstrated 
in Fig. 4B, SFK phosphorylation was not effected when a Syk inhibitor, OXSI-2 or 
Go6976, was used. The critical role of Syk in signaling by fucoidan was illustrated 
by the lack of PLCγ2 phosphorylation, which is an important downstream 
signaling molecule (Fig. 2-4, C and D). Furthermore, fucoidan-induced intracellular 
Ca
2+ mobilization was completely abolished in the presence of either Syk inhibitor 
OXSI-2 or Go6976 (Fig. 2-4E). Inhibition of fucoidan-induced platelet activation 
by OXSI-2 or Go6976 suggests that Syk is an important downstream signaling 
molecule in fucoidan-induced platelet activation.  
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Figure 2-4 The role of Syk in fucoidan-induced aggregation, calcium mobilization, and 
αIIbβ3 activation. (A) Washed, aspirin-treated human platelets were pretreated with vehicle (dimethyl 
sulfoxide), OXSI-2 (2 μM), or Go 6976 (1 μM) for 5 min at 37°C prior to activation with convulxin (CVX; 
100 ng/ml) or fucoidan (50 μg/ml) (US-unstimulated). αIIbβ3 expression was analyzed with PAC-1-FITC 
antibody. Graphs are represented mean ± S.E. of % positive cells from three different experiments (***, p < 
0.01). (B) the effect of Syk inhibitors (OXSI-2 or Go 6976) on SFK phosphorylation induced by fucoidan (50 
μg/ml) in human platelets was analyzed.( C) time course analysis of PLCγ2 tyrosine phosphorylation from 
aspirin-treated human platelets stimulated with fucoidan (50 μg/ml). (D) Platelets were stimulated with 50 
μg/ml of fucoidan for 1 min. PLCγ2 tyrosine phosphorylation was measured in the presence of OXSI2, Go6976, 
or dimethyl sulfoxide. E, washed, aspirin-treated human platelets loaded with 5 μm FURA-2 AM were 
pretreated with OXSI-2 (2 μM) or Go 6976 (1 μM) and activated with fucoidan (50 μg/ml) to measure the 
effect of Syk inhibition in Ca2+ mobilization  
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2.3.4 Fucoidan Mediates Platelet Functional Responses through CLEC-2 
 
The major receptors that trigger tyrosine kinase pathways in platelets are GPVI 
and CLEC-2 (Watson et al., 2005b, Watson et al., 2010, Hsu et al., 2001). Upon 
ligation of collagen to GPVI, the FcR γ-chain ITAM becomes phosphorylated by 
SFK members to initiate downstream signaling (Ezumi et al., 1998). Data 
presented in Figs. 2 and 3 suggest that the profile of activation by fucoidan is 
similar to that of GPVI. Previously, it was shown that FcR γ-chain-null platelets 
are not only unresponsive to collagen but also show no surface expression of GPVI 
(Jarvis et al., 2002). To evaluate whether fucoidan signals through GPVI, we made 
use of FcR γ-chain-null murine platelets. Wild type murine platelets aggregate in 
response to collagen-related peptide (10 µg/ml) (Fig.2-5A), whereas addition of 
collagen related peptide to FcR γ-chain null murine platelets failed to induce 
platelet aggregation (Fig.2-5A). Interestingly, fucoidan induced aggregation 
observed in FcR γ-chain null murine plate- lets was similar when compared with 
wild type murine platelets (Fig.2-5A). FcγRIIa is not present in murine platelets 
but does exist in human platelets. We therefore tested the role of this receptor by 
using the IV.3 monoclonal antibody that binds and blocks FcγRIIa. Blocking of 
FcγRIIa by IV.3 antibody did not affect fucoidan-induced platelet activation (Fig. 
2-5B). These data suggest that fucoidan does not mediate its effects primarily 
through the GPVI or FcγRIIa receptor.CLEC-2, a C-type lectin receptor, has been 
shown to signal independently of the FcR γ-chain in platelets (Watson et al., 2009, 
Watson et al., 2010). The presence of Syk phosphorylation (Hughes et al., 
2010c)and detectable levels of Lat phosphorylation in platelets activated with 
fucoidan (Fig.2-3) suggested that CLEC-2 (Hughes et al., 2008) may be a possible 
receptor candidate for fucoidan on platelets. To determine whether CLEC-2 is the 
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receptor that mediates fucoidan-induced platelet activation, platelet-specific (PF4-
Cre) CLEC-2 receptor knock-out mice platelets were used. Wild-type murine 
platelets aggregated in response to fucoidan, but fucoidan failed to induce platelet 
activation in CLEC-2 receptor null mice (Fig.2-6A). Furthermore, tyrosine 
phosphorylation of the CLEC2 receptor was observed in immunoprecipitation 
studies when washed human platelets where activated with either rhodocytin or 
fucoidan (Fig. 2-6B), suggesting that fucoidan mediates platelet functional 
responses through the CLEC-2 receptor. We thus propose a model for the 
signaling events induced by fucoidan through the CLEC-2 receptor (Fig. 2-7).  
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Figure 2-5 Fucoidan does not activate GPVI or FcγRIIa. (A) Fucoidan-induced platelet 
aggregation on FcR γ-chain-null murine platelets. Wild-type or FcR γ-chain-null murine 
platelets were stimulated with fucoidan (50 μg/ml) and CRP (Collagen Related Peptide) 
allowed to aggregate for 3 min at 37°C under stirred conditions in a Lumi-aggregometer. 
The traces are representative of data from at least three independent experiments. (B) 
Human platelets were stimulated with fucoidan (50 μg/ml) in the absence and presence of 
IV.3 monoclonal antibody (10 μg/ml) for 3 min. The traces are representative of data from 
at least three independent experiments.  
 
 
70  
 
 
 
Figure 2-6 Fucoidan-induced platelet responses are mediated by CLEC-2 receptor.  
(A) Wild-type or CLEC-2 knock-out platelets (2 × 108/ml) were stimulated with fucoidan 
(50 μg/ml) and allowed to aggregate at 37°C under stirred conditions in a Lumi-
aggregometer (n = 10). (B) Washed human platelets (1 × 109/ml) were stimulated with 100 
nm rhodocytin or 50 μg/ml fucoidan. Reaction was terminated by addition of an equal 
volume of 2× lysis buffer. Platelet lysates were precleared, and detergent-insoluble debris 
were removed using centrifuge. Antibodies against CLEC-2 were added to the resultant 
supernatant and incubated overnight with protein A Sepharose. Precipitated proteins were 
separated by SDS-PAGE and Western blotted (WB) with the phosphotyrosine antibody. 
The data are a representation of three experiments.  
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2.4 Discussion 
 
Fucoidan, a sulfated polysaccharide from a brown seaweed, decreases bleeding 
time and clotting time in hemophilia (Liu et al., 2006, Prasad et al., 2008). 
Decreased bleeding times in the hemophilia animal models by in vivo 
administration of fucoidan highlights the beneficial effect of fucoidan as a novel 
treatment (Prasad et al., 2008). Furthermore, in vitro studies by using platelet 
poor plasma from hemophilia animal models and human patients have showed 
that fucoidan inhibits tissue factor pathway inhibitor, thereby contributing to an 
increase in the extrinsic coagulation pathway activity (Liu et al., 2006). The 
effect of fucoidan on platelets, however, has not been studied. In the current 
work, we investigated whether or not fucoidan induces platelet activation and if 
so, what is the receptor that is mediating these signaling events. Our results 
suggest that fucoidan induces platelet activation (Fig.2-1) through a tyrosine 
kinase-dependent pathway (outlined in Fig.2-7). Using pharmacological 
inhibitors, we have shown that SFKs and Syk are crucial for fucoidan-induced 
platelet activation (Figs. 2-2 and 2-3). Our data from platelet-specific CLEC-2 
receptor knock-out murine platelets suggest that CLEC-2 is the physiological 
receptor for fucoidan on platelets (Fig. 2-6A), thereby providing a novel CLEC-
2 receptor agonist other than rhodocytin and podoplanin. 
Previous studies suggest that fucoidan induced platelet activation was 
regulated by two important factors, molecular weight of the compound and the 
difference in sulfate content (Durig et al., 1997). Our results suggest that fucoidan, 
derived from the brown seaweed Fucus vesiculosus, with a high molecular weight 
of 150 –200 kDa and low sulfate content of 8 –11%, induces platelet activation 
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through a tyrosine kinase-dependent pathway that is mediated through the CLEC-
2 receptor (Figs. 2-1 and 2-6). Previously, fucoidan has been shown to have 
antithrombotic effects (Millet et al., 1999, Trento et al., 2001, Durand et al., 2008). 
The reason for such opposite effects of fucoidan on platelets may be due to 
different molecular weights of fucoidan. When platelets are stimulated with 
fucoidan, we see a lag phase, which is reminiscent of GPVI- or CLEC-2 mediated 
activation. Recent studies have shown that the antibody to CLEC-2 induces 
dimerization of the receptor, generating a weak intracellular signal. The further 
clustering of CLEC-2 with a secondary antibody induces rapid and powerful 
activation. Similarly, tetrameric rhodocytin and polymeric podoplanin induce a 
much greater degree of receptor clustering (Watson et al., 2008, Hooley et al., 
2008, Watson and O'Callaghan, 2011). Low molecular weight fucoidan may bind 
to CLEC-2 but may not be able to induce the clustering of the receptors that is 
necessary for platelet activation (Jarvis et al., 2002), whereas high molecular 
weight fucoidan induces rapid receptor clustering and platelet activation. This 
clustering effect is also dependent on the concentration of high molecular weight 
fucoidan added to platelets as shown in Fig. 2-1. 
In our effort to elucidate signaling pathways by which fucoidan activates 
platelets, we have characterized a tyrosine kinase-dependent pathway, which 
leads to αIIbβ3 activation (Fig.2-1B). We also show that key signaling molecules, 
SFKs and Syk, are crucial for fucoidan-induced platelet activation (Figs.2-4). 
Downstream of the GPVI or CLEC-2 receptor, Syk kinase has been shown to 
play an important role in activating other effectors, which ultimately leads to the 
activation of αIIbβ3 (Hughes et al., 2010b, Suzuki-Inoue et al., 2004). Inhibition 
of Syk following GPVI stimulation shuts down all functional responses. 
 
 
73  
Consistent with the previous studies, we observed significant inhibition of PAC-
1 binding in fucoidan-stimulated platelets in the presence of the Syk inhibitor 
OXSI-2 (32) or G06976 (Fig. 4A) (Getz et al., 2011). Platelet activation with 
fucoidan in the presence of the tyrosine kinase inhibitor PP2 also showed 
inhibition of platelet activation (Fig. 2-2). These results suggest for the first time 
that fucoidan-induced platelet activation depends on SFK- and Syk-dependent 
pathways. Fucoidan is known to activate cells such as macrophages and nerve 
cells (Brandenburg et al., 2010, Gao et al., 2012, Jhamandas et al., 2005), but the 
receptor that mediates these signaling events has not been elucidated. Fucoidan 
is considered as one of the agonists for scavenger receptor A in macrophages 
(Hsu et al., 2001) and other cell lines, but to our knowledge, scavenger receptor 
A has not been identified in platelets. Low molecular weight fucoidan was also 
been reported to bind to P-selectin (Molecular Imaging and Contrast Agent 
Database). In resting platelets, however, P-selectin is located on the inner wall of 
denes granules (Koedam et al., 1992, Mazurov et al., 1996) and is only exposed 
on the surface of platelets after activation. Therefore, fucoidan must first activate 
platelets through a receptor to expose P-selectin. Considering all our results, it is 
evident that fucoidan activates platelets through a tyrosine kinase-dependent 
receptor. The major receptors that can trigger tyrosine kinase pathways in 
platelets are GPVI, FcγRIIa, and CLEC-2(Watson et al., 2009, Watson et al., 
2010). Of these, the GPVI receptor signaling depends on the FcR γ-chain (Jarvis 
et al., 2002). However, our data show that platelets lacking the FcR γ-chain are 
unresponsive to collagen-related peptide but still retain their ability to aggregate 
in response to fucoidan (Fig.2-5A). Also, fucoidan is able to induce human 
platelet activation in the presence of the monoclonal antibody IV.3 (Fig.2-5B), 
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which blocks FcγRIIa, and fucoidan also induces activation of murine platelets, 
which lack FcγRIIa. These results suggest that fucoidan does not mediate 
signaling through GPVI or FcγRIIa. CLEC-2 is a C-type lectin receptor that has 
been shown to signal independently of the FcR γ-chain in platelets (Watson et 
al., 2009, Watson et al., 2010). We observed inhibition of platelet functional 
responses in platelet-specific (PF4) CLEC-2receptor knock-out platelets when 
stimulated with fucoidan (Fig. 2-6A). To further support our conclusion that 
fucoidan induces platelet activation through the CLEC-2 receptor, we observed 
fucoidan-induced tyrosine phosphorylation of the CLEC-2 receptor (Fig. 2-6B). 
These results show for the first time that fucoidan mediates platelet activation 
through the CLEC-2 receptor. These results not only support a role for fucoidan as 
a novel drug for hemophilia treatment but also provide a new efficient agonist 
for the CLEC-2 receptor on platelets other than podoplanin and rhodocytin. In 
conclusion, fucoidan is a novel CLEC-2 receptor agonist that activates platelets 
through an SFK-dependent signaling pathway (as outlined in Fig.2-7). The 
stimulatory action of fucoidan on platelets strongly indicates that it may play an 
important role in platelet activation under diseased conditions such as hemophilia.  
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Figure 2-7 Model depicting tyrosine kinase-dependent signaling pathway in platelets 
activated with fucoidan.Fucoidan activates platelets through an SFK-dependent pathway 
through the CLEC-2 receptor. YP represents tyrosine phosphorylation sites on the 
cytoplasmic domain of CLEC-2 receptor.  
 
 
76  
2.5 References  
 
BHAVARAJU, K., KIM, S., DANIEL, J. L. & KUNAPULI, S. P. 2008. Evaluation of 
[3-(1-Methyl-1H–indol –3-yl-methylene)-2–oxo-2, 3–dihydro-1H- indole–5-
sulfonamide] (OXSI-2), as a Syk selective inhibitor in platelets. Eur J 
Pharmacol, 580, 285-290. 
BRANDENBURG, L. O., KONRAD, M., WRUCK, C. J., KOCH, T., LUCIUS, R. & 
PUFE, T. 2010. Functional and physical interactions between formyl-peptide-
receptors and scavenger receptor MARCO and their involvement in amyloid 
beta 1-42-induced signal transduction in glial cells. J Neurochem, 113, 749-60. 
BRASS, L. 2010. Understanding and evaluating platelet function. Hematology Am 
Soc Hematol Educ Program, 2010, 387-96. 
BROOS, K., DE MEYER, S. F., FEYS, H. B., VANHOORELBEKE, K. & 
DECKMYN, H. 2012. Blood platelet biochemistry. Thromb Res, 129, 245-9. 
CHRISTOU, C. M., PEARCE, A. C., WATSON, A. A., MISTRY, A. R., POLLITT, 
A. Y., FENTON-MAY, A. E., JOHNSON, L. A., JACKSON, D. G., 
WATSON, S. P. & O'CALLAGHAN, C. A. 2008. Renal cells activate the 
platelet receptor CLEC-2 through podoplanin. Biochem J, 411, 133-40. 
CLEMETSON, K. J. 2012. Platelets and primary haemostasis. Thromb Res, 129, 220-
4. 
COLONNA, M., SAMARIDIS, J. & ANGMAN, L. 2000. Molecular characterization 
of two novel C-type lectin-like receptors, one of which is selectively expressed 
in human dendritic cells. Eur J Immunol, 30, 697-704. 
DURAND, E., HELLEY, D., AL HAJ ZEN, A., DUJOLS, C., BRUNEVAL, P., 
COLLIEC-JOUAULT, S., FISCHER, A. M. & LAFONT, A. 2008. Effect of 
low molecular weight fucoidan and low molecular weight heparin in a rabbit 
model of arterial thrombosis. J Vasc Res, 45, 529-37. 
DURIG, J., BRUHN, T., ZURBORN, K. H., GUTENSOHN, K., BRUHN, H. D. & 
BERESS, L. 1997. Anticoagulant fucoidan fractions from Fucus vesiculosus 
induce platelet activation in vitro. Thromb Res, 85, 479-91. 
EZUMI, Y., SHINDOH, K., TSUJI, M. & TAKAYAMA, H. 1998. Physical and 
Functional Association of the Src Family Kinases Fyn and Lyn with the 
Collagen Receptor Glycoprotein VI-Fc Receptor γ Chain Complex on Human 
Platelets. J Exp Med, 188, 267-276. 
FRANCISCHETTI, I. M., SALIOU, B., LEDUC, M., CARLINI, C. R., HATMI, M., 
RANDON, J., FAILI, A. & BON, C. 1997. Convulxin, a potent platelet-
aggregating protein from Crotalus durissus terrificus venom, specifically binds 
to platelets. Toxicon, 35, 1217-28. 
GAO, Y., LI, C., YIN, J., SHEN, J., WANG, H., WU, Y. & JIN, H. 2012. Fucoidan, a 
sulfated polysaccharide from brown algae, improves cognitive impairment 
induced by infusion of Abeta peptide in rats. Environ Toxicol Pharmacol, 33, 
304-11. 
GETZ, T. M., MAYANGLAMBAM, A., DANIEL, J. L. & KUNAPULI, S. P. 2011. 
Go6976 abrogates GPVI-mediated platelet functional responses in human 
platelets through inhibition of Syk. J Throm and Haemost, 9, 608-610. 
GRYNKIEWICZ, G., POENIE, M. & TSIEN, R. Y. 1985. A new generation of Ca2+ 
indicators with greatly improved fluorescence properties. J Biol Chem, 260, 
3440-50. 
HOOLEY, E., PAPAGRIGORIOU, E., NAVDAEV, A., PANDEY, A. V., 
CLEMETSON, J. M., CLEMETSON, K. J. & EMSLEY, J. 2008. The crystal 
 
 
77  
structure of the platelet activator aggretin reveals a novel (alphabeta)2 dimeric 
structure. Biochemistry, 47, 7831-7. 
HSU, H. Y., CHIU, S. L., WEN, M. H., CHEN, K. Y. & HUA, K. F. 2001. Ligands 
of macrophage scavenger receptor induce cytokine expression via differential 
modulation of protein kinase signaling pathways. J Biol Chem, 276, 28719-30. 
HUGHES, C. E., AUGER, J. M., MCGLADE, J., EBLE, J. A., PEARCE, A. C. & 
WATSON, S. P. 2008. Differential roles for the adapters Gads and LAT in 
platelet activation by GPVI and CLEC-2. J Thromb Haemost, 6, 2152-2159. 
HUGHES, C. E., POLLITT, A. Y., MORI, J., EBLE, J. A., TOMLINSON, M. G., 
HARTWIG, J. H., O'CALLAGHAN, C. A., FUTTERER, K. & WATSON, S. 
P. 2010. CLEC-2 activates Syk through dimerization. Blood, 115, 2947-55. 
JARVIS, G. E., ATKINSON, B. T., SNELL, D. C. & WATSON, S. P. 2002. Distinct 
roles of GPVI and integrin α(2)β(1) in platelet shape change and aggregation 
induced by different collagens. Br J Pharmacol, 137, 107-117. 
JHAMANDAS, J. H., WIE, M. B., HARRIS, K., MACTAVISH, D. & KAR, S. 2005. 
Fucoidan inhibits cellular and neurotoxic effects of beta-amyloid (A beta) in 
rat cholinergic basal forebrain neurons. Eur J Neurosci, 21, 2649-59. 
KAWASAKI, T., UEMURA, T., TANIGUCHI, M. & TAKASAKI, J. 2006. 
[Pharmacological properties of a specific Gq/11 inhibitor, YM-254890]. Nihon 
Yakurigaku Zasshi, 128, 23-31. 
KOEDAM, J. A., CRAMER, E. M., BRIEND, E., FURIE, B., FURIE, B. C. & 
WAGNER, D. D. 1992. P-selectin, a granule membrane protein of platelets 
and endothelial cells, follows the regulated secretory pathway in AtT-20 cells. 
J Cell Biol, 116, 617-25. 
LI, Z., ZHANG, G., LIU, J., STOJANOVIC, A., RUAN, C., LOWELL, C. A. & DU, 
X. 2010. An important role of the SRC family kinase Lyn in stimulating 
platelet granule secretion. J Biol Chem, 285, 12559-70. 
LIU, T., SCALLAN, C. D., BROZE, G. J., JR., PATARROYO-WHITE, S., PIERCE, 
G. F. & JOHNSON, K. W. 2006. Improved coagulation in bleeding disorders 
by Non-Anticoagulant Sulfated Polysaccharides (NASP). Thromb Haemost, 
95, 68-76. 
MAY, F., HAGEDORN, I., PLEINES, I., BENDER, M., VOGTLE, T., EBLE, J., 
ELVERS, M. & NIESWANDT, B. 2009. CLEC-2 is an essential platelet-
activating receptor in hemostasis and thrombosis. Blood, 114, 3464-72. 
MAZUROV, A. V., VINOGRADOV, D. V., KHASPEKOVA, S. G., 
KRUSHINSKY, A. V., GERDEVA, L. V. & VASILIEV, S. A. 1996. 
Deficiency of P-selectin in a patient with grey platelet syndrome. Eur J 
Haematol, 57, 38-41. 
MILLET, J., JOUAULT, S. C., MAURAY, S., THEVENIAUX, J., STERNBERG, 
C., BOISSON VIDAL, C. & FISCHER, A. M. 1999. Antithrombotic and 
anticoagulant activities of a low molecular weight fucoidan by the 
subcutaneous route. Thromb Haemost, 81, 391-5. 
PACKHAM, M. A. 1994. Role of platelets in thrombosis and hemostasis. Can J 
Physiol Pharmacol, 72, 278-84. 
PASQUET, J.-M., GROSS, B., QUEK, L., ASAZUMA, N., ZHANG, W., 
SOMMERS, C. L., SCHWEIGHOFFER, E., TYBULEWICZ, V., JUDD, B., 
LEE, J. R., KORETZKY, G., LOVE, P. E., SAMELSON, L. E. & WATSON, 
S. P. 1999. LAT Is Required for Tyrosine Phosphorylation of Phospholipase 
Cγ2 and Platelet Activation by the Collagen Receptor GPVI. Mol Cell Biol, 
19, 8326-8334. 
 
 
78  
PRASAD, S., LILLICRAP, D., LABELLE, A., KNAPPE, S., KELLER, T., 
BURNETT, E., POWELL, S. & JOHNSON, K. W. 2008. Efficacy and safety 
of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. 
Blood, 111, 672-9. 
SHANKAR, H., KAHNER, B. N., PRABHAKAR, J., LAKHANI, P., KIM, S. & 
KUNAPULI, S. P. 2006. G-protein-gated inwardly rectifying potassium 
channels regulate ADP-induced cPLA2 activity in platelets through Src family 
kinases. Blood, 108, 3027-34. 
SHUMAN, M. A. & LEVINE, S. P. 1978. Thrombin generation and secretion of 
platelet Factor 4 during blood clotting. J Clin Invest, 61, 1102-6. 
SOBANOV, Y., BERNREITER, A., DERDAK, S., MECHTCHERIAKOVA, D., 
SCHWEIGHOFER, B., DUCHLER, M., KALTHOFF, F. & HOFER, E. 2001. 
A novel cluster of lectin-like receptor genes expressed in monocytic, dendritic 
and endothelial cells maps close to the NK receptor genes in the human NK 
gene complex. Eur J Immunol, 31, 3493-503. 
SPALTON, J. C., MORI, J., POLLITT, A. Y., HUGHES, C. E., EBLE, J. A. & 
WATSON, S. P. 2009. The novel Syk inhibitor R406 reveals mechanistic 
differences in the initiation of GPVI and CLEC-2 signaling in platelets. J  
Thromb Haemost, 7, 1192-1199. 
SPEICH, H. E., GRGUREVICH, S., KUETER, T. J., EARHART, A. D., SLACK, S. 
M. & JENNINGS, L. K. 2008. Platelets undergo phosphorylation of Syk at 
Y525/526 and Y352 in response to pathophysiological shear stress. Am J 
Physiol Cell Physiol, 295, C1045-54. 
SUZUKI-INOUE, K. 2011. Essential in vivo roles of the platelet activation receptor 
CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation. J 
Biochem, 150, 127-32. 
SUZUKI-INOUE, K., FULLER, G. L., GARCIA, A., EBLE, J. A., POHLMANN, S., 
INOUE, O., GARTNER, T. K., HUGHAN, S. C., PEARCE, A. C., LAING, 
G. D., THEAKSTON, R. D., SCHWEIGHOFFER, E., ZITZMANN, N., 
MORITA, T., TYBULEWICZ, V. L., OZAKI, Y. & WATSON, S. P. 2006. A 
novel Syk-dependent mechanism of platelet activation by the C-type lectin 
receptor CLEC-2. Blood, 107, 542-9. 
SUZUKI-INOUE, K., KATO, Y., INOUE, O., KANEKO, M. K., MISHIMA, K., 
YATOMI, Y., YAMAZAKI, Y., NARIMATSU, H. & OZAKI, Y. 2007. 
Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated 
platelet activation, by cancer cells. J Biol Chem, 282, 25993-6001. 
SUZUKI-INOUE, K., WILDE, J. I., ANDREWS, R. K., AUGER, J. M., 
SIRAGANIAN, R. P., SEKIYA, F., RHEE, S. G. & WATSON, S. P. 2004. 
Glycoproteins VI and Ib-IX-V stimulate tyrosine phosphorylation of tyrosine 
kinase Syk and phospholipase Cgamma2 at distinct sites. Biochem J, 378, 
1023-1029. 
TRENTO, F., CATTANEO, F., PESCADOR, R., PORTA, R. & FERRO, L. 2001. 
Antithrombin activity of an algal polysaccharide. Thromb Res, 102, 457-65. 
TSUJI, M., EZUMI, Y., ARAI, M. & TAKAYAMA, H. 1997. A novel association of 
Fc receptor gamma-chain with glycoprotein VI and their co-expression as a 
collagen receptor in human platelets. J Biol Chem, 272, 23528-31. 
UEMURA, T., KAWASAKI, T., TANIGUCHI, M., MORITANI, Y., HAYASHI, K., 
SAITO, T., TAKASAKI, J., UCHIDA, W. & MIYATA, K. 2006. Biological 
properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet 
functions and thrombus formation under high-shear stress. Br J Pharmacol, 
 
 
79  
148, 61-9. 
WATSON, A. A., CHRISTOU, C. M., JAMES, J. R., FENTON-MAY, A. E., 
MONCAYO, G. E., MISTRY, A. R., DAVIS, S. J., GILBERT, R. J., 
CHAKERA, A. & O'CALLAGHAN, C. A. 2009. The platelet receptor CLEC-
2 is active as a dimer. Biochemistry, 48, 10988-96. 
WATSON, A. A., EBLE, J. A. & O'CALLAGHAN, C. A. 2008. Crystal structure of 
rhodocytin, a ligand for the platelet-activating receptor CLEC-2. Protein Sci, 
17, 1611-6. 
WATSON, A. A. & O'CALLAGHAN, C. A. 2011. Molecular analysis of the 
interaction of the snake venom rhodocytin with the platelet receptor CLEC-2. 
Toxins (Basel), 3, 991-1003. 
WATSON, S. P., AUGER, J. M., MCCARTY, O. J. & PEARCE, A. C. 2005. GPVI 
and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost, 3, 1752-
62. 
WATSON, S. P., HERBERT, J. M. & POLLITT, A. Y. 2010. GPVI and CLEC-2 in 
hemostasis and vascular integrity. J Thromb Haemost, 8, 1456-67. 
ZIMMERMAN, T. S. & FULCHER, C. A. 1985. Factor VIII procoagulant protein. 
Clin Haematol, 14, 343-58. 
ZIMMERMAN, T. S., RATNOFF, O. D. & POWELL, A. E. 1971. Immunologic 
differentiation of classic hemophilia (factor 8 deficiency) and von 
Willebrand's dissase, with observations on combined deficiencies of 
antihemophilic factor and proaccelerin (factor V) and on an acquired 
circulating anticoagulant against antihemophilic factor. J Clin Invest, 50, 244-
54.  
 
 
80  
 
 
 
 
Chapter 3 ACTIVATION OF GLYCOPROTEIN VI 
(GPVI) AND C-TYPE LECTIN-LIKE RECEPTOR-
2 (CLEC-2) UNDERLIES PLATELET 
ACTIVATION BY DIESEL EXHAUST 
PARTICLES AND OTHER 
CHARGED/HYDROPHOPIC LIGANDS 
 
This research was originally published in Biochemical Journal. Osama M. Alshehri, 
Samantha Montague, Stephanie Watson, Paul Carter, Najiat Sarker, Bhanu K. Manne, 
Jeanette L.C. Miller, Andrew B. Herr, Alice Y. Pollitt, Chris A. O’Callaghan, Satya 
Kunapuli, Monica Arman, Craig E. Hughes and Steve P. Watson. Activation of 
glycoprotein VI (GPVI) and C-type lectin-like receptor-2 (CLEC-2) underlies platelet 
activation by diesel exhaust particles and other charged/hydrophobic ligands. Biochem 
J, 2015. 468,459-73 © the Biochemical Society 
Word count: 5,964  
This chapter reports that a miscellaneous group of agonists - including DEP, small 
peptides [4N1-1, Champs, and LSARLAF (Leu-Ser-Ala-Arg-Leu-Ala-Phe)], proteins 
(histones), large polysaccharides (fucoidan and dextran sulfate), and lipoproteins 
(Pam3CSK4) - stimulate aggregation and tyrosine phosphorylation of human and 
mouse platelets through the glycoprotein VI (GPVI)–FcRγ-chain complex and/or C-
type lectin-like receptor-2 (CLEC-2). All of the experiments in the paper were 
performed by myself other than those with histones (Figures 3 and 4) and the studies 
on the DT40 cells which were performed with Samantha Montague and Stephanie 
Watson, supported by two dissertation students, Paul Carter and Najiat Sarke. 
- All not shown results have been added to the Appendix except those on pages 93, 
94 and 113 as these were performed by other authors in the manuscript.   
- The not shown result in page 108 is shown in chapter 4 (Supplementary figure 4-
2) 
- I contributed experimental design, performed experiments, analysed data and 
wrote the manuscript.   
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Abstract 
Platelets are activated by a range of stimuli that share little or no resemblance in 
structure to each other or to recognized ligands, including diesel exhaust particles 
(DEP), small peptides [4N1-1, Champs (computed helical anti-membrane proteins), 
LSARLAF (Leu-Ser-Ala-Arg-Leu-Ala-Phe)], proteins (histones) and large 
polysaccharides (fucoidan, dextran sulfate). This miscellaneous group stimulate 
aggregation of human and mouse platelets through the glycoprotein VI (GPVI)–FcRγ -
chain complex and/or C-type lectin-like receptor-2 (CLEC-2) as shown using platelets 
from mice deficient in either or both of these receptors. In addition, all of these ligands 
stimulate tyrosine phosphorylation in GPVI/CLEC-2-double-deficient platelets, 
indicating that they bind to additional surface receptors, although only in the case of 
dextran sulfate does this lead to activation. DEP, fucoidan and dextran sulfate, but not 
the other agonists, activate GPVI and CLEC-2 in transfected cell lines as shown using 
a sensitive reporter assay confirming a direct interaction with the two receptors. We 
conclude that this miscellaneous group of ligands bind to multiple proteins on the cell 
surface including GPVI and/or CLEC-2, inducing activation. These results have 
pathophysiological significance in a variety of conditions that involve exposure to 
activating charged/hydrophobic agents. 
  
 
 
82  
 
3.1 Introduction 
 
The collagen and podoplanin receptors glycoprotein VI (GPVI) and C-type lectin-like 
receptor-2 (CLEC-2) activate platelets through Src and spleen tyrosine kinase (Syk) 
tyrosine kinases via two closely related motifs, known as an immunoreceptor tyrosine- 
based activation motif (ITAM) and hemITAM respectively (Watson et al., 2010). An 
ITAM has two repeats of the amino acid sequence YXXL separated by 6–12 amino 
acids, whereas a hemITAM has a single YXXL motif that lies downstream of an acidic 
amino acid- rich region. Phosphorylation of the conserved tyrosine residues in these 
motifs leads to binding of Syk via its tandem SH2 (Src homology 2) domains (in the 
case of CLEC-2, bridging two receptors) and a signalling cascade that culminates in 
phospholipase C (PLC) γ 2 and platelet activation. 
The GPVI–Fcε receptor 1 (FcR) γ-chain complex has been shown to mediate platelet 
activation to a variety of structurally unrelated peptides that have no structural 
resemblance to collagen or to other known platelet agonists. Activation by the peptide 
LSARLAF (Leu-Ser-Ala-Arg-Leu-Ala-Phe), which is from the non-coding strand of 
the ITGA2B (integrin α2B) gene in a region corresponding to the binding site for the 
fibrinogen γ -chain; 4N1- 1, which is derived from a sequence from the C-terminus 
of thrombospondin; and Champs (computed helical anti-membrane proteins), a 
computationally designed sequence that binds to the transmembrane of integrin 
subunit αIIb, is inhibited in platelets deficient in the GPVI-associated FcR γ-chain 
(Pearce et al., 2004b, Tulasne et al., 2001a, Grygielska et al., 2009) . Additionally, the 
three peptides induce platelet agglutination independently of the FcR γ-chain, 
indicating that they bind to other platelet surface proteins (Pearce et al., 2004b, 
Tulasne et al., 2001a, Grygielska et al., 2009). 
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CLEC-2 has been shown to mediate platelet aggregation by the sulfated 
polysaccharide fucoidan (Manne et al., 2013), which has no structural resemblance to 
the endogenous ligand, podoplanin or to the CLEC-2-specific snake venom toxin 
rhodocytin (also known as aggretin). Podoplanin has been shown to bind to CLEC-2 
through an aspartic–glutamic acid doublet and an O-linked glycan which together form 
a platelet-aggregating (PLAG) domain, with the conserved sequence DEXXXS/T 
(Asp-Glu-Xaa-Xaa- Xaa-Ser/Thr) (Nagae et al., 2014). Rhodocytin (which is not O-
glycosylated) also uses an aspartic-glutamic acid doublet to bind to CLEC-2 in 
association with its negatively charged C-terminus. The negatively charged fucoidan 
may interact with the corresponding sites on CLEC-2 to mediate activation. 
Platelets are activated by other diverse stimuli that have little structural resemblance 
to platelet ligands including diesel exhaust particles (DEP) (Solomon et al., 2013), 
histones (Fuchs et al., 2011) fucoidan and dextran sulfate (Manne et al., 2013) (Getz 
et al., 2013a). In the present study, we have sought to investigate the role of GPVI and 
CLEC-2 in platelet activation by this group of agonists through measurement of protein 
tyrosine phosphorylation and use of transgenic mouse platelets, in combination with 
studies on transfected cell lines. We show that GPVI and/or CLEC-2 mediate platelet 
activation to this miscellaneous group of stimuli but that, in addition, these stimuli also 
induce tyrosine phosphorylation through binding to other surface proteins as shown 
using platelets double-deficient in the two (hem)ITAM receptors. We conclude that 
this diverse group of ligands interact with multiple proteins on the platelet surface and 
that they induce activation through GPVI and/or CLEC-2. 
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3.2 Materials and Methods 
3.2.1 Reagent and antibodies 
 
Champs (KKAYVMLLPFFIGLLLGLIFGGAFWGPARHLKK), LSARLAF and 
4N1- 1 (RFYVVMWK) peptides were manufactured by Severn Biotech. DEP were 
purchased from the National Institute of Standards and Technology. Calf thymus 
histones (CTH) were purchased from Worthington Biochemical. Dextran sulfate, 50 
% solution, was purchased from American Bioanalytical. The synthetic 
tripalmitoylated lipopeptide Pam3-CSK4 [tripalmitoylcysteinylseryl-(lysyl)4], was 
from InvivoGen. All other reagents were purchased from Sigma or other named 
sources (Pearce et al., 2004b, Fuller et al., 2007, Mazharian et al., 2011). 
3.2.2 Transgenic mice 
 
Gp6 
− / − mice [13] and Clec1b
fl/f; PF4-Cre
 (Finney et al., 2012) have been described. 
These two strains were cross-bred to produce mice with platelets double-deficient in 
GPVI and CLEC-2 (Gp6 
− / −; Clec1b
fl/fl; PF4-Cre 
). Clec1b
fl/fl or wild-type mice were used 
as controls. All procedures were undertaken with U.K. Home Office approval (licence 
no. PPL 30/2721 and 30/8286). 
3.2.3 Human platelets 
 
Blood was obtained from healthy drug-free volunteers with informed consent and 
approval from the local ethics committee. Sodium citrate (10 %) was used as the 
anticoagulant. Platelet-rich plasma (PRP) and washed platelets were prepared as 
previously described (Grygielska et al., 2009). Washed platelets were suspended in 
modified Tyrode’s HEPES buffer (134 mM NaCl, 0.34 mM Na2 HPO4 , 2.9 mM KCl, 
12 mM NaHCO3 , 20 mM HEPES, 5 mM glucose and 1 mM MgCl2 , pH 7.3) at between 
2 and 10 × 108/ml. Aggregations and stimulations were performed in a Born (lumi)- 
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aggregometer (ChronoLog), at 37◦C with continuous stirring at 1200 rev/min. Platelets 
were pre-incubated for 1 min with inhibitors or vehicle (0.2 % DMSO unless otherwise 
indicated) before agonist addition. 
3.2.4 Mouse platelets 
 
Blood was taken from the vena cavae of CO2-asphyxiated mice following isofluorane 
anaesthesia and taken into1:10 (v/v) acid citrate/dextrose. Washed platelets were 
prepared as previously described (Pearce et al., 2004b) and resuspended at 2–10 × 10
8 
/ml in Tyrode’s HEPES buffer for measurement of aggregation and protein 
phosphorylation respectively. Platelets were pre-incubated for 1 min with inhibitors or 
vehicle (0.2 % DMSO unless otherwise indicated) before agonist addition. 
3.2.5 Protein phosphorylation  
 
Protein phosphorylation was measured in the presence of integrilin (9 μM), 
indomethacin (10 μM) and apyrase (2 units/ml), with the exception of studies in human 
platelets involving measurement of phosphorylation of CLEC-2 due to the positive- 
feedback action of secondary agonists on CLEC-2 signalling. Platelets were stimulated 
with agonists at 37
◦
C with continuous stirring at 1200 rev/min in a Born (lumi)-
aggregometer. Reactions were stopped and lysed with an equal volume of 2× ice cold 
lysis buffer containing 2 % Igepal CA-630 (Nonidet P-40 equivalent). Cell lysates were 
pre-cleared with Protein A/G– Sepharose or γ -Bind Plus beads (GE Healthcare) for 30–
60 min at 4
◦
C. Insoluble material was then pelleted at 13000 g for 15 min and removed. 
Antibodies and beads were added to platelet lysates and incubated overnight at 4
◦
C, 
followed by washing with lysis buffer and elution with 2× Laemmli sample buffer. 
Whole cell lysates and immunoprecipitated proteins were resolved by reducing 
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SDS/PAGE and transferred onto PVDF membranes. Immunoblotting was performed as 
described previously (Poole et al., 1997). 
3.2.6 NFAT–luciferase reporter assays 
 
DT40 chicken B-cells were grown in RPMI 1640 medium supplemented with 10 % 
FBS, 1 % chicken serum, 100 units/ml penicillin, 100 μg/ml streptomycin, 50 μM β-
mercaptoethanol and 2 mM L-glutamine. Syk-deficient Jurkat human T-cells were 
grown in RPMI 1640 medium supplemented with 10 % FBS, 100 units/ml penicillin, 
100 μg/ml streptomycin and 2 mM L- glutamine. Cells were transfected in 0.4 ml (2 × 
10
7 cells) of serum-free RPMI 1640 medium by electroporation using a GenePulser II 
(Bio-Rad Laboratories) set at 350 V and 500 μF for DT40 cells and at 250 V and 950 μF 
for Jurkat cells. DT40 cells were transfected with 15 μg of the nucdear factor of 
activated T-cells (NFAT)–luciferase reporter and either 10 μg of human CLEC-2 or 2 
μg each of both human GPVI and human FcR γ-chain. Jurkat cells were transfected with 
3.75 μg of the NFAT– luciferase reporter and either 2.5 μg of human CLEC-2 or 0.5 μg 
each of both human GPVI and human FcR γ-chain. After 20 h, live cells were counted 
by Trypan Blue exclusion, diluted to 2 × 10
6 cells/ml in serum- and antibiotic-free 
medium (to avoid potential binding to stimuli) and luciferase assays were carried out 
as described previously (Tomlinson et al., 2007) . 
 
3.3 Data analysis 
 
Results are shown as means ± S.E.M. for a minimum of three experiments. 
Statistical analyses were performed by Student’s t test or using a one-way ANOVA 
with Bonferroni’s post-hoc test. P < 0.05 was considered significant. 
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3.4 Results 
3.4.1 Diesel exhaust particles activate human platelets through Src and Syk 
tyrosine kinases 
 
DEP are carbon black nanoparticles coated with a variety of surface organic materials 
and metals that carry a net surface electrical charge. Several studies have shown that 
they stimulate rapid activation of platelets in Tyrode’s buffer (‘washed platelets’) 
(Solomon et al., 2013). In confirmation of this, we show that DEP stimulate rapid 
concentration-dependent (5–50 μg/ml) aggregation (Figure 3-1Ai). In contrast, they 
have no effect over this concentration range in platelet-rich plasma, presumably due to 
binding to plasma proteins (Figure 1Ai). Aggregation is preceded by shape change and 
reaches a similar maximal level to that of strong platelets agonists as illustrated in 
Figure 1(Aii). The increase in light transmission is blocked in the presence of the αIIbβ3 
antagonist integrilin, confirming that it reflects αIIbβ3-mediated aggregation rather than 
platelet agglutination (Figures 3-1Aii and 3-1Aiii). Shape change and aggregation are 
blocked by the Src kinase inhibitors PP2 and dasatinib or the Syk kinase inhibitor 
PRT318 (aka PRT- 060318) (Figures 3-1Aii and 3-1Aiii). In line with this, DEP stimulated 
tyrosine phosphorylation as demonstrated by Western blotting using the monoclonal 
antibody (mAb) 4G10 (Figure 3-1Bi). The increase in tyrosine phosphorylation is 
blocked by the Src kinase inhibitors PP2 and dasatinib and reduced by the Syk inhibitor 
PRT318 (Figure 3-1Bi). The greater effect of the Src inhibitors over the Syk inhibitor 
indicates that Src kinases lie upstream of Syk. 
The presence of a prominent tyrosine-phosphorylated band at ∼14 kDa (Figure 
3-1Bi), corresponding to the FcR γ-chain, is indicative of GPVI activation. In line with 
this, DEP stimulated tyrosine phosphorylation of Syk and PLCγ2 as shown by 
immunoprecipitation using specific antibodies and Western blotting for 
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phosphotyrosine. The 14 kDa phosphorylated band is present in Syk 
immunoprecipitates (Figure 3-1Bi), confirming its identity as the FcR γ-chain (Gibbins 
et al., 1996). Phosphorylation of all three proteins is blocked in the presence of PP2 or 
dasatinib (Figure 3-1Bi). Phosphorylation of PLCγ2 is also blocked by PRT318, 
whereas phosphorylation of FcR γ-chain and Syk is retained. This is consistent with 
FcR γ-chain and Syk phosphorylation being mediated by Src rather than Syk tyrosine 
kinases as described for GPVI-activated platelets (Spalton et al., 2009a). 
DEP also stimulate phosphorylation of CLEC-2, as shown by 
immunoprecipitation of the C-type lectin-like receptor and Western blotting for 
phosphotyrosine (Figure 3-1Bii). The level of tyrosine phosphorylation of CLEC-2 is 
weak in comparison with that induced by the CLEC-2-specific snake venom toxin 
rhodocytin (appendix 1). In contrast, DEP did not induce tyrosine phosphorylation of 
the other platelet ITAM receptor, Fcγ RIIa (appendix 2). 
These results demonstrate that DEP activate human platelets through Src and 
Syk kinases in association with robust tyrosine phosphorylation of FcR γ-chain 
(indicative of GPVI activation) and weak tyrosine phosphorylation of CLEC-2.  
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Figure 3-1 DEP activate human platelets through Src and Syk tyrosine kinases  
(A) (i) Dose–response curve for aggregation to DEP (0.05–50 μg/ml) in washed human platelets 
and platelet-rich plasma; (ii) Representative aggregation traces to DEP (50 μg/ml) following 
pre-incubation with dasatinib (DAS; 10 μM), PRT318 (5 μM), PP2 (10 μM), integrilin (integ; 
9 μM) or DMSO (0.2 %: vehicle, Veh). (iii) Quantification of maximal aggregation is shown 
as means ± S.E.M., n≥3 (***P <0.001) (B). Washed platelets were pre-incubated with the 
inhibitors described above and stimulated with DEP (50 μg/ml) for 3 min. Experiments were 
performed under stirring conditions in the presence of integrilin (9 μM). (i) Whole-cell lysates 
or Syk and PLCγ 2 immunoprecipitates (IP) were separated by SDS/PAGE and Western blotted 
(WB) for phosphotyrosine using mAb 4G10 before reprobing for the precipitated protein. (ii) 
CLEC-2 was immunoprecipitated using a specific antibody, separated by SDS/PAGE and 
Western blotted for phosphotyrosine before reprobing for CLEC-2. Molecular masses are 
indicated in kDa. Results are representative of a minimum of three experiments.  
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3.4.2 Diesel exhaust particles activate mouse platelets through GPVI 
 
DEP stimulate shape change and aggregation of washed mouse platelets, with a similar 
concentration–response curve and time course to that for human platelets (Figure 3-
2Ai). Aggregation is again inhibited in the presence of PP2, PRT318 or integrilin, 
revealing a residual increase in light transmission mediated by platelet agglutination 
(Figures 3-2Aii and 3-2Aiii). Platelet activation is associated with tyrosine 
phosphorylation of the FcRγ-chain, Syk and PLCγ2, as shown by immunoprecipitation 
and Western blotting with mAb 4G10 (Figure 3-2B). Tyrosine phosphorylation of all 
three proteins was blocked by the Src kinase inhibitor PP2, whereas only 
phosphorylation of PLCγ 2 was blocked by the Syk inhibitor PRT318 (Figure 3-2B), 
consistent with human platelets.  
Mice deficient in GPVI and/or CLEC-2 were used to further investigate the 
mechanism of platelet activation by DEP. Aggregation induced by DEP (50 μg/ml) is 
severely diminished in the absence of GPVI and blocked in GPVI/CLEC-2-double- 
deficient platelets, but unaltered in the absence of CLEC-2 (Figures 3-2Ci and 3-2Cii), 
with a similar result observed with a sub-maximal concentration of DEP (20 μg/ml; 
Supplementary Figure 3-1). The stimulation of tyrosine phosphorylation in whole- cell 
lysates by DEP is reduced but not blocked in the absence of GPVI, with no apparent 
further change in GPVI/CLEC-2- double-deficient platelets (Figure 3-2Di). Tyrosine 
phosphorylation was not altered in CLEC-2-deficient platelets (Figure 3-2Di). Syk 
phosphorylation was markedly inhibited in GPVI-deficient platelets and blocked in 
GPVI/CLEC-2-double-deficient platelets, but unaltered in CLEC-2-deficient platelets 
(Figure 3-2Dii). 
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These results indicate that DEP stimulate tyrosine phosphorylation of Syk 
predominantly through GPVI with a minor contribution from CLEC-2. In addition, 
DEP induce tyrosine phosphorylation independent of the two (hem) ITAM receptors.  
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Figure 3-2 DEP activate mouse platelets through GPVI. (A) (i) Dose-response curve for aggregation 
to DEP (2–50 μg/ml) in washed mouse platelets. (ii) Washed platelets were pre-incubated with integrilin (integ; 9 
μM), PRT318 (5 μM), PP2 (10 μM) or DMSO (0.2%: vehicle, Veh) for 3 min and then stimulated with DEP (50 
μg/ml). (iii) Quantification of maximal aggregation is shown as means ± S.E.M., n=3 (**P < 0.01, ***P < 0.001). 
Washed platelets were stimulated with DEP (50 μg/ml) under stirring conditions for 3 min. Syk was 
immunoprecipitated (IP), proteins were separated by SDS/PAGE and Western blotted (WB) for phosphotyrosine. 
The figure is representative of three experiments. (C) Washed platelets from wild-type (WT), CLEC-2-deficient, 
GPVI-deficient and GPVI/CLEC-2-double-deficient (DKO) mice were stimulated with DEP (250 μg/ml): (i) 
representative aggregation traces; and (ii) quantification of maximal aggregation is shown as means ± S.E.M. from 
three experiments; (***P < 0.001).(D) Tyrosine phosphorylation in washed platelets from WT, CLEC-2-deficient, 
GPVI-deficient and GPVI/CLEC-2-double-deficient mice was induced by incubation with DEP (250 μg/ml) for 3 
min.Tyrosine phosphorylation in (i) whole-cell lysates and (ii) Syk immunoprecipitate were analysed as described 
above. Molecular masses are indicated in kDa. Results are representative of a minimum of three experiments. 
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3.4.3 Histones activate human platelets through Src and Syk tyrosine kinases 
 
Histones are positively charged proteins that play a key role in the organization of DNA 
and in gene regulation. Histones are released from damaged cells and form a central 
component of neutrophil extracellular traps (NETs) which are released by activated 
neutrophils through a process known as NETosis (Fuchs et al., 2011, Yipp and Kubes, 
2013). Histones are elevated in a range of inflammatory disorders and in trauma and 
mediate a wide spectrum of biological effects including activation of endothelial cells 
and platelets (Martinod and Wagner, 2014, Abrams et al., 2013). 
Calf thymus histones (CTH) are a heterogeneous mixture of all histone fractions 
and have been widely used to investigate histone- mediated platelet activation (Fuchs et 
al., 2011, Semeraro et al., 2011). CTH stimulate concentration- dependent shape change and 
aggregation of platelets in Tyrode’s buffer and in plasma, with aggregation blocked by 
an αIIbβ3 receptor antagonist (Figure 3-3A; and results not shown). The CTH dose–
response curve in washed platelets is approximately 10-fold lower than that in platelet-
rich plasma, presumably due to reduced bioavailability as a consequence of plasma 
protein binding (Getz et al., 2013a). The curve is also bell-shaped, with aggregation 
being lost at high concentrations of CTH (Figure 3-3A; and results not shown). In 
contrast, the dose–response curve for ATP secretion is not bell- shaped (results not 
shown), indicating that loss of aggregation at high concentrations of histones is 
probably mediated by electrostatic repulsion of histone-coated platelets. 
The stimulation of aggregation by CTH in platelet-rich plasma is blocked in the 
presence of the Src and Syk inhibitors, dasatinib and PRT318 respectively (Figures 3-
3Bi and 3-3Bii). CTH stimulate a marked increase in tyrosine phosphorylation in 
platelet lysates, which is blocked in the presence of dasatinib and reduced in the 
presence of PRT318 (Figure 3Biii). The FcRγ -chain, Syk and PLCγ 2 were identified as 
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prominent tyrosine-phosphorylated proteins by immunoprecipitation and Western 
blotting with mAb 4G10 (Figure 3-3Biii). The increase in phosphorylation of all three 
proteins was blocked by the Src kinase inhibitor dasatinib. In contrast, only 
phosphorylation of PLCγ 2 was blocked in the presence of the Syk inhibitor PRT318 
(Figure 3-3Biii), indicating that phosphorylation of the FcR γ-chain and Syk is 
downstream of Src kinases. CTH did not induce tyrosine phosphorylation of CLEC-2 
(Figure 3-3Biii). These results indicate that histones activate human platelets through 
the GPVI–FcRγ -chain complex, leading to activation of Src and Syk tyrosine kinases. 
3.4.4 Histones activate mouse platelets through GPVI 
 
CTH also stimulate rapid aggregation of mouse platelets in platelet-rich plasma, which 
is blocked in the presence of dasatinib and markedly reduced in the presence of PRT318 
(Figures 3-4Ai and 3-4Aii). Activation was associated with increased tyrosine 
phosphorylation in whole-cell lysates, with FcR γ-chain, Syk and PLCγ 2, but not CLEC-
2, identified as phosphorylated proteins by immunoprecipitation and Western blotting 
(Figures 3-4Bi - 3-4Biv). Phosphorylation of FcR γ-chain, Syk and PLCγ 2 was blocked 
in the presence of dasatinib, whereas phosphorylation of FcR γ-chain and Syk but not 
PLCγ 2 was preserved (albeit reduced) in the presence of PRT318 (Figures 3-4Bi - 3-
4Biv). These results demonstrate that CTH activate mouse platelets in a similar manner 
to human platelets. 
Confirming a role for the FcR γ-chain, platelet aggregation induced by CTH 
was blocked in the absence of GPVI, but was unaltered in the absence of CLEC-2 
(Figure 3-4C). Similarly, tyrosine phosphorylation of FcR γ-chain, Syk and PLCγ 2 
induced by CTH was blocked in GPVI-deficient and GPVI/CLEC-2-double-deficient 
platelets (Figure 3-4D; and results not shown). Nevertheless, CTH stimulated a weak 
increase in tyrosine phosphorylation in whole-cell lysates of GPVI/CLEC- 2-double-
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deficient platelets (Figure 3-4D) indicative of activation of additional Src kinase-linked 
receptors (although this does not lead to platelet aggregation). These results 
demonstrate that CTHs activate GPVI but not CLEC-2, but that they also bind to 
additional tyrosine kinase- linked surface receptors.  
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Figure 3-3 CTH activate human platelets through Src and Syk tyrosine kinases. (A) Dose 
response curve for aggregation to CTH (0.2–5 mg/ml) in (i) platelet-rich plasma; (ii) dose–
response curve for secretion in platelet-rich plasma. (B) Plasma was pre-incubated with 
dasatinib (DAS; 10 μM) or PRT318 (10 μM) for 3 min before stimulation with CTH (1 mg/ml): 
(i) representative aggregation traces to CTH in the presence of inhibitors or vehicle (Veh; 
DMSO,0.2 %); (ii) quantification of maximal aggregation is shown as means ± S.E.M., n≥3 
(***P < 0.001); (iii) washed platelets were stimulated for 3 min with CTH (50 μg/ml). Whole-
cell lysates were immunoprecipitated (IP) for Syk, PLCγ 2 and CLEC-2, separated by 
SDS/PAGE and Western blotted (WB) for phosphotyrosine with mAb 4G10. Tyrosine 
phosphorylation of co-precipitated FcR γ-chain in the Syk immunoprecipitate, measured in the 
presence of integrilin (Integ), Indomethacin (indom) and apyrase (Apy) and with or without 
DAS and PRT318, is shown. Molecular masses are indicated in kDa. All results are 
representative of a minimum of three experiments. 
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Figure 3-4 CTH activate mouse platelets through GPVI and Src and Syk tyrosine kinases. 
(A) CTH (1 mg/ml) induced aggregation in platelet-rich plasma in the presence or absence of dasatinib (DAS; 10 
μM) or PRT318 (10 μM). Veh, vehicle (DMSO, 0.2 %). (i) Representative aggregation traces and (ii) quantification 
of maximal aggregation is shown as means ± S.E.M., n ≥4 (**P < 0.01, ***P < 0.001). (B) Washed mouse platelets 
were incubated with CTH (50 μg/ml) for 3 min and analysed for tyrosine phosphorylation, measured in the presence 
of integrilin (Integ), Indomethacin (indom) and apyrase (Apy) and with or without DAS and PRT318, in (i) whole-
cell lysates; (ii)Syk immunoprecipitates; (iii) PLCγ 2 immunoprecipitates; and (iv) CLEC-2 immunoprecipitates as 
described in Figure 2. Phosphorylation of co-precipitated FcR γ-chain (middle panel of ii) with Syk is shown. (C) 
Platelet-rich plasma from wild-type (WT), CLEC-2-deficient and GPVI-deficient mice was stimulated with CTH (1 
mg/ml) for 3 min: (i) representative aggregation traces; and (ii) mean ± S.E.M. aggregation, n≥3 (***P < 0.001). (D) 
Washed platelets from WT, GPVI-deficient and GPVI/CLEC-2-double-deficient (DKO) mice were stimulated for 3 
min with CTH (50 μg/ml) under stirring conditions in the presence of integrilin (9 μM). Tyrosine phosphorylation 
in (i) whole-cell lysates, (ii) Syk and (iii) PLCγ 2 immunoprecipitates (IP) were analysed as described above.WB, 
Western blot. Molecular masses are indicated in kDa. The results are from an experiment that is representative of a 
minimum of three experiments. 
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3.4.5 GPVI mediates platelet activation by 4N1-1 and Champs 
 
We have previously reported that the structurally unrelated peptides LSARLAF, 4N1-1 
and Champs stimulate aggregation of washed human and mouse platelets and that 
aggregation is abolished in the absence of the FcR γ-chain (Pearce et al., 2004b, Tulasne 
et al., 2001a, Grygielska et al., 2009). In addition, we reported that all three peptides 
induce αIIbβ3-independent agglutination (Pearce et al., 2004b, Tulasne et al., 2001a, 
Grygielska et al., 2009). The effect of these three peptides in platelets deficient in GPVI 
or in CLEC-2 has not been investigated. To address this, we investigated the effect of 
the peptides on GPVI, CLEC-2 and GPVI/CLEC-2-double-deficient platelets. We 
focused our studies on 4N1-1 and Champs, but also performed preliminary studies with 
LSARLAF (appendix 3). As anticipated from the studies on FcR γ-chain-deficient mice 
(Tulasne et al., 2001a, Grygielska et al., 2009) aggregation of mouse platelets by 4N1-
1 and Champs was inhibited in GPVI-deficient platelets and in the presence of inhibitors 
of Src and Syk tyrosine kinases (Figures 3-5A and 3-5B). In all cases, a residual increase 
in light transmission was observed which is due to αIIbβ3- independent agglutination, 
as it was not blocked by integrilin (appendix 4). Similar observations were previously 
reported in platelets from mice deficient in the FcR γ-chain (Tulasne et al., 2001a, 
Grygielska et al., 2009) . The reduction in aggregation was accompanied by a decrease 
but not abolition of tyrosine phosphorylation to 4N1-1 and Champs in platelet lysates 
from GPVI-deficient mice (Figures 3-5C and 3-5D). In contrast, aggregation was not 
significantly altered to any of the three peptides in the absence of CLEC-2 (appendix 
5).These results demonstrate a critical role for GPVI but not CLEC-2 in mediating 
platelet activation by 4N1-1, Champs and LSARLAF. In addition, the peptides bind to 
one or more other surface receptors that induce tyrosine phosphorylation and platelet 
agglutination.  
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Figure 3-5 4N1-1 and Champs activate mouse platelets through GPVI. Washed platelets 
from wild-type (WT) and GPVI-deficient mice were stimulated with (A) 4N1-1 (100 
μM) and (B) Champs (30 μg/ml). (i) Representative aggregation traces. (ii) Platelets 
were pre-incubated with PP2 (10 μM) and PRT318 (5 μM) for 3 min prior to 4N1-1 or 
Champs stimulation. (iii) Maximum aggregation results from three experiments are 
shown as means ± S.E.M. (*P < 0.05, **P < 0.01, ***P < 0.001). Washed platelets from 
WT and GPVI-deficient mice were stimulated with (C) 4N1-1 (100 μM) or (D) Champs 
(30 μg/ml) for 3 min. Protein phosphorylation was measured as described in Figure 3-
2. Molecular masses are indicated in kDa. Results are representative of three 
experiments. 
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3.4.6 CLEC-2 and GPVI mediate activation of mouse platelets by fucoidan 
 
We have previously reported that the sulfated polysaccharide fucoidan activates human 
and mouse platelets through Src and Syk tyrosine kinases and that activation is lost in 
mouse platelets deficient in CLEC-2 (Manne et al., 2013). In the present study, we show 
that higher concentrations of fucoidan induce partial aggregation of CLEC-2-deficient 
platelets and that this is blocked in mouse platelets double-deficient in GPVI and CLEC-
2 (Figures 3-6Ai and 3-6Aii). Shape change is observed in some but not all experiments 
(Figure 3-6Ai). In contrast, aggregation is not altered in GPVI- deficient mouse platelets 
in response to maximal or sub-maximal concentrations of fucoidan (Figures 3-6Ai and 3-
6Aii; Supplementary Figure 3-2), consistent with results in FcR γ-chain-deficient mouse 
platelets (Manne et al., 2013). 
The stimulation of whole-cell tyrosine phosphorylation by fucoidan was 
inhibited but not abolished in CLEC-2-deficient platelets (Figure 3-6Bi), with no 
apparent change in GPVI-deficient platelets (appendix 6). A further reduction in 
tyrosine phosphorylation is seen in GPVI/CLEC-2-double-deficient platelets, although 
a residual increase in phosphorylation, including a band of 90 kDa, is still present 
(Figure 3-6Bii). This residual phosphorylation is blocked by the Src kinase inhibitors 
PP2 or dasatinib (appendix 7). Tyrosine phosphorylation of Syk by fucoidan is markedly 
inhibited in the absence of CLEC-2 and blocked in GPVI/CLEC-2-double-deficient 
platelets, whereas Syk phosphorylation is not altered in the absence of GPVI (Figure 3-
6Biii). A weak band corresponding to the FcR γ-chain is present in Syk 
immunoprecipitates from control platelets, which is lost in platelets deficient in GPVI, 
GPVI/CLEC-2- double-deficient and, surprisingly, CLEC-2-deficient platelets (Figure 
6Biii). These results confirm that fucoidan activates both GPVI and CLEC-2 in 
platelets, but suggest that it also binds to one or more additional platelet surface 
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receptors which leads to an increase in tyrosine phosphorylation but not platelet 
activation. 
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Figure 3-6 Fucoidan activates mouse platelets through GPVI and CLEC-2. (A) (i) 
Washed platelets from wild-type (WT), CLEC-2-deficient, GPVI-deficient and 
GPVI/CLEC-2-double-deficient (DKO) mice were stimulated with fucoidan (100 
μg/ml) and monitored for aggregation. (ii) Quantification of maximal aggregation, 
shown as means ± S.E.M., n>3 (***P < 0.001). (B) Washed platelets from WT and (i) 
CLEC-2-deficient (ii) GPVI/CLEC-2-double-deficient mice were stimulated with 
fucoidan (100 μg/ml) for 3 min. Protein phosphorylation was measured as described in 
Figure 3-2. (iii) Syk was immunoprecipitated as described in Figure 3-2 and 
phosphotyrosine of co-precipitated FcR γ-chain in the Syk immunoprecipitate is shown. 
WB, Western blot. Molecular masses are indicated in kDa. Results are representative 
of three experiments.  
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3.4.7 CLEC-2 and GPVI mediate activation of mouse platelets by dextran sulfate 
 
Dextran sulfate has been reported to induce aggregation of washed human platelets 
through a Src kinase-dependent but Syk-independent pathway (Getz et al., 2013a). We 
have confirmed this result using two further inhibitors of Src and Syk tyrosine kinases, 
PP2 and PRT318, which block or slow the onset of aggregation respectively (Figures 
3-7Ai and 3-7Aii). In addition, we show that dextran sulfate stimulates tyrosine 
phosphorylation of CLEC-2 in human platelets (Figure 3-7Aiii), which may account 
for the delay in aggregation observed in the presence of PRT318 (Figure 3-7Ai). 
Dextran sulfate stimulates weak aggregation of mouse platelets, which, in 
contrast with human platelets, is inhibited in the presence of PP2 or PRT318 (Figure 3-
7B). A small increase in light transmission is observed in the presence of either inhibitor 
(Figure 3-7B) and in the presence of integrilin (appendix 8), which is likely to be due 
to platelet agglutination. A similar reduction in aggregation is seen in CLEC-2-
deficient and in GPVI/CLEC-2-double-deficient platelets, whereas the response is not 
altered in the absence of GPVI alone (Figures 3-7Ci - 3-7Ciii). Dextran sulfate 
stimulated tyrosine phosphorylation of CLEC-2 and Syk in mouse platelets (Figures 3-
7Di and 3-7Dii). Phosphorylation of Syk was markedly inhibited in the absence of 
CLEC-2 and blocked in GPVI/CLEC-2-double-deficient platelets, but unaltered in the 
absence of GPVI (Figure 3-7Di; and appendix 9). These results demonstrate that dextran 
sulfate induces activation of mouse platelets through a CLEC-2-driven pathway, with a 
minor role for GPVI. In contrast, dextran sulfate activates human platelets through a 
Syk-independent pathway, making it likely that activation is independent of CLEC-2 
and/or GPVI. 
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Figure 3-7 Dextran sulfate activates human and mouse platelets through a Src kinase 
activation. (i) Washed human platelets were pre-incubated with PP2 (10 μM) and 
PRT318 (5 μM) before stimulation with dextran sulfate (DxS; 20 nM). Veh, vehicle 
(DMSO, 0.2 %). (ii) Quantification of maximal aggregation is shown as means ± 
S.E.M., n>3 (***P < 0.001). (iii) CLEC-2 was immunoprecipitated (IP) as described in 
Figure 1. Results are representative of three experiments. Washed mouse platelets were 
pre-incubated for 3 min with PP2 (10 μM) and PRT318 (5 μM) before stimulation with 
dextran sulfate (20 nM). (i) Representative aggregation traces. (ii) Quantification of 
maximal aggregation shown as means ± S.E.M. from three experiments (***P < 0.001). 
(C) (i) Washed platelets from wild-type, CLEC-2-deficient, GPVI-deficient, and (ii) 
GPVI/CLEC-2-double-deficient (DKO) mice were incubated with dextran sulfate (20 
nM) and monitored for aggregation. Results are representative of three experiments. 
(iii) Mean ± S.E.M. aggregation from three experiments (***P < 0.001). (D) (i and ii) 
Protein phosphorylation of Syk and CLEC-2 was measured after dextran sulfate 
stimulation of washed mouse platelets as described in Figure 3-2. WB, Western blot. 
Molecular masses are indicated in kDa. Results are representative of three experiments.  
 
 
105  
3.4.8 Pam3-CSK4 stimulates phosphorylation of the FcR γ–chain 
 
The toll-like receptor (TLR)-1/2 agonist Pam3-CSK4 stimulates aggregation of human 
platelets in association with phosphorylation of a number of proteins that are regulated 
by platelet ITAM receptors, including Syk and PLCγ 2 (Falker et al., 2014). In the present 
study, we show that Pam3-CSK4 induces transient tyrosine phosphorylation of the FcR 
γ-chain in human platelets, which can be detected after 10 s but not after 300 s (Figures 
3-8Ai and 3-8Aii). Syk phosphorylation occurs in parallel with phosphorylation of the 
FcR γ-chain (Figures 3-8Ai and 3-8Aii). In contrast, CLEC-2 is not phosphorylated by 
Pam3-CSK4 in human platelets (appendix 10). Pam3-CSK4 stimulates sustained 
phosphorylation of FcR γ-chain and Syk in mouse platelets, but again has no effect on 
CLEC-2 phosphorylation (Figure 3-8B and appendix 11). This increase in 
phosphorylation of the FcR γ-chain and Syk is blocked in GPVI deficient platelets 
(Figure 3-8B). Surprisingly, however, Pam3-CSK4 induced aggregation is not altered in 
GPVI-deficient mouse platelets (Figures 3-8Ci and 3-8Cii) or the presence of inhibitors 
of Src and Syk tyrosine kinases (appendix 12).These results demonstrate that Pam3-
CSK4 induces platelet aggregation through a tyrosine kinase-independent pathway 
despite robust activation of GPVI (as shown by FcR γ-chain and Syk phosphorylation) 
suggesting that it activates platelets through multiple receptors. 
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Figure 3-8 Pam3-CSK4 activates Syk in human and mouse platelets. (A) (i and ii) Washed 
human platelets were pre-incubated with integrilin (9 μM) and stimulated under stirring 
conditions with Pam3-CSK4 (30 μg/ml) for 10 and 300 s before lysis. Protein phosphorylation 
was measured as described in Figure 3-1. WB, Western blot. Molecular masses are indicated in 
kDa. (ii) Syk was immunoprecipitated and phosphotyrosine of co-precipitated FcR γ-chain in 
the Syk immunoprecipitate (IP) is also shown. Results are representative of three experiments. 
(B) (i and ii) Washed platelets from wild-type (WT) and GPVI-deficient mice were stimulated 
with Pam3-CSK4 (30 μg/ml): (i) representative aggregation traces; and (ii) results shown as 
mean ± S.E.M. aggregation from three experiments. (C) Protein phosphorylation in WT and 
GPVI deficient mouse platelets in response to Pam3-CSK4 (30 μg/ml) for 10 and 300 s was 
measured as described in Figure 3-2. Results are representative of three experiments. 
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3.4.9 The effect of the structurally diverse stimuli GPVI and CLEC-2-
transfected cell lines 
To seek confirmatory evidence that the above agonists directly activate GPVI and/or 
CLEC-2, we investigated their activation of transfected cell lines. We used human GPVI 
and human CLEC- 2 in these studies. We investigated the action of the above agonists 
on GPVI- transfected chicken DT40 B-cells and human Jurkat-T cells using an NFAT–
luciferase reporter as a readout for activation of PLCγ 2 (Gibbins et al., 1996). We 
performed these studies in the absence of serum or antibiotics to prevent a possible 
interaction with one or more of this structurally diverse group of ligands. We used two 
cell lines in case of possible species differences in activation. We observed a similar 
level of activation of GPVI by DEP, fucoidan and dextran sulfate in transfected Jurkat 
T-cells (Figure 3-9A) and DT40 B-cells (appendix 13) to that induced by collagen, but 
not by the other agonists used above, namely CTH, LSARLAF and Pam3-CSK4 (Figure 
3-9B). We were, however, unable to investigate 4N1-1 and Champs as both peptides 
stimulated a marked increase in luciferase activity in mock- transfected cells (appendix 
14). We also investigated whether these stimuli were able to activate CLEC-2 in 
transfected DT40 cells. We were unable to perform similar studies on human Jurkat 
cells as CLEC-2 is unable to signal through the Syk-related kinase ζ -chain-associated 
protein of 70 kDa (Zap-70), which is expressed in these cells (Hughes et al., 2013). 
DEP, fucoidan and dextran sulfate induced activation of CLEC-2, whereas the other 
agonists had no effect (Figures 3-9B and 3-9C). These results therefore confirm that 
DEP, fucoidan and dextran sulfate are able to activate GPVI and CLEC-2. The inability 
of the other stimuli to activate the two platelet (hem)ITAM receptors could reflect a loss 
of avidity due to the absence of other key surface receptors or even binding to inhibitory 
ITIM receptors in these cell lines (see the discussion). 
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Figure 3-9 Miscellaneous platelet stimuli activate GPVI and CLEC-2 in transfected cell 
lines. (A) The effect of DEP (50 μg/ml), fucoidan (150 μg/ml) and dextran sulfate (DxS; 
100 nM) on GPVI-transfected Jurkat T-cells was monitored using an NFAT–luciferase 
reporter assay. Cells were transfected with either an empty vector (mock) or a GPVI–
FcRγ -chain and an NFAT–luciferase reporter as described in the Experimental section 
and stimulated for 6 h. Luciferase activity was measured as previously described 
(Tomlinson et al., 2007). Results are representative of three experiments, and are means 
± S.E.M, n-3 (*P <0.05, **P <0.01). (B) The effects of CTH (100 μg/ml), 4N1-1(100 
μM) and Pam3-CSK4 (50 μg/ml) on GPVI- or CLEC-2-transfected DT40 B-cells was 
monitored using the NFAT–luciferase reporter assay described above. Results are 
means ±S.D. n=3 (**P <0.01). (C) The effect of DEP, fucoidan and dextran sulfate on 
CLEC-2-transfected DT40 cells was monitored using an NFAT–luciferase reporter 
assay as described in the Experimental section and stimulated for 3 h. Results are 
representative of three experiments, and are means ± S.E.M., n-3 (**P <0.01, ***P 
<0.001). Coll, collagen; Rho rhodocytin 
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Table 3-1 Summary of platelet activation by miscellaneous ligands. The Table summarizes 
the mechanism of platelet activation by the ligands that have been used in the present study. 
The columns represent the following: Receptor phosphorylation: phosphorylation of FcR γ-
chain or CLEC-2; Aggregation: dependency on Src and Syk tyrosine kinases; Agglutination: 
whether agglutination (αIIbβ3-independent aggregation) is present. 
 
Ligand Receptor 
phosphorylation 
Aggregation block 
by Src 
Aggregation block 
by Syk 
Agglutin
ation 
DEP FcR γ-chain, CLEC-2 
(weak) 
Yes Yes No 
CTH FcR γ-chain Yes Yes No 
4N1-1 FcR γ-chain Yes Yes Yes 
Champs FcR γ -chain Yes Yes Yes 
Fucoidan FcR γ-chain (weak), 
CLEC-2 
Yes Yes No 
Dextran 
sulfate 
CLEC-2 Yes Yes Yes 
Pam3 -
CSK4 
FcR γ-chain 
(transient) 
No No No 
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3.5 Discussion 
 
The present study has investigated the mechanism of platelet activation by a diverse 
group of ligands that were selected on their known ability to activate platelets but their 
lack of structural resemblance to known platelet agonists. The results imply that all of 
these stimuli induce activation through GPVI and/or CLEC-2 but that they also bind to 
additional Src kinase-coupled surface receptors. However, with the exception of dextran 
sulfate, it appears that this additional binding only induces weak signalling, insufficient 
to cause full platelet activation and aggregation. The three structurally unrelated small 
peptides, Pam3-CSK4 and histones all activate GPVI, whereas DEP, fucoidan and 
dextran sulfate activate both GPVI and CLEC-2, with the former showing a preference 
for the collagen receptor over CLEC-2 and vice versa for fucoidan and dextran. This 
marked heterogeneity in terms of receptor specificity within this group is summarized 
in Table 3-1. 
The mechanism of activation of GPVI and CLEC-2 by DEP, fucoidan and 
dextran sulfate appears to be through direct binding as shown in transfected cell lines. 
In contrast, we did not observe activation of GPVI and/or CLEC-2 in transfected DT40 
or Jurkat cells using the other ligands described above, namely histones, 4N1-1 and 
Pam3-CSK4 (with the caveat that this could not be investigated for Champs and 
LSARLAF because of activation of mock-transfected cells). While we cannot rule out 
that this is due to an alternative conformation of these two proteins relative to that on a 
platelet surface, a more likely explanation is that of too low an affinity as discussed 
above, with binding on platelets being influenced by avidity. The ability of these ligands 
to activate GPVI and/or CLEC-2 on platelets may therefore be the result of enhanced 
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avidity mediated by binding to multiple surface proteins including multiple copies of 
GPVI/CLEC-2. 
Evidence of binding to other surface proteins by the above ligands is provided 
by the observation that all of these stimuli also induce tyrosine phosphorylation 
independently of GPVI and CLEC-2 as shown using GPVI/CLEC-2-double-deficient 
platelets. However, only in the case of dextran sulfate does this lead to activation. It is 
therefore likely that binding to these other receptors facilitates binding to GPVI and 
CLEC-2 through increased avidity. In addition, this could also influence activation of 
one or both of the (hem)ITAM receptors through binding to other surface proteins such 
as tyrosine phosphatase-binding proteins, e.g. cluster of differentiation (CD) 148 (Senis 
et al., 2009, Severin et al., 2011b) and the constitutively phosphorylated ITIM receptor 
G6b-B (Mori et al., 2008). Altering the distribution of GPVI or CLEC-2 relative to 
these proteins could lead to receptor activation. The critical role of GPVI and CLEC-2 
in mediating platelet activation by this diverse group of agonists, relative to other 
receptors, may reflect their ability to induce powerful activation of Syk through ITAM 
and hemITAM-based pathways respectively. In contrast, other surface glycoproteins 
that activate Syk, such as the GPIb-IX-V complex and integrin αIIbβ3, induce relatively 
weak activation of Syk most probably because of the absence of a cytosolic (hem) 
ITAM. 
We have also shown that aggregation induced by low concentrations of the 
ligands that have been used in the present study is partially inhibited by agents that 
prevent the formation (indomethacin) or action (apyrase) of the feedback agonists, 
thromboxane A2 and ADP (appendix 15). This is similar to platelet activation by low 
concentrations of most platelet agonists, including both GPVI and CLEC-2 ligands. 
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The stimuli that form the focus of the present study differ markedly in size, charge and 
hydrophobicity, and include large polysaccharides, charged/hydrophobic peptides, 
highly basic proteins and DEP, which are carbon black nanoparticles with surface 
electrical charge. Such diversity in terms of structure, along with the differential roles 
of GPVI and CLEC-2, indicates that they are unlikely to induce activation through a 
single mechanism, consistent with the differential roles of the two (hem)ITAM 
receptors in mediating activation to these ligands, as described above. Furthermore, this 
structural diversity indicates that they are unlikely to mediate activation through a ‘close-
fitting’ binding interface with a high degree of surface complementarity, but via 
hydrophobic and charge interactions that lead to receptor clustering or altered 
interactions with surrounding proteins. The binding of fucoidan to CLEC-2 is a possible 
example of this and we speculate that this may occur at the binding sites in CLEC-2 for 
the podoplanin aspartic–glutamic acid doublet and O-glycan or the negatively charged 
C-terminus of rhodocytin as predicted from co-crystallization (Jung et al., 2012). The 
binding of podoplanin and rhodocytin to CLEC-2 is abrogated on mutation of just one 
of the four conserved arginines in the C-type lectin-like receptor, emphasizing the 
importance of a charged interaction (Jung et al., 2012). The negatively charged nature 
of fucoidan and dextran sulfate, and the multiple charges on DEP, would be consistent 
with such a mechanism. 
The possibility that this diverse group of agonists could exert their effects on 
platelets through the interaction with a single membrane protein or with the membrane 
bilayer however seems unlikely. The observation that the majority of the stimuli are 
unable to activate GPVI or CLEC-2 in transfected DT40 cells argues against an 
interaction with the phospholipid membrane being the sole cause of activation. The 
diversity of structures also argues against an effect on a single surface receptor. 
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Moreover, we have shown that representative stimuli from this group (i.e. DEP, 
histones, fucoidan and 4N1-1) stimulate granule secretion and tyrosine phosphorylation 
in platelets from patients deficient in the two major platelet glycoprotein receptors, 
GPIbα and integrin αIIbβ3 (not shown and appendix 16). Furthermore, we have also 
shown the stimulation of ATP secretion by this diverse group of ligands is blocked in 
the presence of a Src kinase inhibitor (appendix 17) demonstrating that it is not 
mediated by lysis. Together, these data indicate that this group of ligands bind to 
multiple proteins including GPVI, CLEC-2 and other Src kinase-coupled receptors. 
The differential roles of GPVI over CLEC-2 in platelet activation by the various 
ligands could reflect differences in their proximal signalling events. For example, 
platelet activation by GPVI but not by CLEC-2 is inhibited in the absence of the 
membrane tyrosine phosphatases CD148 (Severin et al., 2011b, Senis et al., 2009). 
Additionally, whereas Src kinases mediate phosphorylation of the ITAM in the GPVI–
FcRγ-chain complex, phosphorylation of the hemITAM in CLEC-2 is mediated by Syk 
(Hughes et al., 2013, Spalton et al., 2009a, Severin et al., 2011b). Moreover, GPVI is 
predominantly monomeric on resting platelets and undergoes dimerization upon 
activation to a high-affinity state that enables binding to collagen (Jung et al., 2012). In 
contrast, CLEC-2 is expressed as a dimer in resting platelets (Hughes et al., 2010b). 
Measurement of GPVI and CLEC-2 dimerization/oligomerization using techniques 
such as FRET and super-resolution microscopy in the presence of this miscellaneous 
group of ligands will provide important insights into the mechanism of regulation. 
Interestingly, GPVI-deficient platelets also have a 50 % reduction in expression of the 
FcR γ-chain (supplementary 4-2). This demonstrates that platelet activation is mediated 
by the GPVI–FcRγ-chain complex rather than through the indirect cross-linking of the 
FcR γ -chain. 
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Several of the stimuli that have been investigated in the present study, namely 
the three charged peptides, DEP and dextran sulfate, also induce platelet agglutination, 
possibly through negation of surface membrane charge or promotion of low-affinity 
interactions between homophilic ligands such as platelet-endothelial cell adhesion 
molecule (PECAM)-1 receptors or ligand pairs such as ephrins and Eph kinases (aka 
ephrin receptors). Many of these low-affinity interactions are thought to play a critical 
role in late-stage platelet activation(Brass et al., 2011). 
The present results are important to a number of physiological and pathological 
processes. Histones are implicated in a variety of pathological conditions, including 
trauma and thrombo- inflammatory disorders such as deep vein thrombosis (Abrams et 
al., 2013, Brill et al., 2012). Histones exert a multitude of effects in the vasculature 
including endothelial cell damage and platelet activation. These effects are likely to be 
mediated by multiple mechanisms including activation of ion channels, TLRs and, as 
shown in the present study, through (hem) ITAM receptors. The significance of platelet 
activation by DEP is less clear as they were unable to induce activation in the presence 
of plasma presumably due to plasma protein binding. On the other hand, they have been 
shown to potentiate aggregation in vivo in the presence of other agonists (Solomon et 
al., 2013) although it is not known whether this involves activation of GPVI and CLEC-
2. Furthermore, other types of nanoparticles may have increased bioavailability in vivo 
and may mediate activation by similar mechanisms to those described above. 
Platelets are activated by several other structurally unrelated stimuli where 
uncertainty exists with regard to the underlying mechanism. For example, the TLR1/2 
ligand Pam3-CSK4 has been shown to stimulate tyrosine phosphorylation of several 
proteins in the (hem)ITAM signalling cascade in human platelets, including Src kinase 
family, Syk, linker of activated T-cells (LAT) and PLCγ 2 (Falker et al., 2014) In the 
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present study, we have shown that Pam3 -CSK4 stimulates transient phosphorylation 
of the FcRγ-chain and Syk but not CLEC-2, and this is lost in GPVI- deficient mice 
even though platelet aggregation is not altered.  
This is in contrast with human platelets where phosphorylation of Syk and the 
downstream LAT signalosome is independent of GPVI (Falker et al., 2014) , although it 
is possible that this may reflect a difference in the methodologies used to block GPVI 
function. Examples of other ligands that induce activation and for whom uncertainty 
exists in regard to the underlying mechanism include oxidised-low density lipoprotein 
(ox-LDL), the ionic sclerosing agent sodium tetradecyl sulfate, the charged inositol 
phospholipid phosphatidylinositol 3, 4, 5-trisphosphate (PIP3) and various amyloid 
proteins. It will be of interest to establish whether mechanisms similar to those described 
in the present study underlie activation by one or more of these ligands. 
In conclusion, the present study demonstrates that a diverse range of ligands 
activate platelets through GPVI and/or CLEC-2. In addition, these ligands activate other 
unidentified Src kinase- coupled surface proteins, although only in the case of dextran 
sulfate does this lead to platelet aggregation. The mechanisms described in the present 
study may have relevance to a variety of physiological and pathological situations 
ranging from the elevation of histones through to exposure to nanoparticles and contact 
with exogenous surfaces.  
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3.7 Supplementary 
 
Supplementary figure 3-1 A submaximal dose of diesel exhaust particles (DEP) activates 
mouse platelets through GPVI. (A) Washed platelets from wild type (WT), CLEC-2-
deficient, and GPVI-deficient mice were stimulated with DEP (20 μg/ml) and monitored for 
aggregation. (B) Quantitation of maximal aggregation, shown as mean ± SEM, from 3 
experiments; (*** P<0.001).  
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Supplementary figure 3-2 A sub-maximal dose of fucoidan activates mouse platelets 
through CLEC-2 alone. (A) Washed platelets from wild type (WT) and GPVI-deficient mice 
were stimulated with fucoidan (50 μg/ml) and monitored for aggregation. (B) Quantitation of 
maximal aggregation, shown as mean ± SEM, from 3 experiments. 
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Chapter 4 FIBRIN ACTIVATES GPVI IN HUMAN 
AND MOUSE PLATELETS 
 
 
 
This research was originally published in Blood. Osama M. Alshehri, Craig E. 
Hughes, Samantha Montague, Stephanie K. Watson, Jon Frampton, Markus Bender, 
and Steve P. Watson. Fibrin activates GPVI in human and mouse platelets. Blood. 
2015; 126:1601-8. © The American Society of Hematology 
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This chapter demonstrates that fibrin binds to GPVI leading to the platelet activation 
and thrombus growth and stability. I contributed to this study by performing all of the 
in vitro experiments other than the GPVI ELISA which was performed by Samantha 
Montague. The in vivo experiments were undertaken by Markus Bender. Stephanie 
Watson performed studies on GPVI-transfected cell lines that were not included in the 
paper. The studies were designed with Craig Hughes. 
 
- All not shown results have been added to the Appendix except those in page 130 
and 136 were performed by one of the other authors in the manuscript 
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Abstract 
The glycoprotein VI (GPVI)-Fc receptor γ (FcRγ) chain is the major platelet signaling 
receptor for collagen. Paradoxically, in a FeCl3 injury model, occlusion, but not 
initiation of thrombus formation, is delayed in GPVI-deficient and GPVI-depleted 
mice. In this study, we demonstrate that GPVI is a receptor for fibrin and speculate 
that this contributes to development of an occlusive thrombus. We observed a marked 
increase in tyrosine phosphorylation, including the FcR γ-chain and Syk, in human 
and mouse platelets induced by thrombin in the presence of fibrinogen and the αIIbβ3 
blocker eptifibatide. This was not seen in platelets stimulated by a protease activated 
receptor (PAR)-4 peptide, which is unable to generate fibrin from fibrinogen. The 
pattern of tyrosine phosphorylation was similar to that induced by activation of GPVI. 
Consistent with this, thrombin did not induce tyrosine phosphorylation of Syk and the 
FcR γ-chain in GPVI-deficient mouse platelets. Mouse platelets underwent full 
spreading on fibrin but not fibrinogen, which was blocked in the presence of a Src 
kinase inhibitor or in the absence of GPVI. Spreading on fibrin was associated with 
phosphatidylserine exposure (procoagulant activity), and this too was blocked in 
GPVI-deficient platelets. The ectodomain of GPVI was shown to bind to immobilized 
monomeric and polymerized fibrin. A marked increase in embolization was seen 
following FeCl3 injury in GPVI-deficient mice, likely contributing to the delay in 
occlusion in this model. These results demonstrate that GPVI is a receptor for fibrin 
and provide evidence that this interaction contributes to thrombus growth and 
stability.  
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4.1 Introduction  
 
Glycoprotein VI is an immunoglobulin superfamily receptor expressed on the 
surface of platelets in association with the Fc receptor γ chain (FcR γ-chain). Ligand 
binding of GPVI results in receptor clustering and Src kinase-dependent tyrosine 
phosphorylation of the FcR γ-chain immunoreceptor tyrosine-based activation motif 
(ITAM). This initiates a signalling pathway involving Src and Syk tyrosine kinases, 
various adapter proteins, and results in activation of phospholipase-C (PLC) γ2 (for 
review see) (Watson et al., 2010). 
GPVI is the major signalling receptor for the extracellular matrix protein, 
collagen (Ryo et al., 1992, Moroi et al., 1989, Arai et al., 1995), and is also activated 
by other endogenous ligands including laminin (Inoue et al., 2006); adiponectin (Riba 
et al., 2008) and the Ig superfamily protein EMMPRIN (CD147/Basigin) (Seizer et 
al., 2009). GPVI is also activated by a variety of exogenous and synthetic ligands 
including collagen-related peptide (CRP), which consists of glycine-proline-
hydroxyproline (GPO) repeats(Knight et al., 1999), the snake venom toxin, convulxin 
(Polgar et al., 1997, Jandrot-Perrus et al., 1997), various artificial peptides including 
4N1-1 and LSARLAF, antisense nucleotides (Flierl et al., 2015) and diesel exhaust 
particles (Alshehri et al., 2015). 
GPVI plays a critical role in haemostasis and thrombosis through integrin 
activation, supporting adhesion and the initial stages of platelet aggregation. Despite 
this, patients and mice deficient in GPVI exhibit mild or no apparent impairment in 
haemostasis due to compensatory pathways of initiation of platelet activation 
including tissue factor-driven thrombin generation (Bynagari-Settipalli et al., 2014) 
and ADP release from damaged cells. GPVI also plays a critical role in the 
maintenance of a healthy endothelial cell layer, a process known as vascular integrity 
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(Boulaftali et al., 2013). The contribution of GPVI to thrombosis varies according to 
the experimental model. This is illustrated by its role in FeCl3 and laser injury models, 
which is dependent on the level of injury to the vessel wall and the degree of exposure 
of the subendothelial matrix (Bender et al., 2011, Dubois et al., 2006, Konstantinides 
et al., 2006, Massberg et al., 2003). In the absence of a breach in the endothelium, 
thrombus formation is mediated by endothelial cell activation leading to tissue factor 
exposure and thrombin generation (Dubois et al., 2006, Konstantinides et al., 2006, 
Massberg et al., 2003, Eckly et al., 2011) 
The focus of research on GPVI in haemostasis and thrombosis has been on its 
interaction with collagen. Paradoxically, however, the time to occlusion rather than 
initiation of thrombus formation has been shown to be prolonged in GPVI-deficient 
and GPVI-depleted mice following FeCl3 injury, suggesting a role for GPVI in 
thrombus growth (Bender et al., 2011) even though collagen is only thought to play a 
role at the site of lesion. In the present study, we provide an explanation for this 
paradox by demonstrating that GPVI is a receptor for fibrin, which is generated from 
fibrinogen by the action of thrombin. Thus, GPVI is a receptor for both collagen and 
fibrin, and plays a critical role in thrombus growth as well as in initiating thrombus 
formation.  
4.2 Materials and Methods  
 
4.2.1 Reagents  
 
Human fibrinogen was obtained from Enzyme Research Laboratories (Swansea, UK). 
The α- phospho-tyrosine (4G10) monoclonal antibody was from Millipore 
(Abingdon, UK). Alexa-488 fibrinogen, Alexa-488 phalloidin, and Alexa-568 
phalloidin were from Molecular Probes (Life Technologies, Paisley, UK). The α-Syk 
antibody (SC-573) was from Insight Biotechnology (Wembley, UK).The α-CLEC-2 
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antibodies (AYP1 and AYP2) have been described previously (Gitz et al., 2014) 
.FITC-Annexin V was from BD Bioscience (Oxford, UK). FITC-conjugated α-mouse 
αIIbβ3, α2, CLEC-2, GPIbα, GPV, GPVI, GPIX, and IgG antibodies were from 
Emfret Analytics (Würzburg, Germany). Dasatinib was from LC Laboratories 
(Woburn, MA, USA). PAR-4 peptide (Ala-Tyr-Pro-Gly-Lys-Phe: AYPGKF) was 
produced by Alta Bioscience (Birmingham, UK). HRP-conjugated secondary 
antibodies and ECL reagent was from Amersham Biosciences (GE Healthcare, Bucks, 
UK). HRP-conjugated secondary antibody for ELISA was from Dako (Ely, UK). The 
α-GPVI antibody (1A12) was provided by Dr Elizabeth Gardiner (Melbourne, 
Australia). SuperSignal ELISA Pico chemiluminescent substrate was from Pierce 
(Rockford, IL, USA). All other reagents were purchased from Sigma Aldrich (Poole, 
UK). 
 
4.2.2 Mice  
 
Gp6-/- mice (GPVI KO) were provided by Dr Jerry Ware (Kato et al., 2003). Itga2b-/- 
mice (αIIb-deficient mice) have been previously described (Emambokus and Frampton, 
2003).Wild-type mice (WT) were generated from breeding of heterozygotes or 
purchased from Harlan Laboratories (Hillcrest, UK). All procedures were undertaken 
with UK Home Office approval under PPL30/2721 and PPL30/8286. 
4.2.3 Washed platelet preparation 
 
Blood was drawn from CO2-asphyxiated mice or from consenting, healthy, drug free 
volunteers into 10% acid citrate dextrose or sodium citrate, respectively. Ethical 
approval for the donation of blood by volunteers was granted by Birmingham 
University Internal Ethical Review (ERN_11-0175). Washed platelets were obtained 
by centrifugation using prostacyclin and resuspended in modified Tyrode’s buffer 
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(134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES 
(4-(2-hydroxyethyl)-1 piperazineethanesulfonic acid), 5 mM glucose, and 1 mM 
MgCl2; pH 7.3) as previously described (Hughes et al., 2015). Platelets were used at 
2 x 107/mL for static adhesion or 5 x108/mL for other studies. 
4.2.4 Protein phosphorylation  
 
Washed platelets were pre-treated with 9μM eptifibatide (where stated), 10μM 
indomethacin and 2 U/ml apyrase or solvent controls. Platelets were stimulated with 
thrombin (1 U/ml) or PAR-4 peptide (AYPGKF; 150 μM) at 37°C with stirring 
(1200rpm) in an aggregometer for 60 sec. Where stated, stimulations were performed 
in the presence of fibrinogen (200 μg/ml) and GPRP (Gly-Pro-Arg-Pro; 5 μM). 
Activation was terminated with 2×ice-cold lysis buffer (300 mM NaCl, 20 mM Tris, 
2 mM EGTA, 2 mM EDTA, 2% IGEPAL CA-630 (NP-40 equivalent); pH 7.4 plus 
2.5 mM Na3VO4, 100 μg/ml AEBSF, 5 μg/ml leupeptin, 5 μg/ml aprotinin, 0.5 μg/ml 
pepstatin). Whole cell lysates were prepared by boiling a sample of lysate with SDS 
sample buffer. Syk was immunoprecipitated with α-Syk antibody (SC-573) and 
protein A-Sepharose beads for 2 hrs. The beads were then washed and proteins eluted 
by boiling in SDS sample buffer. IPs and WCLs were then separated by SDS-PAGE, 
electro-transferred, and Western blotted. Western blots were imaged with a Licor 
Odyssey-FC (Cambridge, UK) or autoradiographic film.  
4.2.5 Platelet spreading  
 
Coverslips were coated in the presence of 200 μg/ml fibrinogen (± 5 μM GPRP) for 
60 min followed by washing with phosphate-buffered saline and then blocking with 
5 mg/ml heat-inactivated bovine serum albumin for 60 min. Fibrin-coated coverslips 
were generated by the addition of 1 U/ml thrombin for 15 min to coverslips that had 
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been incubated with 200 μg/ml fibrinogen for 30 min. Thrombin was neutralised by 
addition of 5 U/ml hirudin for 30 min. Following coating, coverslips were washed and 
blocked with 5 mg/ml heat inactivated bovine serum albumin for 60 min. Platelets 
were spread on fibrinogen or fibrin for 45 min at 37˚C before washing with Tyrode’s 
buffer followed by fixation with paraformaldehyde (3.7%). Where stated, platelets 
were pre-incubated with dasatinib (10 μM) or hirudin (5 U/ml). For actin staining, 
platelets were permeablised with 0.1% Triton X-100 and stained with Alexa-488 
phalloidin for 45 min. In some studies, Alexa-488-fibrinogen was used for fluorescent 
imaging to monitor conversion to fibrin, in which case, platelets were counterstained 
with Alexa-568 phalloidin for 45 min. For phosphatidylserine (PS) staining, platelets 
were incubated with FITC-Annexin V in Tyrode’s buffer plus 2 mM CaCl2 for a 
further 15 min, followed fixation, and counter-staining for actin using Alexa-568 
phalloidin for 45 min. Platelets were imaged on a Zeiss Axiovert 200 M microscope. 
Platelet surface area was analysed using ImageJ (NIH, Bethesda, USA).  
4.2.6 Flow cytometry  
 
Surface glycoprotein expression was measured in wild type and GPVI-deficient 
mouse platelets by staining whole blood with selected FITC-conjugated antibodies 
and analyzing with a BD Accuri C6 flow cytometer (BD Biosciences, Oxford, UK).  
4.2.7 GPVI ELISA  
 
Binding of GPVI to fibrin/fibrinogen was measured using an adapted version of a 
soluble GPVI ELISA (Al-Tamimi et al., 2009b). Wells of a Nunc Maxisorp micro-
titre plate (Thermo Scientific, Paisley, UK) were coated with fibrin/fibrinogen using 
the same protocol as above. Wells were washed six times with 100 μl of PBS-T 
(0.2%), blocked with 1% (w/v) BSA for 1hr at RT, and then washed six times with 
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PBS-T. GPVI ectodomain (prepared from NEM treated plasma) was added to the 
wells for 1 hr at RT, followed by washing six times with PBS-T. A standard curve 
was generated by a serial dilution of GPVI ectodomain into GPVI-depleted plasma. 
Primary antibody, (1A12; 1 μg/ml) was then incubated for 1hr followed by six 
washes. Secondary, α- mouse HRP-conjugated antibody (2.6 μg/ml) was then 
incubated for 1 hr, followed by six washes, followed by 100μl of SuperSignal 
substrate for 1 min. Light emission was measured using a Wallac-Victor2 
luminescence plate reader (PerkinElmer, Waltham, MA, USA) for 10 sec/well. 
Amounts of bound GPVI were calculated from the standard curve.  
4.2.8 Intravital microscopy  
 
4-5 weeks old WT or GPVI KO mice (Bender et al., 2013) were anesthetised, and the 
mesentery was exteriorised through a midline abdominal incision. Arterioles (40-60 
µm diameter) were visualised with a Zeiss Axiovert 200 inverted microscope (x10) 
equipped with a 100-W HBO fluorescent lamp source, and a CoolSNAP-EZ camera 
(Visitron Systems, Puchheim, Germany). Digital images were recorded and analysed 
offline using Metavue software. Injury was induced by topical application of a droplet 
of FeCl3 from 3-mm2 filter paper saturated with 20% FeCl3. The droplet rapidly 
dissipated through the vessel. Adhesion and aggregation of fluorescently labelled 
platelets (Dylight-488 conjugated α-GPIX Ig derivative) in arterioles were monitored 
for 40min or until complete occlusion occurred (blood flow stopped for longer than 
1min).  
4.3 Statistical analysis 
 
Statistical analysis was by ANOVA with a Bonferroni post-test, or for the ELISA, a 
one-tailed t-test. For in vivo experiments, results are shown as the mean ± SD of a 
minimum of six mice. Statistical analysis was by t –test. 
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4.4 Results  
4.4.1 Fibrin stimulates tyrosine phosphorylation in human and mouse platelets 
through GPVI.  
 
The binding of fibrinogen to integrin αIIbβ3 induces outside-in signalling leading to 
activation of Src and Syk tyrosine kinases and a signalling cascade that culminates in 
activation of PLCγ2 (Wonerow et al., 2003, Clark et al., 1994). In addition, αIIbβ3 is 
a receptor for fibrin, which binds to multiple sites in the αIIb β-propeller (Podolnikova 
et al., 2014). It is not known however whether binding of fibrin to the integrin also 
induces outside-in signalling. To address this, we compared tyrosine phosphorylation 
in human platelets stimulated by thrombin, which stimulates fibrin formation, and by 
a PAR-4 peptide. The contribution of fibrin polymers to tyrosine phosphorylation in 
this assay can be established using GPRP, which blocks polymerization of fibrin 
monomers.  
Thrombin stimulates tyrosine phosphorylation in human platelets under 
aggregating conditions, which is slightly increased in the presence of added fibrinogen 
(Suppl. Fig. 4-1). A similar increase in tyrosine phosphorylation is induced by the 
PAR-4 peptide. For both agonists, tyrosine phosphorylation is marginally reduced or 
unaltered in the presence of GPRP. These results indicate that fibrin does not play a 
major role in mediating tyrosine phosphorylation under aggregating conditions, which 
is predominantly mediated through binding of fibrinogen to integrin αIIbβ3 as 
previously reported (Watson et al., 2005b, Huang et al., 1993, Haimovich et al., 1993)  
A role for fibrin in mediating tyrosine phosphorylation may however have 
been masked by outside-in signalling by fibrinogen. To address this, we performed 
studies in the presence of eptifibatide, which blocks the binding of fibrinogen to 
αIIbβ3. Under these conditions, thrombin stimulates a much smaller increase in 
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tyrosine phosphorylation in platelet lysates, which is increased significantly in the 
presence of fibrinogen, including a band of 72 kDa, which was identified as Syk by 
immunoprecipitation and western blotting (Fig. 4-1Ai) (NB a decrease in Syk signal 
in the Syk reprobes corresponds with the increase in phosphorylated Syk. This is due 
to the blotting antibody not detecting phospho-Syk). In addition, a tyrosine 
phosphorylated band of 14 kDa was present in Syk immunoprecipitates, which 
corresponds to the FcR γ-chain. The marked increase in tyrosine phosphorylation, 
including Syk and the FcR γ-chain, is blocked in the presence of GPRP indicating that 
it is mediated fibrin polymerisation. In contrast, tyrosine phosphorylation induced by 
a PAR-4 peptide (which is unable to generate fibrin) is not altered in the presence of 
added fibrinogen or GPRP. A similar set of results are seen in mouse platelets 
stimulated by thrombin and by the PAR-4 peptide in the presence of eptifibatide (Fig. 
4-1Aii and appendix 18). These results show that fibrin increases tyrosine 
phosphorylation in human and mouse platelets, including Syk and FcR γ-chain.  
We used αIIb-deficient mouse platelets to investigate whether integrin αIIbβ3 
is required for the increase tyrosine phosphorylation induced by fibrin in the presence 
of eptifibatide (in view of the possibility that the increase was mediated by binding of 
fibrin to separate site on the integrin). As shown in (Fig.4-1Bi), tyrosine 
phosphorylation, including Syk and the FcR γ-chain, was again induced by thrombin 
in the presence of fibrinogen despite the absence of αIIb-integrin subunit, and this was 
blocked in the presence of GPRP. These results demonstrate that fibrin stimulates 
tyrosine phosphorylation of Syk and FcR γ-chain in mouse platelets independent of 
the major platelet integrin, αIIbβ3. The pattern of tyrosine phosphorylation was 
similar to that induced by activation of GPVI, including phosphorylation of the FcR 
γ-chain. To investigate a possible role for GPVI, we studied the effect of thrombin in 
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mouse platelets deficient in GPVI in the presence of eptifibatide to block binding of 
fibrinogen to integrin αIIbβ3. Platelets from these mice have approximately 50% of 
the wild type level of the GPVI-binding partner, the FcR γ-chain, while the level of 
other major platelet glycoprotein receptors was similar to that in wild type platelets 
(Suppl. Fig. 4-2). Further, activation of platelets by thrombin is not altered in GPVI- 
deficient mice (not shown) suggesting that the levels of PAR-4 are unchanged. Fibrin 
stimulated only a minor increase in tyrosine phosphorylation in GPVI-deficient 
platelets, and failed to induce phosphorylation of Syk or the FcR γ-chain (Fig. 4-1Bii). 
The minor increase in phosphorylation in platelet lysates was not altered in the 
presence of GPRP (Fig. 4-1Bii). These results demonstrate that the marked increase 
in tyrosine phosphorylation, including the FcR γ-chain and Syk, by fibrin in platelets 
is mediated by GPVI. The podoplanin receptor CLEC-2, which signals through a 
similar pathway to that of GPVI, was not phosphorylated (Suppl. Fig. 4-3) ruling out 
a role for the C-type lectin-like receptor in the response to fibrin.  
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Figure 4-1 Fibrin stimulates tyrosine phosphorylation in a GPVI-dependent manner. 
Platelets from (Ai) human, (Aii) mice, (Bi) αIIb-deficient mice, and (Bii) GPVI-deficient mice were 
stimulated with thrombin (1 U/mL) or PAR-4 peptide (150 mM) in the presence of eptifibatide and, 
where shown, fibrinogen (200 mg/mL) and GPRP (5 mM). Stimulations were stopped after (A) 1 
or (B) 3 minutes with the addition of 23 lysis buffer. A sample of the WCL was removed, and the 
remaining lysate was used to IP Syk. WCLs and IPs were separated by SDS-polyacrylamide gel 
electrophoresis and western blotted for pTyr, Syk, and the FcR γ-chain, which coprecipitates with 
Syk. The results are shown as representative of 3 experiments. 
B (i) (ii) 
A (i) (ii) 
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4.4.2 Fibrin stimulates platelet spreading and pro-coagulant activity via GPVI  
 
We next asked whether activation of GPVI by fibrin could induce platelet activation. To 
address this, we monitored spreading of mouse platelets on a fibrin surface and compared 
this to spreading on fibrinogen. To ensure a similar level of coating of fibrin and 
fibrinogen, coverslips were coated with fibrinogen prior to treatment with thrombin 
(hirudin was later added to block thrombin as described in the methods). We used Alexa-
488 fibrinogen to visualise fibrin and fibrinogen. Fibrinogen forms a homogenous surface 
on the coverslip, which was converted to a heterogeneous network of fibrin following 
treatment with thrombin. Large areas of fibrin are easily distinguishable (Suppl. Fig. 4-
4), but following longer exposures, smaller areas of fibrin can be seen. Both large and 
smaller coatings of fibrin are associated with platelet adhesion and spreading (Fig. 4-2A 
and appendix 19).  
Mouse platelets form actin stress fibres and lamellipodia sheets on polymerised 
fibrin but not on fibrinogen, which induces formation of filopodia and partial lamellipodia 
(Fig. 4-2B).Actin nodules (Calaminus et al., 2008) and filopodia can be seen in platelets 
that have undergone partial spreading, which is likely to reflect an earlier stage of 
spreading on fibrin (appendix 20). Spreading on fibrin is blocked by the Src kinase 
inhibitor dasatinib but unaltered in the presence of hirudin, demonstrating that it is not 
mediated by residual thrombin (Fig. 4-2B). Spreading of platelets on fibrin was abolished 
in the absence of GPVI (Fig. 4-2C) demonstrating that fibrin induces spreading through 
the collagen receptor. Fibrin also supports full spreading of human platelets (Suppl. Fig. 
4-5). Interestingly, mouse platelets underwent full spreading on fibrin in the presence of 
GPRP, which prevents polymerisation of fibrin (Fig. 4-3A). This demonstrates both fibrin 
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monomers and fibrin polymers are able to induce full spreading of platelets indicating 
that they share the epitope for binding to, and activation of GPVI. The inhibitory effect 
of GPRP on GPVI activation in suspension studies as shown in (Fig. 4-1) is likely to be 
due to loss of avidity (and therefore the ability to crosslink GPVI) rather than loss of 
binding to fibrin. This is overcome by presentation of fibrin monomers on a 2-
dimensional surface. We modified a previously described ELISA assay (Al-Tamimi et 
al., 2009b) to verify that monomeric and polymerised fibrin bind to GPVI. Using this 
assay, we observed a similar level of binding of the ectodomain of GPVI to fibrin 
monomers and fibrin polymers (Fig. 4-3B). In contrast, GPVI did not bind to immobilised 
fibrinogen (Fig. 4-3B). 
During the latter stages of platelet activation, phosphatidylserine (PS) is exposed 
on the outer leaflet of the plasma membrane and provides a negatively charged, pro-
coagulant surface for the generation of thrombin. This process is important for thrombus 
formation in vivo as it generates thrombin on the platelet surface, which serves both as a 
positive feedback step in platelet activation and mediates conversion of fibrinogen to 
fibrin, thereby stabilising the thrombus. As fibrin generation is an integral part of this 
positive feedback loop, and activation of GPVI is associated with PS exposure, we 
determined whether fibrin induces PS exposure in platelets by measurement of binding 
of FITC-conjugated Annexin V (Munnix et al., 2005). Fibrin induced a 3-fold increase 
in number of PS-exposing platelets compared to fibrinogen, which was inhibited in 
GPVI-deficient platelets (Fig. 4-4A). Thus, fibrin stimulates PS exposure through 
activation of GPVI.  
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Figure 4-2 Fibrin stimulates spreading in a GPVI-dependent manner. Fibrinogen was coated 
onto glass coverslips, and converted into fibrin by treatment with thrombin. Hirudin was used to 
neutralise any residual thrombin before washing and blocking. (A) Alexa-488 fibrinogen was used 
to visualise fibrin formation. Platelets (2×107/ml) were allowed to spread on coated coverslips, 
followed by actin staining with Alexa-568 phalloidin. Scale bar = 5 μm. (B) Platelets (2×107/ml) 
were allowed to spread on non-fluorescent fibrinogen or fibrin-coated coverslips, followed by actin 
staining with Alexa-488 phalloidin. Where shown, platelets were pre-incubated with dasatinib (10 
μM) or hirudin (5 U/ml). Scale bar = 5 μm. (C) WT or GPVI KO platelets were allowed to spread 
on fibrinogen or fibrin-coated coverslips, followed by actin staining with Alexa-488 phalloidin. 
Scale bar = 5 μm. The results are shown as mean ± SEM of three experiments. *P*<0.01; 
***P<0.001. 
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Figure 4-3 Fibrin polymerisation is not essential for platelet spreading or GPVI binding. (A) 
Fibrinogen was coated onto glass coverslips, and converted into fibrin by treatment with thrombin. 
GPRP (5 μM) was used to inhibit polymerisation of fibrin monomers. Hirudin was used to 
neutralise any residual thrombin before washing and blocking. Platelets (2×107 /ml) were allowed 
to spread, followed by actin staining with Alexa-488 phalloidin. Scale bar = 5μm. The results are 
representative of three experiments. (B) Fibrinogen was coated onto the wells of Nunc Maxisorp 
plates, and converted into fibrin by treatment with thrombin. GPRP (5 μM) was used to inhibit 
polymerisation of fibrin monomers. The ectodomain of GPVI was incubated, and following 
washing, adherent GPVI was detected with a HRP-conjugated antibody. The results are shown as 
mean ± SEM of three experiments performed in duplicate. *P<0.05; **P<0.01.  
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4.4.3 Time to occlusion but not initiation of thrombus formation following FeCl3 
injury is diminished in GPVI-deficient platelets  
 
The observation that GPVI is a receptor for fibrin raises the question as to whether the 
delayed occlusion in a FeCl3 injury model (Bender et al., 2011)is due to loss of activation 
of GPVI by fibrin rather than by collagen, which is not present in the growing thrombus. 
To address this, we studied thrombus formation by intravital fluorescence microscopy 
following FeCl3-injured mesenteric arterioles in GPVI-deficient mice. The onset of 
aggregation occurred at similar times after injury in wild type and GPVI-deficient mice 
indicating that it was likely to be mediated by endothelial cell activation rather than by 
exposure to collagen (Fig. 4B and supplementary video). Complete vessel occlusion was 
observed within 20 min in wild type vessels ( (Bender et al., 2011) and not shown). In 
contrast, vessel occlusion was markedly delayed or absent in GPVI-deficient mice and 
constant embolisation was seen (Fig. 4-4B and supplementary video). The rate of 
embolisation from thrombi of more than 10 µm was increased by 6.6 fold in GPVI-deficient 
mice. Consequently, most vessels remained open or occlusion was significantly delayed. 
These results demonstrate a critical role for GPVI in thrombus stabilisation relative to 
thrombus initiation in this model of FeCl3-injury.  
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Figure 4-4 GPVI KO platelets have reduced PS exposure and reduced thrombus stability. (A) 
WT or GPVI-deficient platelets were allowed to spread on fibrinogen or fibrin- coated 
coverslips, followed by incubation with FITC-Annexin V. Actin was counterstained with 
Alexa-568 phalloidin to count total number of adherent platelets (appendix 21). Scale bar, 
20μm. The results are shown as mean ± SEM of 3 experiments. (B) Representative 
fluorescent images before and after injury. Asterisk indicates vessel occlusion. 
Embolisation rate was determined by counting embolised thrombus fragments (size 
>10µm) after an initial thrombus had formed (thrombus size at least 10µm). Observation 
period: 40 minutes or until vessel occlusion. The results are shown as mean ± SD of 6 or 
more mice. ***P <0.001.   
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4.5 Discussion 
 
Until now, the focus on the role of GPVI in haemostasis and thrombosis has been on the 
onset of response because of expression of the ligands, collagen and laminin, in the sub-
endothelial matrix. Strikingly however, a marked delay in vessel occlusion rather than in 
initiation of thrombus formation is seen in mice-deficient in GPVI in a FeCl3 injury model 
indicating a role for GPVI in thrombus growth(Bender et al., 2011) . In the present study, 
we identify fibrin as a novel ligand for GPVI. We speculate that loss of this interaction 
mediates the delay in vessel occlusion, and the increase in embolisation in GPVI-deficient 
mice following topical FeCl3 injury.  
The interaction of fibrinogen with platelets is dependent on sustained activation 
of the integrin through the platelet ADP receptor, P2Y12 (Stefanini et al., 2015) but 
becomes irreversible over time, as a result of conversion to fibrin. Fibrin is formed from 
fibrinogen by the action of the protease thrombin. Thrombin exposes a site of interaction 
allowing the fibrin monomers to polymerise. These are then cross-linked by Factor XIIIa 
forming covalently linked polymers.  
Fibrin polymers stabilise the growing thrombus through crosslinking of surface 
receptors, including integrin αIIbβ3, and by clot retraction, which links the integrin to the 
platelet cytoskeleton. The interaction of fibrin and fibrinogen with αIIbβ3 is mediated 
through distinct epitopes. Fibrinogen binds to αIIbβ3 via the carboxy-terminal peptide 
sequence of the γC-peptide (GAKQAGDV). In contrast, fibrin binds to the integrin 
through a unique sequence in the γC-peptide, ATWKTRWYSMKK, which binds to the 
αIIb β-propeller (Podolnikova et al., 2014, Podolnikova et al., 2005). The distinct roles 
of these epitopes are illustrated by the differential effects of mutation of these sequences 
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on adhesion and clot retraction (Rooney et al., 1998, Cohen et al., 1989). In the present 
study, we show that fibrin but not fibrinogen activates GPVI thereby indicating the 
presence of additional functional differences between the closely related matrix proteins. 
Further work is required to establish the structural basis of this. In our initial experiments, 
we asked whether fibrin stimulates tyrosine phosphorylation in human and mouse 
platelets through integrin αIIbβ3. Under aggregating conditions, fibrin polymerisation is 
associated with a relatively minor increase in tyrosine phosphorylation, most likely 
because this is masked by fibrinogen-dependent αIIbβ3-outside-in signalling. Consistent 
with this, tyrosine phosphorylation is dramatically reduced by the αIIbβ3-blocker 
eptifibatide, which blocks binding of fibrinogen but not fibrin to the integrin. Tyrosine 
phosphorylation is markedly increased however in the presence of added fibrinogen in 
the presence of eptifibatide following stimulation by thrombin but not a PAR-4 peptide, 
with the FcR γ-chain and Syk being identified as major phosphorylated proteins. Studies 
on mouse platelets deficient in the integrin subunit, αIIb, confirmed that phosphorylation 
is independent of integrin αIIbβ3. 
An increase in FcR γ-chain and Syk phosphorylation is indicative of GPVI 
activation. Consistent with this, tyrosine phosphorylation of FcR γ-chain and Syk by 
fibrin was abolished in GPVI-deficient platelets, which express 50% of the wild type 
level of FcR γ-chain and normal levels of the other major platelet glycoprotein receptors. 
The increase in phosphorylation was blocked by GPRP demonstrating that it is mediated 
by fibrin polymers and not by monomeric fibrin. However, both immobilised monomeric 
and polymerised fibrin induce spreading of platelets demonstrating that polymerisation 
is not essential for binding and activation of the glycoprotein receptor. Further, activation 
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of GPVI by immobilised fibrin leads to PS exposure, which is also abolished in GPVI-
deficient platelets. This suggests that on a monolayer, the avidity of the fibrin surface is 
able to support GPVI activation in the absence of cross-linking of fibrin. In solution, 
fibrin requires polymerisation to induce clustering and activation of GPVI. Confirmation 
of binding of GPVI to both monomeric and polymerised fibrin was shown using a 
modified ELISA.  
This study therefore adds to the growing number of ligands of the collagen 
receptor on platelets, which includes the endogenous proteins, laminin, adiponectin, and 
EMMPRIN, as well as a range of miscellaneous exogenous ligands including small 
charged peptides, sulphated sugars, antisense nucleotides and diesel particles (Flierl et 
al., 2015, Alshehri et al., 2015). 
This work is of significance with regard to the delay in occlusion and increased 
embolisation that is seen following FeCl3 injury in GPVI-deficient mouse platelets, which 
we speculate is due to loss of platelet activation by fibrin and a corresponding reduction 
in aggregation and PS exposure and therefore reduced thrombin generation. Following 
submission of this manuscript, Mammadova-Bach et al demonstrated that fibrin supports 
thrombin generation in human platelets through activation of GPVI (Mammadova-Bach 
et al., 2015). We therefore propose that activation of GPVI by fibrin plays a key feedback 
role in promoting coagulation and thrombin formation during haemostasis and 
thrombosis. 
 These findings add to the potential significance of GPVI as an anti-thrombotic 
target (Zahid et al., 2012, Dutting et al., 2012) by extending its role to the propagation of 
an occlusive thrombus. This unexpected role, coupled with its relatively minor role in 
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haemostasis as shown by the mild bleeding seen in GPVI-deficient human and mouse 
(Kato et al., 2003, Hermans et al., 2009, Matus et al., 2013) platelets, indicates that 
targeting the binding of fibrin to GPVI may prevent vessel occlusion at sites of arterial 
thrombosis, without causing a major bleeding diathesis.  
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4.7 Supplementary  
 
 
Supplementary figure 4-1 Tyrosine phosphorylation in human platelets under aggregation 
conditions. Human platelets (5×108/ml) were stimulated with thrombin (1 U/ml) or PAR-4 peptide 
(150 μM) under aggregating conditions and, where indicated, in the presence of fibrinogen (200 
μg/ml) and GPRP (5 μM). Aggregations were stopped after 1min with the addition of 2× lysis 
buffer. A sample of the whole cell lysate (WCL) was removed and the remaining lysate used to 
immunoprecipitate (IP) Syk. WCLs and IPs were separated by SDS-PAGE and Western blotted for 
pTyr and Syk (phospho-FcR γ–chain co-precipitates with Syk. The results are representative of 
three experiments. 
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Supplementary figure 4-2 GPVI KO platelets express lower levels of FcRγ -chain, but normal 
levels of surface glycoproteins. Platelet lysates were prepared from WT and GPVI-deficient 
platelets (5×108/ml), and proteins separated by SDS-PAGE and western blotted for FcRγ –chain 
(A) and quantified (B). The results are shown as mean ± SEM of three experiments. (C) Platelets 
from WT and GPVI-deficient platelets were analysed by flow cytometry for the stated proteins. 
The results are shown as mean ± SD of four experiments. *P<0.05, ** P<0.01. 
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Supplementary figure 4-3 Fibrin does not stimulate tyrosine phosphorylation of CLEC-2. 
Human platelets (5×108/ml) were stimulated with thrombin (1 U/ml) in the presence of eptifibatide 
(9 μM), fibrinogen (200 μg/ml), and where shown, GPRP (5 μM). Aggregations were stopped after 
1 min with the addition of 2× lysis buffer and the lysate used to immunoprecipitate (IP) CLEC-2. 
IPs were separated by SDS-PAGE and western blotted for tyrosine phosphorylation and CLEC-2. 
The results are representative of three experiments. 
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Supplementary figure 4-4 Thrombin treatment converts fibrinogen into polymerised fibrin 
networks. Fibrinogen was coated onto glass coverslips, and converted into fibrin by treatment with 
thrombin. Alexa-488 fibrinogen was used to visualise fibrin formation. Scale bar = 5μm. 
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Supplementary figure 4-5 Fibrin stimulates spreading in human platelets. Fibrinogen was 
coated onto glass coverslips, and converted into fibrin by treatment with thrombin. Hirudin was 
used to neutralise any residual thrombin before washing and blocking. Human platelets (2×107/ml) 
were allowed to spread on fibrinogen or fibrin-coated coverslips, followed by actin staining with 
Alexa-488 phalloidin. Scale bar = 5μm. 
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Chapter 5 CLEC-2 EXPRESSION IS MAINTAINED 
ON ACTIVATED PLATELETS AND ON PLATELET 
MICROPARTICLES 
 
This research was originally published in Blood. Eelo Gitz, Alice Y. Pollitt, Jerney J. Gitz-Francois, 
Osama Alshehri, Jun Mori, Samantha Montague, Gerard B. Nash, Michael R. Douglas, Elizabeth 
E. Gardiner, Robert K. Andrews, Christopher D. Buckley, Paul Harrison and Steve P. Watson. 
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This chapter reports that CLEC-2 activation induces proteolytic cleavage of GPVI and 
FcγRIIa but not of itself and that CLEC-2 but not GPVI is detected on platelet derived 
microparticles. I contributed in this paper by characterisation of new mouse monoclonal 
antibodies against human CLEC-2 namely AYP1 and AYP2 (figure 5-1 A). I have designed 
and performed experiments, and analysed the data that presented in Figure 5-1A. The 
manuscript was written by one of other authors.  I read the manuscript prior to submission 
and made comments. 
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Abstract 
The C-type lectin-like receptor CLEC-2 mediates platelet activation through a hem- 
immunoreceptor tyrosine-based activation motif (hemITAM). CLEC-2 initiates a Src- and 
Syk-dependent signaling cascade that is closely related to that of the 2 platelet ITAM 
receptors: glycoprotein (GP) VI and FcγRIIa. Activation of either of the ITAM receptors 
induces shedding of GPVI and proteolysis of the ITAM domain in FcγRIIa. In the present 
study, we generated monoclonal antibodies against human CLEC-2 and used these to 
measure CLEC-2 expression on resting and stimulated platelets and on other 
hematopoietic cells. We show that CLEC-2 is restricted to platelets with an average copy 
number of ∼2000per cell and that activation of CLEC-2 induces proteolytic cleavage of 
GPVI and FcγRIIa but no to fit self. We further show that CLEC-2 and GPVI are 
expressed on CD41+ microparticles in megakaryocyte cultures and in platelet-rich plasma, 
which are predominantly derived from megakaryocytes in healthy donors, whereas 
microparticles derived from activated platelets only express CLEC-2. Patients with 
rheumatoid arthritis, an inflammatory disease associated with increased microparticle 
production, had raised plasma levels of microparticles that expressed CLEC-2 but not 
GPVI. Thus, CLEC-2, unlike platelet ITAM receptors, is not regulated by proteolysis and 
can be used to monitor platelet-derived microparticles 
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5.1  Introduction  
 
Platelets play an essential role in limiting blood loss from the damaged vasculature, but can 
also block blood ﬂow in diseased vessels through formation of an occluding 
thrombus.(Jackson, 2011a). Platelet adhesion and activation are ordinarily triggered by 
exposure to subendothelial extracellular matrix proteins. Initial adhesion to the damaged 
vessel wall is regulated through the interaction of the glycoprotein (GP)Ib-V-IX complex 
with von Willebrand factor immobilized on exposed collagen ﬁbers. Platelet activation and 
recruitment to a growing thrombus is regulated by the collagen receptor GPVI and the 
platelet-secreted agonists adenosine diphosphate and thromboxane (TX)A2 (Broos et al., 
2011). Thrombin, generated through the coagulation cascade, further activates platelets and 
strengthens clot formation by converting ﬁbrinogen into ﬁbrin. Adenosine diphosphate, 
TxA2, and thrombin signal via heterotrimeric G protein-coupled receptors. The collagen 
receptor GPVI signals through an immunoreceptor tyrosine-based activation motif (ITAM) 
via its associated subunit, the FcR γ-chain. The signals from G protein-coupled receptors 
and GPVI synergize to mediate activation of integrin αIIbβ3-dependent platelet 
aggregation (Broos et al., 2011).  
Human platelets express 2 other receptors that signal through a closely related 
pathway to that of GPVI: the low afﬁnity immunoglobulin ITAM receptor FcγRIIa and the 
podoplanin hemITAM receptor C-type lectin-like receptor 2 (CLEC-2). FcγRIIa signals 
through a single ITAM in its cytosolic domain and is a critical mediator of platelet activation 
in immune thrombocytopenia (McKenzie et al., 1999, Stolla et al., 2011, Urbanus et al., 
2013), heparin-induced thrombocytopenia (Warkentin et al., 2011), bacterial infection 
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(Tilley et al., 2013, Arman et al., 2014), and cancer (Mitrugno et al., 2014). CLEC-2, a type 
II transmembrane protein, signals via a single YxxL sequence known as a hemITAM and is 
the receptor for the type I transmembrane GP podoplanin, which is widely expressed outside 
of the vasculature, including lymphatic endothelial cells, type 1 lung alveolar cells, lymph 
node stromal cells, and the choroid plexus epithelium. Podoplanin is also present on 
inﬂammatory macrophages (Hou et al., 2010, Kerrigan et al., 2012) on a subset of activated 
T-helper (Th)17 cells (Peters et al., 2011, Miyamoto et al., 2013).The function of CLEC-2 
in hemostasis is, however, unclear, with reports indicating that it either plays a minor role 
(May et al., 2009, Suzuki-Inoue, 2011) or that it plays no role (Hughes et al., 2010a). More 
recently, CLEC-2 has been shown to play a vital collaborative role with GPVI in thrombosis 
(Bender et al., 2013). 
There is increasing recognition that platelet (hem)ITAM receptors play a pivotal role 
in processes beyond hemostasis. Platelet-speciﬁc deletion of CLEC-2, or deletion of one of 
its downstream signaling proteins, Syk, SLP-76, or PLCγ2, leads to a number of 
developmental problems including blood-lymphatic mixing in midgestation (Suzuki-Inoue, 
2011, Bertozzi et al., 2010, Finney et al., 2012).  
GPVI and CLEC-2 are also required for the maintenance of vascular integrity at sites of 
inﬂammation. Mice with reduced platelet counts and deﬁciency in GPVI and CLEC-2 exhibit 
severe bleeding following inﬂammatory challenge, and this is independent of the major 
platelet receptors involved in hemostasis including integrin aIIbb3 (Boulaftali et al., 2013). 
In patients with rheumatoid arthritis, GPVI signaling ampliﬁes inﬂammation through 
collagen-dependent platelet microparticle production (Boilard et al., 2010).  
(hem)ITAM receptors signal through Src and Syk tyrosine kinases. Src family 
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kinases and/or Syk phosphorylate the conserved YxxL motifs, which allow Syk to bind to 
2 phosphorylated tyrosines via its tandem SH2 domains. Activation of Syk in this way 
gives rise to a signaling cascade that triggers PLCγ2 and Ca21 mobilization, generation of 
TxA2, integrin activation, and granule secretion (Bergmeier and Stefanini, 2013). 
Activation of GPVI or FcγRIIa is also associated with extracellular metalloproteinase-
mediated ectodomain shedding of GPVI (Gardiner et al., 2007) and intracellular calpain 
mediated cleavage of FcγRIIa, resulting in deletion of the ITAM domain (Gardiner et al., 
2008). Signiﬁcantly, activation of either receptor results in proteolysis of the other, and in 
both cases, this is dependent on Src and Syk activation (Gardiner et al., 2008, Gardiner et 
al., 2004). 
In the present study, we generated monoclonal antibodies (mAbs) to human CLEC-
2 and used one of these, AYP1, to measure the level of CLEC-2 in resting and stimulated 
human platelets and on microparticles. We show that in contrast to GPVI and FcγRIIa, 
CLEC-2 is not regulated by proteolysis on activation or in response to stimulation of GPVI 
and FcγRIIa and that CLEC-2 but not GPVI is expressed on microparticles derived from 
activated platelets. The physiological signiﬁcance of these ﬁndings is discussed 
5.2 Materials and Methods 
5.2.1 Antibodies and other materials 
 
A recombinant extracellular fragment of human CLEC-2 (aa 68-229) was produced as 
described (Christou et al., 2008) used to raise mouse α-human CLEC-2 mAbs AYP1 and 
AYP2 (IgG1). A detailed description of other antibodies and materials used can be found 
in the Supplemental Methods. 
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5.2.2 Patients 
Citrated blood samples from healthy individuals and from patients with rheumatoid 
arthritis were obtained with informed consent approved by the local ethics committee 
(ERN_11-0175 and 071Q270612, respectively). All patients with rheumatoid arthritis 
satisfied the 1987 American College of Rheumatology (ACR) criteria for rheumatoid 
arthritis(Arnett et al., 1988). 
5.2.3 Cell isolation and culture, protein deglycosylation, Western blots and 
measuring sGPVI 
 
A detailed description can be found in the Supplemental Methods. 
5.2.4 Microparticle preparation 
For analysis of microparticles, platelet-free plasma (PFP) was collected from citrated 
venous blood by double centrifugation at 2,500g for 15 minutes (Lacroix et al., 2013) 
Microparticles within PFP were used for subsequent studies. Microparticles from 
activated platelets were collected by incubating washed platelets with indicated agonists 
for one hour at 37°C, followed by double centrifugation at 2,500g for 15 minutes. 
Microparticles from megakaryocyte cultures (day 12) or from platelet concentrates (day 
5) were collected using the same centrifugation protocol. Freshly prepared 
microparticles were analysed by flow cytometry.  
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5.2.5 Flow cytometric analysis 
Platelets and microparticles were analysed by flow cytometry using an AccuriTM 
C6 flow cytometer (BD Biosciences). Platelets were characterized by forward scatter 
(FSC) and side scatter (SSC). Appropriate antibodies, as indicated in the figure 
legends, were added and incubated for 15 minutes at 37°C. A total of 10,000 events 
were analysed for each sample. Microparticles were characterized using an APC-
conjugated antibody against integrin αIIb (CD41a; BD Biosciences) against an 
isotype- matched control. The threshold was set on fluorescence (FL4) to exclude 
background noise. CD41+ microparticles were then analysed for surface expression 
of CLEC-2 and GPVI using Alexa Fluor 488-conjugated AYP1 and 1G5, 
respectively, and appropriate isotype-matched controls. Antibodies were centrifuged 
at 18,000g for 5 minutes to remove protein aggregates prior to assay. All other 
reagents were filtered with a 0.22 µ M filter. 
Leukocytes were analysed using a FACSverse flow cytometer (BD 
Biosciences). Antibody incubations were on ice for 20 minutes. Peripheral blood 
mononuclear cells (PBMCs) and polymorphonuclear cells (PMNs) were first 
discriminated by their FSC and SSC characteristics. Live cells were selected based 
on negative staining for Sytox Red followed by selection for negative staining of 
CD41. An antibody against CD45 was used as a general marker for leukocytes. The 
following markers were used to distinguish leukocyte subsets: CD3 (T-cell), CD11c 
(dendritic cell), CD14 (monocyte), CD16 (neutrophil) and CD19 (B-cell). The 
leukocyte subsets were analysed for surface expression of CLEC-2 by Alexa Fluor 
488-conjugated AYP1 relative to isotype-matched controls. 
5.2.6 Statistical analysis 
Data are means ± SEM, unless stated otherwise. Statistical analysis was performed 
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using GraphPad Prism 5 (San Diego, CA, USA) using Mann-Whitney test. P-values 
less than 0.05 were considered significant. 
5.3 Results 
5.3.1 Characterisation of mouse monoclonal antibodies against human CLEC-
2 
The extracellular domain of human CLEC-2 was used to generate mAbs to the C-
type lectin receptor. One of these antibodies, AYP1 (IgG1), immunoprecipitated a 
32 and 40 kDa doublet from lysates of control and rhodocytin-stimulated human 
platelets (Figure 5-1A). A second mouse α-human CLEC-2 mAb, AYP2 (IgG1), 
recognized the two bands by Western blot, which correspond by molecular mass to 
differential glycosylated forms of human CLEC-2 described previously (Suzuki-
Inoue et al., 2006) (Figure 1A,B). AYP1 did not detect CLEC-2 by Western blot, 
indicating that the antibody binds to a conformational epitope that is lost during the 
denaturing conditions of SDS-PAGE (not shown). Probing for tyrosine 
phosphorylation demonstrated that AYP1 immunoprecipated both non 
phosphorylated and phosphorylated forms of CLEC-2 (Figure 5-1A). AYP1 but not 
AYP2 recognised surface expressed CLEC-2 when analysed by flow cytometry as 
shown using doxycycline-treated 293T Rex cells (Figure 5-1C) (Chaipan et al., 
2006b). AYP1 also detected CLEC-2 on human platelets by flow cytometry but did 
not detect expression on monocytes, neutrophils, T- and B-cells or dendritic cells in 
whole blood (Figure 5-1D; gating strategy described in Supplemental Figure 5-1A). 
Analysis of leukocytes with a commercially available polyclonal antibody against 
CLEC-2 confirmed these findings (Supplemental Figure 5-1B). This restricted 
distribution of CLEC-2 agrees with the BioGPS database (Supplementary Figure 5-
2) and shows that the C-type lectin receptor is selectively expressed on platelets in 
human blood. We used an established flow cytometry assay (Best et al., 2003) to 
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determine the level of expression of CLEC-2 in healthy individuals. The receptor 
was present at 2016 ± 239 (mean ± SD) copies per platelet (Figure 2A-D). This is 
within the same order of magnitude as the other platelet ITAM receptors GPVI 
(1250-9600) (Best et al., 2003, Chen et al., 2002, Burkhart et al., 2012) and FcγRIIa 
(1000-4000) (Kelton, 2005). 
The full characterization of antibodies recognizing human platelets is complicated 
by expression of FcγRIIa, which can bind the Fc portion of antibodies. To address 
this, we generated Fab fragments of AYP1 and demonstrated that these antibody 
fragments also bound to human platelets. Furthermore, AYP1 Fab fragments were 
able to block platelet activation triggered by rhodocytin and Podoplanin suggesting 
that these ligands have binding sites on CLEC-2 that overlap with the AYP1 epitope 
(Figure 5-3A and 5-3B). Crosslinking of the AYP1 Fab fragments with a secondary 
antibody induced powerful platelet aggregation (Figure 5-3C) and enhanced 
fibrinogen binding and P-selectin expression (Figure 5-3D), which was blocked by 
inhibition of Src and Syk tyrosine kinases using PP2 and PRT 060318, respectively. 
This is consistent with CLEC-2-mediated platelet activation requiring receptor 
clustering and activation of Src and Syk tyrosine kinases. 
AYP1 thus recognizes CLEC-2 in its native conformation and can be used to inhibit 
Podoplanin and rhodocytin-mediated platelet activation. A second mouse mAb, 
AYP2, can be used to recognize the denatured form of CLEC-2 following SDS-
PAGE.  
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Figure 5-1 AYP1 recognizes CLEC-2 on human platelets. (A) Washed platelets were incubated 
for 5 minutes at 37°C under stirring conditions in the absence and presence of 100 nM rhodocytin, 
followed by lysis and immunoprecipitation with 2 µg/mL of goat α-human CLEC-2 (previously 
characterized antibody), AYP1 or IgG1 coupled to protein-G sepharose. Proteins were separated on a 
12% SDS- PAGE gel under reducing conditions, transferred onto a PVDF membrane and probed with 
AYP2. Membranes were subsequently stripped and reprobed with α-phosphotyrosine antibody 4G10. 
(B) Deglycosylation reduces CLEC-2 to a single band. Lysates of resting platelets were incubated in the 
absence or presence of Peptide-N-Glycosidase F (PNGase F), probed with AYP2 and stripped and 
reprobed with an antibody against α-tubulin. (C) Analysis of AYP1 binding to 293T Rex cells with 
doxycycline-inducible protein expression of CLEC-2. Cells were incubated in the absence or presence 
of 1 µ g/mL of doxycycline for 24 hours and AYP1 binding was determined by flow cytometry using a 
FITC-conjugated sheep α-mouse secondary antibody. (D) Flow cytometric analysis of CLEC-2 on 
platelets and leukocytes. Platelets and leukocytes were isolated and incubated with saturating 
concentrations of either Alexa Fluor-488 (AF-488) conjugated α-CLEC-2 antibody AYP1 or isotype- 
matched control for 30 minutes at room temperature (platelets) or on ice (leukocytes) and analysed 
immediately. Leukocyte subset discrimination is described in Supplementary Methods and gating 
strategy is shown in Supplemental Figure 5-1A. Data are representative of at least 3 independent 
experiments.  
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Figure 5-2 Quantification of platelet CLEC-2 expression.The number of surface copies of 
CLEC-2 per platelet was determined using the mouse α-human CLEC-2 antibody AYP1 
and the Platelet Calibrator Kit from Biocytex. (A) Washed platelets were pre-incubated 
with 2.5 µg/mL AYP1 (saturating concentration) at room temperature for indicated times 
and subsequently incubated with a FITC-conjugated α-mouse antibody for another 15 
minutes. Flow cytometric analysis shows that binding of AYP1 remains stable over the 
tested time period. (B) Calibrator beads, coated with batch- defined increasing 
concentrations of mouse IgG1 antibody molecules (i: 4400, ii: 29000 and iii: 10800), were 
stained with FITC-conjugated α mouse antibody and analysed by flow cytometry. (C) The 
geometric mean fluorescence intensity (MFI) of the three bead populations were plotted 
against the corresponding number of mouse IgG1 molecules. Linear regression revealed 
an R2 of 0.996. (D) Washed platelets were pre-incubated with AYP1 for 30 minutes at room 
temperature and incubated FITC-conjugated α-mouse antibody. The MFI was determined 
by flow cytometry and used to quantify surface expression of CLEC-2 by extrapolation 
from the linear regression line of (C). CLEC- 2 copy number was determined for ten donors 
of diverse ethnic backgrounds (aged 23 to 55 years) with a mean of 2016 ± 239 (mean ± 
SD). 
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Figure 5-3 The effect of AYP1 on CLEC-2 signalling. (A,B) Washed platelets were pre-
incubated with 2.5 µ g/mL AYP1 Fab fragments for 15 minutes at room temperature and 
stimulated with (A) 100 nM rhodocytin or (B) 10 µg/mL hPDPN-Fc for 15 minutes at 37°C. 
(A) Platelet activation by rhodocytin was determined by flow cytometric analysis of P-
selectin expression and fibrinogen binding and (B) Podoplanin binding using a PE-
conjugated α-human Podoplanin antibody. (C) Aggregation of washed platelets induced 
by 100 nM rhodocytin or AYP1 Fab (2.5 µg/mL) crosslinked with 20 µg/mL α-mouse Fab-
specific F(ab)2 fragments. Single incubation with either AYP1 Fab or α-mouse F(ab)2 
fragments did not trigger aggregation. The traces are representative of three independent 
experiments. (D) Flow cytometric analysis of P-selectin expression and fibrinogen binding 
induced by crosslinking AYP1 Fab. Washed platelets were incubated with AYP1 Fab, α- 
mouse F(ab)2, or both for 15 minutes at 37°C and immediately analysed. Pre-incubation 
with either the Syk inhibitor PRT-060318 (PRT; 5 µM) or the Src family kinase inhibitor 
PP2 (20 µM) for 10 minutes at room temperature prevented platelet activation induced by 
crosslinking AYP1 Fab. Data are presented as the ratio of MFI of treated over control 
platelets (n=4). 
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5.3.2 CLEC-2 is not regulated by shedding or internalisation upon platelet 
activation 
 
The newly generated antibodies were used to investigate whether CLEC-2 is regulated 
by proteolytic cleavage as is the case for GPVI and FcγRIIa. Washed platelets were 
incubated under a variety of conditions that cause down-regulation of GPVI and 
FcγRIIa, and in addition, were subject to CLEC-2 stimulation by rhodocytin or 
crosslinked AYP1. Incubation with N-ethylmaleimide (NEM), a reagent which reacts 
with free sulfhydryl groups, or the calmodulin antagonist W7, which both induce 
metalloproteinase-mediated shedding of GPVI (Gardiner et al., 2004, Arthur et al., 
2005), had no effect on surface expression of CLEC-2 as measured by flow cytometry 
or cleavage of CLEC-2 as measured by western blot (Figure 5-4A and 5-4B).Binding 
of GPVI by CRP, or FcγRIIa by crosslinked IV.3 Fab fragments, or CLEC-2 by 
crosslinked AYP1 Fab, also failed to alter surface expression or induce cleavage of 
CLEC-2. A reduced level of CLEC-2 expression was observed by flow cytometry but 
not by western blotting when platelets were stimulated by rhodocytin, which is likely 
to reflect competition between rhodocytin and AYP1 for binding to the C-type lectin-
like receptor. To investigate this further, we monitored the time course of rhodocytin 
binding to platelets by flow cytometry using a previously described polyclonal Ab.30 
Figure 5-4C shows that binding of rhodocytin is stable for up to 120 minutes. Similarly, 
crosslinked AYP1 Fab remained stably bound to CLEC-2 over the tested incubation 
time. In line with these findings, incubation with NEM, W7 or a rat α-mouse CLEC-2 
mAb also failed to induce proteolytic cleavage of murine CLEC-2 (Supplemental 
Figure 5-3). Together, these findings indicate that CLEC-2 is not shed or internalized 
from the platelet surface upon auto-activation or in response to activation of GPVI and 
FcγRIIa, or agents which induce cleavage of the two ITAM receptors.  
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Figure 5-4 CLEC-2 is not shed or internalized following activation. (A, B) Washed platelets 
were incubated with vehicle control (veh; DMSO), NEM (2 mM), W7 (150 µ M), CRP (10 
µg/mL), IV.3 Fab (5 µg/mL) crosslinked with 20 µg/mL α-mouse Fab-specific F(ab)2 
fragments (xIV.3), rhodocytin (100 nM) or AYP1 Fab (2.5 µg/mL) crosslinked with 20 µg/mL 
α-mouse Fab-specific F(ab)2 fragments (xAYP1) for 1 hour at 37°C. (A) Platelet lysates were 
blotted and probed with AYP2. Membranes were subsequently stripped and reprobed with an 
antibody against α-tubulin. Quantification is presented as the mean ratio of treated over control 
platelets (n=3). (B) Flow cytometric analysis of the surface expression of CLEC-2. After 
treatment, platelets were incubated with Alexa Fluor 488-conjugated AYP1 for 15 minutes at 
37°C and immediately analysed. Alexa Fluor 488-conjugated AYP1 Fab was used to assess 
CLEC-2 expression after AYP1 Fab crosslinking. (C) Analysis of surface-bound rhodocytin 
and crosslinked AYP1 Fab. Washed platelets were incubated with rhodocytin or xAYP1 for 
indicated times at 37°C. Surface-bound rhodocytin was determined by incubation with rabbit 
α-rhodocytin antibody, followed by incubation with F(ab)2 fragments of FITC-conjugated 
swine α-rabbit IgG. Surface-bound xAYP1 was assessed by incubation with F(ab)2 fragments 
of polyclonal FITC-conjugated sheep α-mouse IgG. Data are presented as the ratio of MFI of 
treated over control platelets (n=5). 
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5.3.3 Activation of CLEC-2 induces proteolytic cleavage of GPVI and FcγRIIa 
GPVI and FcγRIIa are regulated by metalloproteinase-mediated ectodomain shedding 
(Gardiner et al., 2007) and by intracellular calpain-mediated cleavage (Gardiner et al., 
2008, Nazi et al., 2011), respectively. We therefore investigated whether CLEC-2 
ligation also affects expression of GPVI by probing platelet lysates with an α-human 
GPVI cytoplasmic tail antibody which detects full-length (~62 kDa) and the 
proteolytically cleaved remnant (~10 kDa) of platelet-associated GPVI and of FcγRIIa 
by probing with a western blotting antibody against the low affinity immune receptor 
(Figure 5). In agreement with previous reports (Gardiner et al., 2008, Gardiner et al., 
2004), incubation with NEM, W7, CRP or crosslinked IV.3 Fab induced shedding of 
GPVI (Figure 5-5A). Similarly, we show that CLEC-2 activation by rhodocytin or by 
AYP1 Fab crosslinking induces proteolysis of GPVI and concomitant generation of the 
remnant GPVI fragment. CLEC-2-mediated shedding of GPVI was confirmed by flow 
cytometry (Figure 5-5B). Further, proteolysis of GPVI in response to CLEC-2 was 
inhibited by the broad-range metalloproteinase inhibitor, GM6001, and by selective 
inhibition of Src (PP2) and Syk (PRT-060318) kinases (Figure 5-5B). Pre-incubation 
with the membrane-permeable calpain inhibitor E64d did not prevent CLEC-2-induced 
shedding of GPVI (Figure 5-5B). Western blot analysis revealed that activation of 
CLEC-2 also resulted in proteolytic cleavage of FcγRIIa, which was inhibited by E64d, 
PRT-060318 and PP2, but not by GM6001 (Figure 5-5C). No loss of FcγRIIa was 
detected by flow cytometry (Figure 5-5D), confirming earlier findings that the 
extracellular domain remains platelet-associated after proteolysis (Gardiner et al., 
2008). These results collectively demonstrate that CLEC-2 signalling induces 
metalloproteinase-dependent shedding of GPVI and calpain-dependent proteolytic 
cleavage of FcγRIIa and that this proteolysis requires activation of Src and Syk tyrosine 
kinases.  
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Figure 5-5 Activation of CLEC-2 leads to proteolytic cleavage of GPVI and FcγRIIa. (A) 
Washed platelets were incubated with vehicle control (veh; dimethylsulfoxide), NEM (2 
mM),W7 (150 mM), CRP (10 mg/mL), IV.3 Fab (5 mg/mL) cross-linked with 20 mg/mL a-
mouse Fab-specific F(ab)2 fragments (xIV.3), rhodocytin (100 nM), or AYP1 Fab (2.5 mg/mL) 
cross-linked with 20 mg/mL a-mouse Fab-specific F(ab)2 fragments (xAYP1) for 1 hour at 
37°C. Platelet lysates were blotted and probed with an antibody against the cytoplasmic tail of 
GPVI, which detects both full-length and the cytoplasmic tail remnant of GPVI. Blot is 
representative for at least three independent experiments. (B) Flow cytometric analysis of the 
surface expression of GPVI. Washed platelets were preincubated with the calpain inhibitor 
E64d (100 mM), the metalloproteinase inhibitor GM6001 (100 mM), the Syk inhibitor PRT-
060318 (PRT; 5 mM), or the Src family kinase inhibitor PP2 (20 mM) for 10 minutes at room 
temperature, followed by incubation with AYP1 Fab (2.5 mg/mL) cross-linked with 20 mg/mL 
a-mouse Fab-specific F(ab)2 fragments (xAYP1) for 15 minutes at 37°C. After treatment, 
platelets were incubated with Alexa Fluor 488-conjugated a-GPVI antibody 1G5 for 15 minutes 
at 37°C and immediately analysed. (C) Washed platelets incubated under the conditions of B 
were blotted and probed with mouse a-human FcγRIIa-biotin. The blot is representative for at 
least three independent experiments (D) Flow cytometric analysis of FcγRIIa surface 
expression on platelets after AYP1 Fab cross-linking. Data are presented as the ratio of MFI of 
treated over control platelets (n =3).  
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5.3.4 Microparticles from activated platelets retain CLEC-2 but lose GPVI 
expression 
 
Megakaryocytes and activated platelets shed small submicron fragments into the 
circulation, accounting for between 70% and 90% of microparticles in the blood 
stream (Horstman and Ahn, 1999, Joop et al., 2001, Berckmans et al., 2001) as shown 
by positive staining for the megakaryocyte/platelet integrin subunit αIIb (CD41). In 
healthy individuals, the majority of circulating CD41+ microparticles originates from 
megakaryocytes rather than from activated platelets (Flaumenhaft et al., 2009, Rank 
et al., 2010).We analyzed CD41+ microparticles isolated from plasma, primary human 
megakaryocytes, and activated platelets for surface expression of CLEC-2 and GPVI. 
CD41+ microparticles isolated from plasma of healthy volunteers expressed CLEC-2 
and GPVI (Figure 5-6A). These microparticles stained negative for CD45, indicating 
that they were not fused with microparticles of leukocyte origin (supplemental Figure 
5A). A similar level of CLEC-2 and GPVI expression was found on 
CD41+ microparticles isolated from megakaryocytes cultured for 12 days (Figure 5-
6B 5-6C). In contrast, microparticles derived from platelets activated with either CRP 
or AYP1 Fab cross-linking contained CLEC-2 but not GPVI, suggesting that treatment 
of microparticle formation in platelets results in proteolytic cleavage of the collagen 
receptor. Incubation of CD41+microparticles isolated from plasma with CRP or cross-
linked AYP1 Fab failed to induce loss of either receptor, indicating that microparticles 
are not capable of GPVI proteolysis (supplemental Figure 5-5B). Microparticles 
formed by incubating platelets with concentrations of CRP or AYP1 Fab that do not 
induce full activation, or microparticles formed during storage of platelet concentrates, 
also retained CLEC-2 but lost GPVI expression (supplemental Figure 5-5C - 5-5E). 
Together, these findings indicate that the presence of GPVI can be used to distinguish 
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microparticles derived from either megakaryocytes or activated platelets. 
Elevated platelet-derived microparticle levels are associated with a number of 
cardiovascular and inflammatory diseases, including arterial thrombosis(Mallat et al., 
2000, Lee et al., 1993) 4344 heparin-induced thrombocytopenia(Hughes et al., 2000) 
45, immune thrombocytopenia (Jy et al., 1992), malaria infection (Couper et al., 
2010), AIDS48 and rheumatoid arthritis (Boilard et al., 2010, Knijff-Dutmer et al., 
2002). To verify whether the presence of GPVI on microparticles allows 
discrimination of megakaryocyte- from platelet-derived microparticles, we isolated 
microparticles from peripheral blood plasma samples from patients with rheumatoid 
arthritis and analyzed CLEC-2 and GPVI levels on CD41+ microparticles. As 
expected, the total number of CD41+ microparticles was increased in the patient group 
(Table 5-1). Levels of CLEC-2 were similar to levels on microparticles from healthy 
controls, but GPVI levels were markedly decreased (Figure 5-6D - 5-6E; Table 5-1). 
This reduction agrees with an increase in levels of plasma soluble GPVI (Table 5-1). 
These results suggest that measurement of GPVI levels on CD41+/CLEC-
2+ microparticles in plasma can be used to determine whether patients have increased 
levels of microparticles derived from activated platelets. 
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Figure 5-6 Microparticles from activated platelets maintain CLEC-2, but lose GPVI 
expression. (A) Microparticles were isolated from fresh PRP as described in the methods 
section and (left) CD41+ microparticles were analyzed for (center) CLEC-2 and (right) GPVI 
expression using Alexa Fluor 488-conjugated α-CLEC-2 antibody AYP1 and α-GPVI antibody 
1G5, respectively. True positivity was determined using isotype-matched controls. (B-C) 
CD41+ microparticles isolated from PRP from a 12-day megakaryocyte (MK) culture or from 
washed platelets (WP) that were incubated for 1 hour at 37°C with CRP (10 µg/mL) or AYP1 
Fab (2.5 µg/mL) cross-linked with 20 µg/mL α-mouse Fab-specific F(ab)2 fragments (xAYP1) 
were analyzed for (B) CLEC-2 and (C) GPVI expression. Data are presented as the ratio of MFI 
of CLEC-2 or GPVI over isotype controls (n = 4). (D-E) Analysis of microparticles from 
healthy controls and patients with rheumatoid arthritis. CD41+ microparticles isolated from 
fresh PRP were analyzed for (D) CLEC-2 and (E) GPVI expression. Data are presented as the 
ratio of MFI over isotype controls (mean ± standard deviation; n = 10).  
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NS, not significant  
Table 5-1 CD41+ microparticles and sGPVI levels in rheumatoid arthritis patients. 
Parameters Rheumatoid 
arthritis (n = 10) 
Healthy 
controls (n = 
10) 
P 
Platelet count (×106/L)    
 Median 250 297 NS 
 Range 178-306 143-350 
CD41+ microparticles (×106/L)    
 Median 1372 164 <.01 
 Range 619-7325 33-295 
CLEC-2 on CD41+ microparticles 
(ratio MFI over isotype) 
   
 Median 1.6 1.7 NS 
 Range 1.4-2.2 1.4-2.2 
GPVI on CD41+ microparticles 
(ratio MFI over isotype) 
   
 Median 1.6 2.2 <.01 
 Range 1.3-1.8 1.8-2.7 
sGPVI (ng/mL)    
 Median 27 8 <.01 
 Range 14-50 6-17 
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5.4 Discussion  
 
In the present study, we generated human mAbs to CLEC-2 and demonstrated the 
following: (1) in peripheral blood of healthy individuals, CLEC-2 is restricted to 
platelets with a copy number of 2016 ± 76 per cell; (2) CLEC-2 is not regulated by 
proteolytic cleavage or internalization following autoactivation or in response to 
activation of the ITAM receptors GPVI and FcγRIIa; (3) activation of CLEC-2 leads to 
Src and Syk kinase-mediated proteolytic cleavage of GPVI and FcγRIIa; (4) 
megakaryocyte-derived microparticles express CLEC-2 and GPVI, whereas 
microparticles derived from activated platelets lose GPVI; and (5) the greater expression 
of CLEC-2 relative to GPVI on microparticles and increased soluble GPVI levels in 
patients with rheumatoid arthritis provides evidence of activation of platelets in the 
circulation during this inﬂammatory disorder. 
CLEC-2 was ﬁrst identiﬁed during a bioinformatic screen of human myeloid 
cells for C-type lectin-like receptors, with mRNA transcripts reported in monocytes, 
granulocytes, and dendritic cells (Colonna et al., 2000).A later study of the human 
transcriptome found high levels of CLEC-2 mRNA in bone marrow, liver, and whole 
blood, but not in leukocytes (supplemental Figure 2) (Su et al., 2004b). In agreement 
with this study, we observed expression of CLEC-2 on platelets but not on myeloid and 
lymphocyte populations isolated from peripheral blood. Del Rey and colleagues were 
also unable to detect CLEC-2 expression on cells other than platelets in synovial ﬂuid of 
rheumatoid arthritis patients and failed to detect the receptor on human immature and 
mature dendritic cells (Del Rey et al., 2014). Expression of CLEC-2 on human cells 
other than platelets has thus far only been identiﬁed on the monocytic leukemia THP-
1 cell line (Chang et al., 2010). On the other hand, studies in mice using a selective 
mAb, 17D9, have reported expression of CLEC-2 on a broad range of hematopoietic 
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cells, including neutrophils, natural killer cells, tissue-resident dendritic cells, and 
macrophages, along with enhanced expression during inﬂammatory insults (Kerrigan 
et al., 2009, Mourao-Sa et al., 2011a, Acton et al., 2012). The functional signiﬁcance 
of this differential distribution is not known. 
Of considerable interest in this study is the observation that, in contrast to the 
related ITAM receptors GPVI and FcγRIIa, CLEC-2 is not regulated by proteolytic 
cleavage on activation or in response to activation of either of the ITAM receptors. 
Shedding of GPVI is mediated by a disintegrin and metalloproteinase family pathway 
(Bender et al., 2010). In contrast, proteolysis of FcγRIIa occurs via activation of 
calpain. Both receptors are also cleaved after treatment with the calmodulin inhibitor 
W7 to dissociate calmodulin from a binding site within the cytoplasmic tails of GPVI 
and FcγRIIa (Gardiner et al., 2008). There is no identiﬁable calmodulin binding motif 
within the cytoplasmic tail of CLEC-2. 
These observations give rise to the question as to why the levels of GPVI and 
FcγRIIa are controlled by proteolytic cleavage but not those of CLEC-2. Down-
regulation of GPVI and FcγRIIa by proteolysis may help to limit uncontrolled platelet 
activation (and thereby thrombus formation) in the circulation either in response to 
weak constitutive signaling by either receptor (Tomlinson et al., 2007, Mori et al., 
2008), or in the case of FcγRIIa, in response to contact with immune complexes. It 
could also be important to limit the time and extent of platelet activation, for example, 
in relation to the role of GPVI in the maintenance of vascular integrity, although this 
would also apply to CLEC-2 (Boulaftali et al., 2013). Chronic ligand engagement of 
GPVI could contribute to persistent platelet activation and inﬂammation in the vessel 
wall, as observed in rheumatoid arthritis, deep vein thrombosis, and atherosclerosis, 
and this would be countered by shedding. 
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One potential explanation as to why CLEC-2 is not subject to the same 
regulatory pathways could be related to the absence of podoplanin in the vasculature 
or in the immediate vicinity of damage to the vessel wall. Furthermore, functional 
engagement of CLEC-2 and podoplanin may require a sustained interaction. In this 
context, it may be important to recognize CLEC-2 as both a signaling receptor and a 
ligand that regulates podoplanin signaling. The role of CLEC-2 and podoplanin in 
prevention of blood-lymphatic mixing (Suzuki-Inoue et al., 2010, Bertozzi et al., 2010, 
Finney et al., 2012) and in maintenance of integrity in high endothelial venules 
(Herzog et al., 2013) may require sustained activation of podoplanin to permit changes 
such as gene regulation to occur. At the same time, it is possible that the shedding of 
GPVI by CLEC-2 may represent an important mechanism to limit thrombus growth 
during contact between the 2 vasculatures. Although the present results demonstrate 
that CLEC-2 is not down-regulated on human platelets in vitro, it is noteworthy that 
down-regulation of CLEC-2 has been described in mouse platelets in vivo on exposure 
to a rat a-mouse CLEC-2 mAb, INU1(May et al., 2009). The molecular basis of this 
down-regulation and its physiological signiﬁcance are unclear. We showed that the 
binding of CLEC-2 induces proteolysis of GPVI and FcγRIIa. In the same context, 
GPVI is capable of inducing proteolysis of FcγRIIa and vice versa (Gardiner et al., 
2008). The physiological implication of this is unclear, as this could reﬂect the shared 
signaling mechanisms by all 3 receptors. Shedding of GPVI by CLEC-2 during 
lymphatic development may represent an important mechanism to limit thrombus 
growth during this important physiological process. Alternatively, CLEC-2–induced 
proteolysis of GPVI and FcγRIIa could regulate a novel pathway of regulation of 
platelet function. 
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Platelet-derived microparticles are generated in response to a range of 
pathologic processes, and their determination and characterization may provide 
insights into the molecular mechanism of disease (Boilard et al., 2010, Mallat et al., 
2000, Knijff-Dutmer et al., 2002). They may also play physiological roles in processes 
ascribed to platelet function. For example, microparticles could potentially mediate 
some of the functions ascribed to CLEC-2 on platelets in processes such as 
development of the lymphatics and lymph nodes (Bénézech et al., 2014). Using ﬂow 
cytometry, we demonstrate that megakaryocyte-derived microparticles in plasma of 
healthy individuals express CLEC-2 and GPVI, whereas GPVI is absent from 
microparticles derived from activated platelets. It has recently been shown that 
megakaryocyte-derived microparticles can be distinguished from platelet-derived 
micro- particles by the absence of surface-expressed P-selectin and lysosome- 
associated membrane protein-1 and by the presence of full-length ﬁlamin A 
(Flaumenhaft et al., 2009). In line with our study, microvesicles derived from mouse 
megakaryocytes also stained positive for GPVI (Flaumenhaft et al., 2009).As P-
selectin and lysosome-associated membrane protein-1 are also expressed by other cells 
(McEver et al., 1989, Sarafian et al., 1998) and determination of ﬁlamin A requires 
isolation of microparticles and western blotting, screening for CD41+/CLEC-2+/ 
GPVI2- microparticles by ﬂow cytometry may provide an attractive alternative to 
quantitate platelet-derived microparticles in circulation. This is illustrated in the 
present study by analysis of plasma samples from patients with the chronic 
inﬂammatory disease rheumatoid arthritis, which is associated with increased 
microparticle production (Boilard et al., 2010, Knijff-Dutmer et al., 2002). Increased 
microparticle production in rheumatoid arthritis patients has been attributed to 
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collagen-mediated platelet activation around the vasculature of the joint, which is in 
close contact with ﬁbroblast-like synoviocytes and extracellular matrix (Boilard et al., 
2010). Importantly, in the present study, we show that the majority of the circulating 
micro- particles lack GPVI but retain CLEC-2 and CD41 expression in this 
inﬂammatory disorder, suggesting that they are partly derived from megakaryocytes 
and part from platelet activation. The reduced levels of GPVI expression on 
microparticles and elevated levels of soluble GPVI in patients with rheumatoid 
arthritis support the role of these measurements as biomarkers of disease. 
In summary, we describe a novel mouse mAb against human CLEC-2, AYP1, 
and use this to demonstrate the restricted distribution of CLEC-2 to platelets, the 
resistance of the C-type lectin receptor to proteolysis, and the CLEC-2–induced 
cleavage of GPVI and FcγRIIa. The observation that microparticles derived from 
activated platelets retain CLEC-2 but lose GPVI highlights the potential use of 
measurement of surface expression of platelet receptors to screen for platelet 
activation in a wide variety of cardiovascular and inflammatory diseases.  
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5.6 Supplementary  
5.6.1 Supplemental methods 
5.6.1.1 Materials and antibodies 
We used the following products (with sources): human serum albumin fraction V 
(First Link Ltd., Wolverhampton, UK), calpain inhibitor E64d (L-3-carboxy-trans-
2,3-epoxypropionyl-L-leucylamido-(3-methyl)butane),broad-range matrix 
metalloproteinase inhibitor GM6001, N-ethylmaleimide (NEM) and calmodulin 
inhibitor W7 (Calbiochem, La Jolla, CA), enhanced chemiluminescence reagent 
(Thermo Fisher Scientific, Waltham, MA), PLATELET calibrator kit (Biocytex, 
Marseille, France), Calcium ionophore (A23187), Histopaque-1119 and -1077, 
paraformaldehyde and Src family kinase inhibitor PP2 (Sigma-Aldrich, Dorset, UK), 
Lymphoprep (Axis-Shield, Oslo, Norway), MiniMACS CD34 MicroBead kit, human 
thrombopoietin (TPO), human stem cell factor (SCF), interleukin (IL)-3, IL-6 and Flt3 
ligand (Myltenyi Biotec, Surrey, UK), prostacyclin (PGI2) (Cayman Chemical, Ann 
Arbor, MI), PRT-060318 (Portola Pharmaceuticals Inc., San Francisco, CA) and 
Sytox Red live/dead cell staining solution and StemPro-34 medium (Life 
Technologies, Paisley, UK). Rhodocytin was purified from Calloselasma rhodostoma 
venom as previously described (Eble et al., 2001). Crosslinked collagen-related-
peptide (CRP) was purchased from Dr. Richard Farndale (Cambridge University, 
UK). Human IgG1 Fc-tagged recombinant human podoplanin (hPDPN-Fc) was 
generated as described (Schacht et al., 2005). 
The following antibodies were used: goat IgG, polyclonal goat human CLEC-
2, goat human FcγRIIa-biotin (R&D Systems, Minneapolis, MN), donkey goat IgG-
FITC (Jackson Immunoresearch, Suffolk, UK), goat mouse IgG (Fab specific), FITC-
conjugated sheep mouse IgG (whole molecule) F(ab’)2 fragments and mouse human 
tubulin (Sigma-Aldrich), APC conjugated mouse human P-selectin (Biolegend, San 
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Diego, CA), PE-Cy7-conjugated mouse human CD3, APC-eFluor® 780 conjugated 
mouse human CD14 and PE-conjugated rat human podoplanin clone NZ-1.3 
(eBioscience, San Diego, CA), PE-Cy7-conjugated mouse human CD11c and CD16, 
PE-Cy5-conjugated mouse human CD19, PE- and APC-conjugated mouse human 
integrin IIb (CD41), PE-conjugated mouse IgG1 and mouse human CD45 (BD 
Biosciences, Oxford, UK), FITC-conjugated mouse human CD34 (Myltenyi Biotec), 
HRP-conjugated sheep mouse, donkey rabbit IgG and streptavidin (GE Healthcare, 
Little Chalfont, UK), FITC-conjugated swine rabbit F(ab)2 (Dako, Glostrup, 
Denmark), mouse phosphotyrosine 4G10 (Merck Millipore, Billerica, MA) and Alexa 
Fluor-488 conjugated goat rat IgG and fibrinogen (Life Technologies). Mouse human 
GPVI clone 1G5 (Gardiner et al., 2007), rabbit human GPVI cytoplasmic tail (Gardiner 
et al., 2007) and polyclonal rabbit rhodocytin antibody (Suzuki-Inoue et al., 2006) were 
generated as described in the corresponding references. Mouse human FcγRIIa 
monoclonal antibody IV.3 was produced and purified in-house from a hybridoma cell 
line purchased from ATCC (Middlesex, UK). Conjugation of antibodies to Alexa Fluor-
488 (LifeTechnologies) was performed according to the manufacture’s protocol with 
an average fluorophoreto-protein ratio of 8. Fab fragments of the mouse human CLEC-
2 antibody AYP1 and FcγRIIa2 antibody IV.3 were made using a kit from Thermo 
Fisher Scientific. Rat mouse CLEC-2 antibody 17D9 was from AbD Serotec (Oxford, 
United Kingdom) and dialyzed using a Slide-A-Lyzer Dialysis Cassette (Thermo Fisher 
Scientific) to remove azide. Antibodies were matched with isotype controls from the 
same company or, in the case of in-house produced antibodies, from R&D Systems. 
5.6.1.2 Platelet preparation 
 
Venous blood from healthy drug-free volunteers was taken into sodium citrate (f.c. 
0.32%). Washed platelets were obtained by centrifugation using prostacyclin (PGI2; 1 
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μg/mL) to prevent activation during the isolation procedure (Suzuki-Inoue et al., 2003). 
Platelets were resuspended in modified-Tyrode’s buffer (134 mM NaCl, 0.34 mM 
Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM N-2-hydroxyethylpiperazine-N’-2- 
ethanesulfonic acid (HEPES), 5 mM glucose, 1 mM MgCl2, 1 mM CaCl2, 2.5 μM 
ZnCl2; pH 7.3). Platelets were used at a concentration of 2x10
8/mL or as indicated. 
Platelet concentrates were prepared by the buffy coat method and stored according to 
the UK blood transfusion services guidelines (Services, 2005) 
For preparation of mouse platelets, blood was collected from terminally CO2-
narcosed mice by cardiac puncture into 1:10 (vol:vol) acid citrate dextrose (120mM 
sodium citrate, 110mM glucose, 80mM citric acid). Washed platelets were prepared as 
previously described (Pearce et al., 2004a) and resuspended in modified-Tyrode’s 
buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM N-
2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), 5 mM glucose, 1 mM 
MgCl2, 1mM CaCl2, 2.5 μM ZnCl2; pH 7.3). Platelets were used at a concentration of 
2x108/mL. 
5.6.1.3 In vitro culture of human megakaryocytes 
 
CD34+ cells were isolated from human umbilical cord blood by Lymphoprep density 
gradient centrifugation followed by magnetic cell sorting using MiniMACS CD34 
MicroBead kit according to the manufacturer’s instructions. The purity of the isolated 
population was based on CD34 expression determined by flow cytometry and always 
exceeded 90%. CD34+ cells were cultured for 5 days in StemPro-34 medium 
supplemented with 20ng/ml human thrombopoietin (TPO), 50 ng/ml human stem cell 
factor (SCF), 10 ng/ml interleukin (IL)-3, 10 ng/ml IL-6 and 50 ng/ml Flt3 ligand. To 
induce megakaryocyte development, 1 ng/mL SCF, 30 ng/ml TPO, 7.5 ng/ml IL-6 and 
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13.5 ng/ml IL-9 were added to the culture media on day 5 of subculture and incubated 
for an additional 12 days. Microparticles were isolated at the end of the culture. 
5.6.1.4 Leukocyte isolation 
 
Human peripheral blood mononuclear cells (PBMCs) and polymorphonuclear cells 
(PMNs) were isolated from EDTA-anticoagulated blood by gradient separation using 
Histopaque according to the manufacturer’s protocol. Freshly prepared PBMCs and 
PMNs were resuspended in PBS at 1x106 cells/mL and analysed by flow cytometry. 
5.6.1.5 Cell culture 
 
293T Rex cells with doxycycline-inducible expression of CLEC-2 (Chaipan et al., 
2006b) were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% 
foetal calf serum and antibiotics. Protein expression of CLEC-2 was induced by treating 
the cells with 1μg/mL of doxycycline for 24 hours. 
5.6.1.6 Protein deglycosylation 
 
Proteins in platelet lysates were deglycosylated using Peptide-N-Glycosidase F 
(PNGase F) from New England Biolabs (Hitchin, UK) according to the manufacturer’s 
instructions. In short, lysates were denatured for 10 minutes at 100oC and incubated 
without or with PNGase F for 2 hours at 37oC. 
5.6.1.7 Measurement of sGPVI 
 
Levels of sGPVI were determined in plasma from healthy controls and patients with 
rheumatoid arthritis in triplicate by enzyme-linked immunosorbent assay (ELISA) as 
previously described (Al-Tamimi et al., 2009a) 
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5.6.1.8 Immunoprecipitations and western blots 
 
For immunoprecipitations, washed platelets (5x108/mL) were lysed with an equal 
volume of 2x lysis buffer (20 mM Tris/HCL (pH 7.5), 300 mM NaCl, 2 mM EGTA, 2 
mM EDTA, 2% NP-40, 2 mM PMSF, 5 mM Na3VO4, 10 μg/mL leupeptin, 10 μg/mL 
aprotinin, and 1 μg/mL pepstatin). Proteins were captured by antibodies bound to 
protein G-Sepharose. For lysate analysis, platelet suspensions were fixed for 15 minutes 
at 4oC with 1% paraformaldehyde, centrifuged (15,000g, 2 minutes) and dissolved in 
1x lysis buffer. Sample buffer (5x) was subsequently added under reducing conditions. 
Samples were separated by SDS-PAGE alongside a molecular weight marker and 
transferred onto a polyvinylidene difluoride (PVDF) membrane. After blocking, the 
membranes were incubated with primary antibody overnight, washed, and then 
incubated with horseradish peroxidase-conjugated secondary antibody for 1 hour. 
Protein bands were visualized by enhanced chemiluminescence. Quantification was 
performed with ImageJ software.  
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Supplemental Figure 5-1 Flow cytometric analysis of CLEC-2 expression on platelets and 
leukocytes. (A) Gating strategy. Freshly prepared platelets, peripheral blood mononuclear cells 
(PBMCs) and polymorphonuclear cells (PMNs) were identified by forward scatter (FSC) and 
side scatter (SSC). Sytox Red- cell populations (live cells) were gated and analysed for CD41 
expression.Surface expression of CLEC-2 on platelets was performed within the CD41+ gate 
and on PBMCs and PMNs in the CD41- gate. (B) Platelets and CD45+ cells were analysed for 
CLEC-2 expression using another, commercially available polyclonal goat human CLEC-2 
antibody (R&D Systems). Antibody binding was assessed with a secondary donkey goat IgG-
FITC antibody.  
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Supplemental Figure 5-2 Tissue- and cell-specific analysis of CLEC-2 mRNA expression 
in humans.This dataset has been generated and described elsewhere (Su et al., 2004a) and the 
graphic representation was created using the gene portal BioGPS.org.(Wu et al., 2009)  
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Supplemental Figure 5-3 Murine CLEC-2 is not susceptible to proteolytic cleavage. (A) 
Washedmouse platelets were incubated with vehicle control (veh; DMSO), NEM (2 mM), W7 
(150 μM) or with rat mouse CLEC-2 mAb 17D9 (10 μg/mL) for 1 hour at 37oC. Platelet lysates 
were blotted and probed with 17D9 for detection of CLEC-2. (B) Flow cytometric analysis of 
the surface expression of murine CLEC-2. Washed mouse platelets were incubated with vehicle 
control (veh; DMSO), NEM (2 mM) or W7 (150 μM) for 1 hour or with rat mouse CLEC-2 
mAb 17D9 (10 μg/mL) for 15 minutes and 1 hour at 37oC. DMSO, NEM and W7 treated 
platelets were pre-incubated with 17D9 for 15 minutes, followed by incubation with Alexa 
Fluor 488-conjugated goat rat IgG for 15 minutes at room temperature. 17D9 treated platelets 
were also incubated with Alexa Fluor 488-conjugated goat rat IgG for 15 minutes at room 
temperature. All samples were immediately analysed. Data are representative of three 
independent experiments.  
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Supplemental Figure 5-4 Podoplanin induces proteolytic cleavage of GPVI and 
FcγRIIa.Washed platelets were incubated with IV.3 Fab (5 μg/mL) to block FcγRIIa and either 
incubated on a petri dish coated with BSA (20 μg/mL) or hPDPN-Fc (20 μg/mL) for 1 hour at 
37oC. Non-adhered platelets on the BSA-coated petri dish were removed and lysed. Adhered 
platelets on the hPDPN-Fc coated petri dish were lysed and protein concentrations in both 
lysates were equalized before loading onto a gel. Following blotting, the membrane was probed 
with an antibody against the cytoplasmic tail of GPVI, which detects both full-length and the 
cytoplasmic tail remnant of GPVI, and with mouse human FcγRIIa-biotin. The blots are 
representative for three independent experiments.  
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Supplemental Figure 5-5 Analysis of CD41+ microparticles. (A) CD41+ microparticles 
isolated from PRP or isolated leukocytes (positive control) were analysed for CD45 expression 
by flow cytometry. Data are representative of three independent experiments. (B) 
Microparticles isolated from PRP were incubated for 1 hour at 37oC with CRP (10 μg/mL) or 
AYP1 Fab (2.5 μg/mL) crosslinked with 20 μg/mL mouse Fab-specific F(ab)2 fragments 
(xAYP1) and analysed for CLEC-2 and GPVI expression. Data are presented as the ratio of 
MFI of CLEC-2 or GPVI over isotype controls. (C-E) Analysis of CLEC-2 and GPVI 
expression on microparticles formed during suboptimal platelet activation or platelet storage. 
(C) Washed platelets were incubated for 1 hour at 37oC with indicated concentrations (μg/mL) 
of CRP or AYP1 Fab crosslinked with 20 μg/mL mouse Fab-specific F(ab)2 fragments (xAYP1) 
and analysed for P-selectin expression and fibrinogen binding. Data are presented as the ratio 
of MFI of treated over control platelets. (D, E) CD41+ microparticles formed during these 
incubations or after platelet storage for five days were analysed for (D) CLEC-2 and (E) GPVI 
expression. Data are presented as the ratio of MFI of CLEC-2 or GPVI over isotype controls 
(n=3).  
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6.1 Summary 
 
The major two finding of this thesis are (i) that DEP nanoparticles and several 
structurally unrelated charged/hydrophobic agonists, fucoidan, dextran sulphate, 
peptides 4N1-1 and Champs, and the synthetic lipoprotein Pam3-CSK4, activate 
platelets through the (hem)ITAM receptors GPVI and CLEC-2; and (ii) the 
identification of fibrin as a novel ligand for GPVI.  
I have determined that platelet activation by the diverse group of ligands named 
above is mediated by Src and Syk tyrosine kinases, and is dependent on GPVI and/or 
CLEC-2 receptors. DEP, fucoidan and dextran sulphate induce activation through direct 
binding to GPVI and/or CLEC-2, while it remains unclear whether activation of GPVI 
by 4N1-1, Champs and Pam3-CSK4 is mediated by direct binding or by an indirect 
action (that presumably leads to clustering of GPVI). In addition, I have shown that 
fibrin binds directly to GPVI.  
In the thesis, I demonstrate that miscellaneous charged/hydrophobic agents 
activate GPVI and CLEC-2 in platelets, including PAM3-CSK4.  This observation 
indicates the need for caution in ascribing the mechanism of platelet activation to 
PAM3-CSK4 to TLR2, especially since the signalling pathway through which its 
specific receptor, TLR2, activates platelets is not clear.  In light of the present 
observations, further studies on the mechanism of platelet activation by PAM3-CSK4, 
including the use of blocking antibodies to TLR2, are warranted. 
These observations have important implications for haemostasis and life-
threatening arterial thrombosis. The observation that fibrin binds to and activates GPVI 
advances the ‘textbook’ model of platelet activation, with fibrin mediating both clot 
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consolidation and further platelet activation (including PS exposure and thrombin 
generation). The discovery that structurally diverse ligands such as DEP activate 
platelets through Src and Syk tyrosine kinases raises the possibility that inhibition of 
either class of kinase could be used to reduce the risk of arterial thrombosis in areas of 
increased exposure to car exhaust fumes and other nanoparticles, albeit that there 
remains a need for further experimental evidence to confirm a causal link.  
6.2 The mechanism of platelet activation by structurally unrelated 
charged/hydrophobic ligands 
 
I have shown that GPVI and CLEC-2 can be activated in vitro by structurally diverse 
ligands. In moderate concentrations, several of the ligands are selective to one or other 
of the two ITAM receptors, although at higher concentrations, they activate both 
receptors. This raises the question as to how these diverse stimuli induce activation of 
multiple receptors over a similar concentration range, including whether this involves 
direct binding to the receptor or to associated membrane proteins.  
6.2.1 Do DEP and other hydrophobic/charged ligands activate platelets by 
clustering of GPVI and CLEC-2 in lipid rafts? 
 
GPVI and CLEC-2 signal in cholesterol-rich domains of the surface membrane known 
as lipids (Wonerow et al., 2002, Locke et al., 2002, Pollitt et al., 2010, Manne et al., 
2015). These domains are rich in signaling proteins including the Src family kinases 
(SFKs) Fyn and Lyn, although Src itself is excluded from these domains (Watson et al., 
2010). Receptor activation is mediated by translocation and clustering of the two 
receptors in the cholesterol-rich lipids rafts, which brings them into contact with Src 
and Syk family kinases. Depletion of membrane cholesterol with -methylcyclodextrin, 
thus leading to membrane raft disruption, inhibits signaling by GPVI and CLEC-2 
 
 
194  
(Wonerow et al., 2002, Pollitt et al., 2010). It seems likely that this diverse group of 
stimuli mediate activation by inducing clustering of GPVI and CLEC-2 in lipid rafts.  
DEP are made up of spherical carbon nanoparticles that contain the organic 
materials sulphate and nitrate. The surface of DEP carries an electrical charge which 
may underlie binding to GPVI and CLEC-2, with the multimeric nature of DEPs leading 
to crosslinking of both receptors. A similar mechanism may mediate platelet activation 
by other charged and hydrophobic ligands. In this way clustering of GPVI and CLEC-
2 in lipid rafts could lead to receptor activation. 
It is also possible that one or more of this group of ligands could bind to other 
membrane proteins and indirectly promote clustering of the two receptors, although this 
may not necessarily occur in lipid rafts. While direct evidence of this is not available, 
it is noteworthy that several of the ligands used in this study induce tyrosine 
phosphorylation at similar concentrations that mediate binding to GPVI and CLEC-2. 
6.2.2 Do other receptors contribute to platelet activation? 
 
In Chapter 2, I demonstrated that low and intermediate concentrations of fucoidan 
induce platelet aggregation and phosphorylation through CLEC-2 but that at higher 
concentrations it also activates GPVI and other tyrosine kinase-linked membrane 
proteins. The significance of the latter to platelet activation is not known. Fucoidan has 
been reported to bind to several receptors on macrophages such as Toll-like receptor-4 
(TLR-4) and scavenging receptors (SRs) (Teruya et al., 2009). Platelets express both 
TLR4 receptor and the SRs CD36, SRBI, LOX-1 and CD68 (Valiyaveettil and Podrez, 
2009), and both TLR4 and CD36 are coupled to Src kinases (Gong et al., 2008, 
Magwenzi et al., 2015). Several of the other ligands used in this study may also bind to 
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several surface receptors through charge/hydrophobic interactions, and it is possible 
that these contribute to platelet activation. 
6.2.3 Does dextran sulphate activate human platelets through a novel signaling 
pathway?  
 
Dextran sulphate has been shown to activate human platelets through SFKs independent 
of Syk as discussed in Chapter 3. This demonstrates that dextran sulphate signals in 
human platelets through a novel pathway that may be independent of GPVI and CLEC-
2. In contrast, as shown in Chapter 3 using transgenic mice, activation of mouse 
platelets by dextran sulphate is mediated by CLEC-2 and GPVI, indicating an important 
species difference. PI3K-Akt offers a possible pathway through which dextran sulphate 
can induce platelet aggregation and secretion, as dextran sulphate has been reported to 
activate PI3K and Akt independently of the P2Y12 receptor (Getz et al., 2013b), 
although this pathway alone is likely to be insufficient to mediate platelet activation. 
Thus, the mechanism underlying activation by dextran sulphate remains to be 
determined and also why this is induced by dextran sulphate in human but not in mouse 
platelets. 
6.2.4 Differential features between human and mouse platelets activation by 
Dextran sulfate  
 
Mouse platelets are the gold-standard animal for platelet studies, primarily because of 
the availability of a large number of transgenic mice strains. Nevertheless, there are a 
number of significant differences between mouse and human platelets including the 
absence of FcRIIA and PAR-1 in mouse platelets.  While these differences do not 
invalidate the use of mouse platelets, they indicate the need for caution and the 
importance of confirming observations between human and mouse platelets as far as 
possible. The observation of the differential dependence on Syk activation by Dextran 
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sulphate in this study further indicates an important difference between platelets from 
the two species. The explanation for this difference is not known.  However, the present 
results also show that dextran sulfate activates CLEC-2 in both human and mouse 
platelets. 
6.2.5 Mechanism of platelet activation and platelet agglutination by 4N1-1 and 
Champs peptides 
 
It has previously been reported that the peptide 4N1-1 stimulates aggregation of washed 
human and mouse platelets, and that aggregation is abolished in the absence of the FcR 
-chain, suggesting that it is mediated through GPVI. A residual increase in light 
transmission is seen in FcR -chain-deficient or integrin αIIb-subunit deficient mouse 
platelets in response to high concentrations of 4N1-1, reflecting agglutination. 
Similarly, Champs peptide induces agglutination in mice deficient in the integrin 
subunit αIIb or the FcR -chain. The observation that both peptides induce platelet 
agglutination at similar concentrations to those at which activate the GPVI/FcR -chain 
complex suggests that multiple interactions take place with surface proteins over a 
similar concentration range, with agglutination possibly being mediated by 
neutalisation of surface platelet charge. 
6.2.6 Conclusions on the mechanism of platelet activation by 
charged/hydrophobic ligands 
 
There appear to be multiple interactions with surface proteins that underlie platelet 
activation by the series of charged/hydrophobic ligands used in this study. At the centre 
of these is activation of GPVI and CLEC-2, the major two tyrosine kinase signalling 
receptors which induce powerful activation of platelets through Src and Syk tyrosine 
kinases. In addition, the observation of increased protein tyrosine phosphorylation 
and/or agglutination in platelets from mice deficient in both receptors demonstrates that 
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this group of ligands bind to other surface proteins or possibly to the phospholipid 
themselves, and that in some cases this can lead to functional responses. The similar 
concentrations at which these events are seen suggest a major role for 
charged/hydrophobic interactions in mediating these interactions. The multimeric 
nature of many of these ligands is likely to lead to clustering of membrane proteins, 
including GPVI and CLEC-2. Whether activation occurs in membrane-specific 
domains such as lipid rafts or tetraspanin domains remains to be determined. 
6.2.7 The clinical significance of GPVI and CLEC-2 as receptors for DEPs 
 
There is considerable interest in the possible role of DEP in platelet activation and 
thrombus formation through exposure in the environment but little direct evidence that 
this occurs because of the challenge in designing a random controlled trial (RCT). 
Polycyclic aromatic hydrocarbons are one of the toxic compounds of DEPs, along with 
other chemical compounds, such as carbon monoxide and dioxide (Zielinska et al., 
2004). In addition, DEP induce a localised inflammatory response (Siegel et al., 2004), 
which could also contribute to platelet activation and pathogenic thrombosis. Exposure 
to pollutants is linked to series health issues, notably in the frail and elderly, but the 
underlying mechanisms remain to be determined. DEP exposure is linked to a variety 
of health conditions, including cardiovascular and lung disease, and cancer (Krivoshto 
et al., 2008), with platelet activation foremost as the underlying mechanism. 
One way to address the potential role of DEPs in mediating thrombus formation 
is determination of the mechanism of platelet activation, and to develop or identify 
pharmaceutical agents that block activation. Even then, it will be difficult to design a 
RCT that specifically addresses the potential for DEPs to induce thrombus formation 
through this pathway due to the long term nature over which the pathology occurs and 
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the present of other compounding factors. Nevertheless, the work in this thesis is 
important in that it establishes the mechanism of platelet activation by DEPs. 
 
6.2.8 GPVI and CLEC-2 as targets for development of novel antiplatelet drugs 
 
Patients at risk of arterial thrombosis are treated long term with antiplatelet agents 
including aspirin and P2Y12 receptor antagonists such as clopidogrel. These antiplatelet 
agent target the two feedback agonists, thromboxane A2 and ADP which activate 
platelets through GPCRs. However, both sets of drugs induce bleeding which in some 
cases can be life-threatening (Swieringa et al., 2014). It is therefore important to 
develop new forms of antiplatelet drugs that prevent thrombosis in the absence of a 
bleeding diathesis. 
GPVI/FcRγ complex and CLEC-2, along with FcγRIIA in human platelets, are 
the only three receptors that activate platelets through a hem(ITAM)-driven pathway 
that involves Src and Syk tyrosine kinases. A small number of patients have been 
identified with function-disrupting mutations in GPVI in association with mild bleeding 
e.g. (Hermans et al., 2009). In addition, GPVI knockout mouse also exhibit a mild 
increase in tail bleeding times in some but not all studies(Dutting et al., 2012). In 
contrast, the general consensus is that neither CLEC-2 nor FcγRIIA play a role in 
haemostasis due to the absence of an identified ligand at the site of vascular damage 
and normal bleeding in mice deficient in CLEC-2 (FcγRIIA is absent in the rodent 
genome). Thus, CLEC-2 and FcγRIIA could represent novel targets as antiplatelet 
agents for thrombotic conditions in which they play a role, such as the up-regulation of 
podoplanin that is seen in liver in Salmonella infected mice (Hitchcock et al., 2015) 
It is also possible that activation of (hem)ITAM receptors could be beneficial to 
patient with bleeding disorders. It has been reported that fucoidan decreases the 
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bleeding time in murine models of haemophilia A and B and that this leads to an 
increase in survival (Liu et al., 2006). It may also be possible to use fucoidan in 
combination with other antiplatelet drugs to reduce the side effects of the bleeding.  
 
6.3 The binding of fibrin to the GPVI receptor  
 
As discussed in Chapter 4, fibrin was identified as a novel ligand for GPVI. The delay 
in vessel occlusion and the increase in embolisation in GPVI-deficient mice, following 
topical FeCl3 injury may be explained by the loss of this interaction. Fibrin activates 
platelets through the GPVI signalling pathway, as summarised in Figure 6-1. The 
stabilisation of the platelet aggregate by the conversion of fibrinogen to fibrin is the last 
stage in thrombus formation, but our results now suggest that this can lead to further 
platelet activation. Thus, GPVI may play an essential role in stabilisation of the 
aggregate through its interaction with fibrin as well as in the initiation of aggregation 
through the interaction with collagen. 
GPVI collagen-binding domain residues have been mapped (Horii et al., 2006). 
It will be important to establish if fibrin binds to the same residues as it may be possible 
to interfere with the binding of one but not the other ligand. In this way, it may be 
possible to block the interaction of GPVI with fibrin or collagen, and potentially 
develop a novel antithrombotic drug that does not give rise to bleeding (at the moment, 
we do not know if the bleeding diathesis is due to loss of interaction with collagen 
and/or fibrin). Thus, if collagen and fibrin are shown to bind to separate sites, then the 
development of inhibitors that block just one of these interactions may lead to a new 
form of treatment of cardiovascular disease without excessive bleeding. Further, with 
increasing recognition of the importance of personalised medicine, and that thrombosis 
can have many causes, it may be that selective inhibition of the interaction with fibrin 
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or collagen is beneficial under different conditions such as the increase in thrombosis 
observed in diabetes, ischemic attack and stroke which are associated with elevated 
fibrinogen levels and, in some cases GPVI/FcR expression (Vinik et al., 2001, Cabeza 
et al., 2004, Di Napoli and Singh, 2009, Bigalke et al., 2010). In addition, anti-GPVI 
agents may help us investigate whether there is a link between fibrin or collagen and 
GPVI in patients who suffer from atherosclerosis and cardiovascular diseases.  
6.4 Final thoughts  
 
The results obtained from this thesis demonstrate the primary role of GPVI and the 
CLEC-2 in the activation of platelets by a miscellaneous group of ligands including 
fibrin. This may lead to new ways to target platelet activation in pathological diseases, 
such as exposure to DEP, or by selective inhibition of GPVI activation by fibrin. Further 
the absence of a recognised role for CLEC-2 in haemostasis, and the absence of 
information on the significance of the binding of fibrin to GPVI in haemostasis, 
indicates that it may be possible to develop inhibitors of these two receptors that target 
thrombosis in the absence of excessive bleeding. 
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Figure 6-1 Signalling pathway of GPVI receptor, following the activation of platelets by 
fibrin. Fibrin binds directly to GPVI, leading to the phosphorylation of SFK and Syk and 
platelet activation, which induces inside-out signalling and the activation of integrin αIIbβ3.  
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Appendices 
 
Appendix 1. 
 
 
 
 
Rhodocytin stimulates tyrosine phosphorylation of CLEC-2. Washed human 
platelets were stimulated with Rhodocytin (100 nM) for 3 min. Experiments were 
performed under stirring conditions in the presence of Integrilin (9 μM). CLEC-2 was 
immunoprecipitated using a specific antibody, separated by SDS PAGE and Western 
blotted for pTyr before reprobing for CLEC-2. Results are representative of a minimum 
of three experiments. 
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Appendix 2. 
 
 
 
 
 
Diesel exhaust particles (DEP) do not induce tyrosine phosphorylation of FcγRIIa. 
Washed human platelets were stimulated with DEP (50 μg/ml), thrombin (1 U/ml) and 
mAb IV.3 (2 μg/ml), crosslinked with a secondary cross-linker sheep α-mouse F(ab)2 
(15 μg/ml) for 3 min. The latter was used as a positive control for FcγRIIa 
phosphorylation. Fcγ RIIa was immunoprecipitated using mAb BAF 133, separated by 
SDS PAGE and western blotted for pTyr before reprobing with for the ip’d protein. 
Results are representative of a minimum of three experiments. 
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Appendix 3. 
 
 
 
LSARLAF activates mouse platelets through GPVI. Washed platelets from (A) wild 
type (WT), GPVI-deficient mice and CLEC-2-deficient mice were stimulated with 
LSARLAF (1 mM), and (B) Platelets were pre-incubated with PP2 (10 µM) and 
PRT318 (5 µM) for 3 min prior to stimulation; Representative aggregation results from 
3 experiments are shown as mean ±SEM (*** P<0.001). Results are representative of 
three experiments 
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Appendix 4. 
 
 
 
 
 
 
 
 
4N1-1, Champs and LSARLAF induce platelets agglutination. Platelets were pre-
incubated with integrillin (9µM) for 3 min prior to 4N1-1, Champs or LSARLAF 
stimulation. Results are representative of three experiments. 
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Appendix 5. 
 
 
4N1-1 and Champs do not activate mouse platelets through CLEC-2. Washed 
platelets from wild type (WT) and CLEC-2-deficient mice were stimulated with (A) 
4N1-1 (100 μM) and (B) Champs (30 μg/ml). Representative aggregation traces 
shown with mean results from three experiments ± SEM.  
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Appendix 6. 
 
 
 
Fucoidan stimulates tyrosine phosphorylation in GPVI-deficient platelets. Washed 
platelets prepared from GPVI-deficient mice were stimulated with fucoidan (100 
μg/ml) for 3 min. Tyrosine phosphorylation of whole cell lysates were separated by 
SDS-PAGE and western blotted for pTyr using mAb 4G10. Results are representative 
of three experiments 
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Appendix 7. 
 
 
 
 
 
Stimulation of tyrosine phosphorylation by fucoidan is blocked by PP2. 
Mouse platelets were pre-incubated with PP2 (10 µM) for 3 min prior to 
stimulation with Fucoidan (100 μg/ml). Protein separated by SDS-PAGE and 
Western blotted for pTyr. The figure is representative of three experiments. 
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Appendix 8. 
 
 
 
 
Dextran sulphate induces platelet agglutination. Washed human platelets were pre-
incubated with integrilin (9 μM) for 3 min before stimulation with dextran sulphate (20 
nM). Results are representative of three experiments 
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Appendix 9. 
 
 
 
 
 
 
Inhibition of Syk phosphorylation in GPVI/CLEC-2-double-deficient by 
dextran sulphate. Protein phosphorylation of Syk was measured after dextran 
sulphate (20 nM) stimulation of washed platelets from wild-type (WT) and 
GPVI/CLEC-2-deficient mice. Results are representative of three experiments. 
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Appendix 10. 
 
 
 
 
CLEC-2 is not phosphorylated by Pam3-CSK4 in human platelets. Washed human 
platelets were preincubated with integrilin (9 μM) and stimulated under stirring 
conditions with Pam3-CSK4 (30 μg/ml) for 10 and 300 sec or Rhodocytin (100 nM) 
before lysis. CLEC-2 was immunoprecipitated using a specific antibody, separated by 
SDS PAGE and Western blotted for pTyr before reprobing for CLEC-2. Results are 
representative of three experiments. 
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Appendix 11. 
 
 
 
 
 
CLEC-2 is not phosphorylated by Pam3-CSK4 in mouse platelets. Washed mouse 
platelets were preincubated with integrilin (9 μM) and stimulated under stirring 
conditions with Pam3-CSK4 (30 μg/ml) before lysis. CLEC-2 was immunoprecipitated 
using a specific antibody, separated by SDS PAGE and Western blotted for pTyr before 
reprobing for CLEC-2. Results are representative of three experiments. 
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Appendix 12. 
 
 
 
Pam3-CSK4 induce platelet aggregation in the presence of PP2 and PRT318. 
Platelets were pre-incubated with PP2 (10 µM) and PRT318 (5 µM) for 3 min prior to 
stimulation with Pam3-CSK4 (30 μg/ml). Results are representative of three experiments 
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Appendix 13. 
 
 
 
 
Miscellaneous platelet stimuli activate GPVI in transfected cell lines. The effect of 
diesel exhaust particles (DEP), fucoidan and dextran sulphate on GPVI- transfected 
DT40 cells was monitored using an NFAT-luciferase reporter assay. Cells were 
transfected with either an empty vector (mock) or GPVI/FcR γ-chain and an NFAT-
luciferase reporter and stimulated for 6 hours. Luciferase activity was measured as 
previously described in chapter 3. Results are representative of three experiments, mean 
± SEM, n ≥3 (* P<0.05, ** P<0.01). 
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Appendix 14. 
 
 
 
 
4N1- and Champs activate Mock, GPVI and CLEC-2 in transfected cell lines. The 
effect of 4N1-1 and Champs on Mock, GPVI and CLEC-2 transfected DT40 cells was 
monitored using an NFAT-luciferase reporter assay. Cells were transfected with either 
an empty vector (mock) or GPVI/FcR γ-chain and an NFAT-luciferase reporter and 
stimulated for 6 hours. Luciferase activity was measured as previously described in 
chapter 3. Results are representative of three experiments. There was no significant 
difference. 
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Appendix 15. 
 
 
 
Platelets aggregation induced by low concentrations of the ligands in the presence 
of indomethacin and apyrase. Washed platelets were pre-incubated with the inhibitors 
(10 μM) indomethacin and (2 U/ml) apyrase and stimulated with DEP (5 μg/ml), 
fucoidan (30 μg/ml), DxS (5 nM), 4N1-1 (20 μM), Champs (2.5 μg/ml) and 
LASERLAF (0.25 mM). Results are representative of three experiments. There was no 
significant difference. 
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Appendix 16. 
 
 
 
DEP, CTH, 4N1-1 and fucoidan induce platelets tyrosine phosphorylation from 
patients deficient in integrin αIIbβ3 and GPIbα .Washed human platelets from 
patients deficient in (A) integrin αIIbβ3 and (B) GPIbα were stimulated with DEP (50 
μg/ml), CTH (50 μg/ml) 4N1-1 (100 μM) or Fucoidan (100 μg/ml) for 3 min. Protein 
phosphorylation was measured as described in Figure 3-2. Molecular masses are 
indicated in kDa. Results are shown from a single experiment. 
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Appendix 17. 
 
 
 
Stimulation of ATP secretion by diverse group of ligands is blocked in the presence 
of a Src kinase inhibitor. ATP was measured using luciferin-luciferase. 
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Appendix 18. 
 
 
 
 
 
 
 
 
Platelets stimulated by thrombin and PAR-4 peptide. Mouse platelets from WT 
mice were stimulated with thrombin (1 U/mL) or PAR-4 peptide (150 mM) in the 
presence of eptifibatide. WCLs were separated by SDS-polyacrylamide gel 
electrophoresis and western blotted for pTyr. The results are shown as representative 
of 3 experiments.  
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Appendix 19 
 
 
 
 
Smaller coatings of fibrin are associated with platelet adhesion and spreading. 
Alexa-488-fibrinogen was used to visualise fibrin formation. Platelets (2×107/ml) were 
allowed to spread on fibrin coated coverslips, followed by actin staining with Alexa-
568-phalloidin. Scale bar = 5μm. Results are representative of three experiments. 
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Appendix 20. 
 
 
 
 
 
Actin nodules and filopodia in platelets that have undergone partial spreading. 
Mouse platelets (2×107 /ml) were allowed to spread on fibrin coated coverslips, 
followed by actin staining with Alexa-488-phalloidin. Scale bar = 5μm. Actin nodules 
can be seen as bright spots in the upper land part of the figure. The figure is 
representative of three experiments. 
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Appendix 21. 
 
 
 
Using Alexa-568-phalloidin to counterstain actin: Mouse platelets (2×107 /ml) were 
allowed to spread on fibrin coated coverslips, followed by incubation with FITC-
Annexin V (green). Actin was counterstained with Alexa-568-phalloidin (magenta) to 
count total number of adherent platelets. Scale bar =10μm. The result is representative 
of three experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
